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ABSTRACT 
The proteome of a cell is highly dynamic, constantly changing in response to environmental 
stimuli as well as during disease progression. To better understand human diseases, much 
recent work has focused on proteins to either identify disease targets through proteomics or 
produce therapeutics via protein engineering. Noncanonical amino acids are tools for altering 
the chemical and physical properties of proteins, providing a facile strategy not only to label 
proteins but also to engineer proteins with novel properties. My thesis research has focused 
on the development and applications of noncanonical amino acids in identifying, imaging, 
and engineering proteins for studying human diseases.  
Noncanonical amino acids have been incorporated to tag and enrich newly synthesized 
proteins for mass spectrometry through a method termed BONCAT, or bioorthogonal 
noncanonical amino acid tagging. BONCAT allows time resolution in studies of the 
proteome, and is ideal for studying proteomic responses within defined windows of time. 
Chapter 2 describes the investigation of the proteomic response of human breast cancer cells 
to induced expression of tumor suppressor microRNA miR-126 by combining BONCAT 
with another proteomic method, SILAC or stable isotope labeling by amino acids in cell 
culture. This proteomic analysis led to the discovery of a direct target of miR-126, shedding 
new light on its role in suppressing cancer metastasis.  
In addition to mass spectrometry, noncanonical amino acids can also be utilized to 
fluorescently label proteins. Incorporation of a methionine analogue, azidohomoalanine 
(Aha), allows subsequent labeling of proteins using copper-catalyzed azide-alkyne 
cycloaddition. This approach is limited to visualizing snapshots of the proteome in fixed cells 
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due to the cytotoxicity of copper. Utilizing the recent development of strain-promoted 
copper-free azide-alkyne cycloaddition, Chapter 3 details the synthesis of a set of cell-
permeant cyclooctyne probes and demonstration of selective labeling of newly synthesized 
proteins in live mammalian cells. Similar to live cell imaging, the ability to selectively label a 
particular cell type within a mixed cell population is important to interrogating many 
biological systems. Tumor cells and the surrounding microenvironment are considered a 
functional whole, and methods for selective labeling of one cell type within such a complex 
heterogeneous mixture are needed for studying tumor microenvironments in vitro and in 
vivo. By taking advantage of the metabolic differences between cancer and normal cells, 
Chapter 5 discusses efforts to develop selective labeling of cancer cells using a glutamine 
analogue. 
Although many noncanonical amino acids have been incorporated into proteins, there has 
been no example of global replacement of a polar amino acid. Polar amino acids typically 
occupy solvent-exposed positions on the protein surface, and incorporation of noncanonical 
amino acids at these positions should allow easier modification and cause less perturbation 
compared to replacements at the interior positions of proteins. Chapter 4 describes the first 
demonstration of global replacement at polar amino acid positions and its application in 
developing an alternative PEGylation strategy for therapeutic proteins. 
Synthetic polymers have also attracted attention in biomedical research. Advances in 
catalysis and polymer synthesis have enabled the creation of materials with desired function 
and structural diversity. The appendix includes three studies on synthesis of novel polymeric 
materials that can either achieve controlled-release of anti-cancer drugs or provide support 
for cell adhesion or growth. 
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CHAPTER 1 
Introduction 
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Importance of biological polymers in human diseases. Biological polymers make all of the 
functions of life possible. DNA encodes genetic information within all living organisms and 
is transcribed into messenger RNA (mRNA), which is then translated to produce the final 
product, proteins. Proteins are polymers of amino acids, and they perform many cellular 
functions, such as replicating genetic materials, catalyzing metabolic reactions, and 
destroying toxins. While genomics has provided valuable information for understanding 
many diseases, the study of proteins, or proteomics, attracts growing attention because 
alterations in protein function and regulation are characteristics of many human diseases. For 
example, accumulation of misfolded proteins that form fibrillar aggregates is central to 
neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s disease.1 
Moreover, pro-survival protein Bcl-2 is often upregulated in solid tumor cells and is 
considered an attractive target for cancer therapy.2 Such changes in the proteome are 
important for understanding diseases as well as identifying therapeutic targets; however, the 
complexity of the proteome makes investigations challenging. While the human genome 
encodes ~30,000 genes, alternative splicing and posttranslational modifications produce 
multiple products per gene, making the proteome much more complex. Interrogation of such 
a complex system is further complicated by the dynamic nature of the proteome; new 
proteins are made and transported while pre-existing ones are degraded.  
Residue-specific incorporation of noncanonical amino acids. To identify a proteomic 
response to a stimulus such as a disease, proteins made within a time window must be 
examined. It is difficult to distinguish newly synthesized proteins from the pre-existing ones 
as all proteins share similar amino acid building blocks. Residue-specific incorporation of 
reactive amino acids provides a facile strategy to tag newly synthesized proteins (Scheme 
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1.1).3 This method takes advantage of the endogenous cellular machinery to allow co-
translational incorporation of noncanonical amino acids (ncAAs). The incorporation of 
ncAAs is operationally similar to conventional protein labeling using 35S-Met, but faster and 
simpler, as it does not involve handling of radioactive materials. The resulting tagged 
proteins are chemically and physically distinct from pre-existing proteins. Separation of new 
and pre-existing proteins allows focused studies, such as identification and visualization, of 
proteins made in any time window of interest.  
Isolating proteomic response using ncAAs. In proteomic studies, mass spectrometry (MS) 
is routinely used to identify proteins; however, because MS detects the most abundant 
peptides in a mixture, sample complexity limits depth of peptide and protein identification.4 
To reduce sample complexity prior to MS, it has been demonstrated that newly synthesized 
proteins can be selectively enriched using a method termed BONCAT, or bioorthognal 
noncanonical amino acid tagging.5  This method involves residue-specific incorporation of a 
reactive methionine analogue, azidohomoalanine (Aha),6 to tag newly synthesized proteins 
with azides and subsequent purification of tagged proteins using alkyne-containing affinity 
probes.7 In addition to protein identification, quantification of the proteomic changes can be 
achieved using SILAC, or stable isotope labeling by amino acids in cell culture.8 Using a 
combined approach of BONCAT and SILAC,9 we have investigated the proteomic changes 
that occur in response to induced expression of a tumor suppressor microRNA (miRNA) in 
human breast cancer cells.  These studies discovered a new direct target of miR-126 (Chapter 
2).  
Illuminating the proteome using ncAAs. While MS analysis identifies proteins, 
fluorescence microscopy provides spatial and temporal information about the proteome. 
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Fluorescent labeling of proteins inside live cells has revolutionized biological studies by 
allowing researchers to directly monitor dynamic cellular processes. Fluorescent proteins 
such as GFP are commonly used for live cell imaging.10 While this method has enabled 
visualization of many targets, it requires the addition of a 30 kDa tag, which can cause 
perturbations in the localization and activity of the target proteins. Furthermore, investigating 
global protein synthesis and transport requires a strategy free of genetic manipulations.  
Proteomic imaging can be achieved through metabolic incorporation of small bioorthgonal 
tags, such as ncAAs. Incorporation of methioine analogues, homopropargylglycine (Hpg) 
and Aha, tags newly synthesized proteins with alkyne and azide functional groups,6, 11 
allowing for subsequent labeling by copper-catalyzed azide-alkyne cycloaddition.12 While 
this approach fluorescently labels newly synthesized proteins, it only provides snapshots of 
the proteome in fixed cells.13 To allow labeling of live cells, the strain-promoted azide-
alkyne cycloaddition was developed to eliminate the use of the cytotoxic copper catalyst.14 
To provide new tools for live cell imaging, we have synthesized a set of cell-permeant 
cyclooctyne fluorophores and identified optimum conditions for selective labeling of newly 
synthesized proteins in living cells (Chapter 3).15 
Similar to strain-promoted azide-alkyne cycloaddition, hydrazide-ketone chemistry can also 
proceed under physiological conditions.16 To expand the chemical toolbox for live cell 
labeling, we have demonstrated imaging of live bacterial cells through incorporation of the 
glutamine analogue, L-glutamic acid γ-hydrazide (Gah) (Chapter 4). Moreover, by taking 
advantage of the differences in glutamine metabolism between cancer and normal cells,17 we 
have explored the possibility of using Gah to selectively label cancer cells (Chapter 5). 
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Replacing polar amino acids with ncAAs for modifying therapeutic proteins. In addition 
to providing tools for interrogating the proteome to better understand human diseases, 
residue-incorporation of ncAAs also offers a way to engineer therapeutic proteins. The 
incorporation of ncAAs has significantly increased the possibility of engineering proteins 
with novel properties by expanding the building blocks beyond the 20 canonical amino 
acids.18 In an effort to further expand the chemical toolbox for protein engineering, we have 
demonstrated the first example of replacing polar residues (glutamine) with reactive ncAAs 
(Gah) (Chapter 4). Polar residues are often solvent-exposed,19 and incorporation of ncAAs at 
these positions should allow easier access for modifications and cause less structural 
perturbation than replacement of a nonpolar residue. Furthermore, using the bioorthogonal 
reactive groups introduced at glutamine positions, we are seeking to develop a strategy for 
PEGylating therapeutic proteins at multiple sites (Chapter 4). 
Synthetic polymers for studying and treating human diseases. In addition to biological 
polymers, synthetic polymeric materials also play essential roles in advancing knowledge and 
treatment of human diseases. Synthetic polymers can be fabricated into materials in various 
shapes with desired pore sizes and different mechanical properties.20 These versatile 
materials have extensive applications, such as tissue engineering and drug delivery. To create 
materials with desired functional and structural diversity, much effort has been made in 
advancing polymer synthesis. The development of ring-opening metathesis polymerization 
(ROMP) using fast-initiating ruthenium catalysis has enabled synthesis of diverse side-chain 
functional polymers with controllable molecular weights and low polydispersities.21 In 
collaboration with colleagues in the laboratory of Robert Grubbs, we demonstrated two 
applications of this polymerization method: synthesis of bivalent-brush polymers capable of 
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releasing anticancer drugs upon photo activation (Appendix I and II)22 and generation of 
thin-film hydrogels for supporting cell adhesion and growth (Appendix III).23 
Summary. Motivated by developing new tools for interrogating human diseases, my thesis 
research has focused on the development and applications of noncanonical amino acids. I 
have demonstrated the powerful use of ncAAs for investigating proteomic response to tumor 
suppressor microRNA, capturing proteomic dynamics in live cells, and engineering 
therapeutic proteins. The methods and applications demonstrated in my thesis work should 
enable many disease studies by providing the scientific community with new tools to 
identify, illuminate, and modify proteins.  
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Scheme 1.1. Residue-specific incorporation of ncAAs for tagging of newly synthesized 
proteins and its applications.  
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CHAPTER 2 
Pro-metastatic GPCR CD97 is a Direct Target of  
Tumor Suppressor miR-126   
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Abstract 
Many studies have shown that expression of microRNA-126 (miR-126) is downregulated in 
cancer cells. Overexpression of miR-126 is found to inhibit cancer metastasis, consistent with 
its identity as a tumor suppressor. To better understand the regulatory effects of miR-126, we 
combined BONCAT and SILAC to analyze the proteomic response to miR-126 
overexpression in the human metastatic breast cancer cell line MDA-MB-231. Among the 
list of responsive proteins, we discovered a direct target of miR-126, CD97. CD97 is a 
member of the epidermal growth factor seven-span transmembrane (EGF-TM7) family of 
adhesion G-protein-coupled receptors (GPCRs) and plays an important role in mediating 
cell-cell interaction. Expression of CD97 is upregulated in various cancers, and its 
overexpression has been shown to promote cancer metastasis by stimulating tumor cell 
migration and invasion. Furthermore, CD97 plays a non-cell-autonomous role in activating 
endothelial cell migration to promote angiogenesis, an essential process in cancer metastasis. 
The discovery that tumor suppressor miR-126 directly targets the metastasis promoter CD97 
provides new mechanistic insights into roles of miR-126 in inhibiting both cell-autonomous 
and non-cell-autonomous cancer progression. 
 
Introduction 
microRNAs (miRNAs) are a family of small noncoding RNAs that regulate gene expression 
posttranscriptionally and have been predicted to control more than 60% of all protein-coding 
genes in mammals.1 miRNAs play essential roles in many biological processes, including 
angiogenesis and tumorigenesis.2 Unsurprisingly, dysregulation of certain miRNAs has been 
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observed in various human cancers.3	   For instance, miR-126, a microRNA involved in 
angiogenesis,4 has been reported to exhibit reduced expression in many types of human 
cancers including breast, lung, gastric, and prostate.5 miR-126 has been defined as a 
metastasis suppressor because its overexpression was found to suppress the in vivo metastasis 
of breast cancer cells to lung and bone.5d  Much effort has since been made to understand the 
roles of miR-126 in metastatic progression; however, the underlying mechanism of 
regulation remains incompletely understood.   
In this study, we investigated the regulatory effects of miR-126 in human breast cancer cells 
by combining SILAC and BONCAT to determine the influence of miR-126 overexpression 
on protein synthesis. BONCAT (bioorthogonal noncanonical amino acid tagging) is used to 
isolate proteins synthesized within specified time intervals, and provides the temporal 
resolution needed to study proteomic responses to various stimuli.6 Moreover, BONCAT 
reduces sample complexity, a major limitation in protein identification using mass 
spectrometry, by removing the pre-existing proteome.7 To quantify proteomic changes, 
SILAC was used in conjunction with BONCAT.8 SILAC (stable isotope labeling by amino 
acids in cell culture) is a widely used method for mass spectrometry (MS)-based quantitative 
proteomics.9 Using this combined approach, we have discovered that a metastasis-promoting 
adhesion G-protein coupled receptor (GPCR), CD97, is a direct target of miR-126, shedding 
new light on its role in tumor suppression.  
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Results 
Inducible expression of miR-126 in human breast cancer cells. In order to assess the 
proteomic response to miR-126 overexpression, we modified the metastatic human breast 
cancer cell line MDA-MB-231 by lentiviral transduction with the SparQTM Cumate Switch 
system. The resulting cell line (designated MDA-CuO-miR) is characterized by constitutive 
expression of GFP as a selection marker and by cumate-inducible expression10 of a miR-126 
precursor (Figure 2.2a). Because endogenous miR-126 is encoded by intron 7 of the 
epidermal growth-factor-like domain 7 (EGFL7) gene,11 we designed the precursor sequence 
to include the pre-miR-126 and flanking regions from the intron of EGFL7 to ensure proper 
transcription and processing of miR-126. Cells were separated on the basis of GFP 
fluorescence to obtain cell populations with similar numbers of transgene integrations 
(Figure 2.1).  
Next, we assessed the induced expression of miR-126 in these cells by using the reverse 
transcriptase polymerase chain reaction (RT-PCR) (Figure 2.2b). At 2, 8, 24, and 72 h after 
induction with various concentrations of cumate, cells were harvested and total RNA was 
isolated. The abundance of mature miR-126 was measured and relative expression was 
calculated by using commercially available probes designed to bind mature miR-126.12 
Expression of miR-126 increased with induction time, and overexpression became significant 
8 h after induction. miRNA expression was about 8-fold higher compared to cells without 
cumate at 24 h and more than 10-fold higher 72 h post-induction. While induction time is the 
most important determinant of miR-126 expression, increasing cumate concentration above 
150 µg/mL had a small additional effect. To achieve an expression level that is both 
significant and physiologically relevant for proteomic studies, we chose to induce with 300 
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µg/mL cumate for 24 h. It has been reported that expression of miR-126 can be reduced by 
~6-fold in some cancers.13 
Assessing regulatory effects of miR-126 using proteomics. To quantify proteomic changes 
in response to miR-126 overexpression, cells were first adapted in SILAC medium 
containing either light lysine (Lys) or heavy lysine with an 8-Da mass shift (Lys8) for five 
doubling times to ensure near quantitative incorporation of Lys+8 in the heavy culture. 
Expression of miR-126 was induced in the heavy culture by addition of cumate. A label-
swap experiment was performed to control for changes in protein expression caused by the 
isotopes, where cumate was added to the light culture instead. At 24 h post induction, both 
cultures were treated with azidohomoalanine (Aha), a methionine analogue that can be 
subsequently conjugated with affinity probes via copper-catalyzed azide-alkyne 
cycloaddition.14 Cells were incubated with Aha for 4 h before they were harvested and lysed; 
lysates were then mixed at equal protein concentrations. This mixture was subjected to 
reaction with an acid-cleavable biotin tag15 to allow for isolation of newly synthesized 
proteins for MS analysis.  
MS data analysis revealed many proteins that exhibit significant changes of at least 20% in 
expression. To address the possible effects of the inducer, control experiments were 
performed in which cumate was added both to MDA-CuO-miR cells and to a control cell line 
(MDA-CuO) transduced with empty vector. A set of 33 responsive proteins was identified by 
applying two criteria: the protein must 1) be quantified on the basis of six or more peptide 
ratio measurements, and 2) exhibit at least a 20% change in expression with consistent 
direction of regulation in both sets of experiments described above (Table 2.1). We imagined 
that this set of proteins would include some that are directly regulated by miR-126, and 
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others that are affected indirectly. The most prevalent mechanism of regulation by human 
miRNAs involves translational repression as a consequence of miRNA binding in the 3’-
untranslated region (UTR) of the target transcript.16 To identify potential direct targets, we 
cross-referenced the down-regulated proteins with the lists of predicted targets of miR-126 
obtained from the following resources: MicroCosm17 using the miRanda algorithm (v3.0),18 
Target Scan (v6.2),1b, 19 and microRNA.org20 using mirSVR algorithm,21 and identified one 
predicted target, CD97. The fact that Cd97 is an established promoter of tumor metastasis22 
made this observation especially intriguing. 
miR-126 regulates CD97 expression via direct binding to its 3’ UTR. To determine 
whether CD97 is a direct target of miR-126, a widely used luciferase reporter assay was 
employed. First, the miR-126 precursor sequence used for MS studies was cloned 
downstream of the CMV promoter in an expression vector pcDNATM3.1(+) to generate 
pcDNA3.1(+)-miR126. Next, the entire 3’-UTR of CD97 was cloned downstream of a firefly 
luciferase reporter construct pMIR-REPORTTM and cotransfected with either pcDNA3.1(+)-
miR126 or pcDNA3.1(+) empty vector into human embryonic kidney (HEK293) cells. To 
validate this assay, several controls were also included (Figure 2.3a). pMIR does not contain 
any 3’-UTR downstream of luciferase so the reporter signal from this construct should not be 
affected by miR-126. As a positive control for repressed luciferase expression, two miR-126 
binding sites were introduced to create 2miR. Further, the 3’-UTR of insulin receptor 
substrate-1 (IRS1), a known direct target of miR-126,23 was cloned downstream of the 
luciferase reporter to provide a reference for efficient knockdown. As expected, luciferase 
expression from reporter constructs containing 2miR and IRS1 was decreased in cells 
expressing miR-126. In the presence of miR-126, cells expressing reporter construct 
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containing CD97 3’-UTR exhibited a ~40% decrease in luciferase activity, an even more 
significant knockdown than the decrease of ~20% observed for known target IRS1 (Figure 
2.3b). These results provide the first evidence that CD97 is a direct target of miR-126.  
In order to identify possible miR-126 binding sites, we aligned the 3’-UTR of CD97 with the 
mature miR-126 sequence using the microRNA target prediction algorithm RNAhybrid24 and 
found extensive sequence complementarity, including a 5-nucleotide seed-matched site 
(Figure 2.4a). We created several luciferase reporter constructs containing CD97 3’-UTR 
mutants and evaluated the effects of miR-126 on expression (Figure 2.4a). Guided by the 
predicted binding site, we made CD97-ex by removing all 11 interacting nucleotides and 
CD97-M3-126 by introducing three point mutations in the predicted binding region. A 
control construct, CD97-R1, has three point mutations at a random site that is not predicted 
to bind miR-126. To address the possibility that the flanking sequences may produce false-
positive results, we did not use empty vector as the control for miR-126 expression.  Instead, 
we constructed pcDNA3.1+-miR-ex, which lacks the pre-miR-126 sequence and leaves the 
flanking regions intact. Compared to cells expressing miR-ex, cells cotransfected with miR-
126 and the luciferase construct containing CD97 3’-UTR exhibited a significant knockdown 
of ~40% in luciferase activity. Expression can be rescued either by removing the predicted 
binding site or by introducing three point mutations in the binding site (Figure 2.4b). In 
contrast, mutating three nucleotides at an arbitrary site within the CD97 3’-UTR had little 
effect on luciferase activity. From these results, we have determined the binding site for miR-
126 in the 3’-UTR of CD97. 
In addition to miR-126, pre-miR-126 contains another known microRNA, miR-126*. Since it 
has been shown that miR-126 and miR-126* can repress expression of the same target by 
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binding to different sites in the 3’ UTR,25 we assessed whether miR-126* also targets CD97. 
In contrast to miR-126, the predicted binding site in the CD97 3’ UTR does not share strong 
sequence complementarity with the seed region of miR-126* (Figure 2.5a). We constructed 
three luciferase reporter constructs: CD97-M3-126* contains three mutations in the predicted 
binding site for miR-126*, CD97-M3-126+126* has mutations in both of the binding regions 
predicted for miR-126 and for miR-126*, and CD97-M3-R1+R2 is a control construct with 
mutations at two random sites. Similar to previous experiments, mutations at random sites 
within the 3’UTR of CD97 did not affect the robust suppression of luciferase activity by 
miR-126 (Figure 2.5b). While mutations in the predicted binding site for miR-126* also had 
little effect on the luciferase signal, the additional mutation in the miR-126 binding site 
abolished the suppression of luciferase activity. These results indicate that miR-126, not 
miR-126*, controls expression of CD97. 
 
Discussion 
Reduced expression of miR-126 is observed in many cancers, identifying it as a putative 
tumor suppressor. To better understand its role in cancer metastasis, we investigated the 
regulatory effects of miR-126 on protein synthesis in human breast cancer cells and 
identified 29 responsive proteins that exhibit miR-126-dependent expression. Further, we 
discovered that miR-126 represses expression of CD97 by binding directly to its 3’ UTR. 
This discovery establishes a link between two well-documented observations in cancer 
biology: the downregulation of tumor suppressor miR-1265d, 23, 26 and the overexpression of 
CD97.27   
20	  
	  
CD97 is an adhesion G-protein coupled receptor (GPCR) involved in cell adhesion and 
migration.28  Expression levels of CD97 were found to correlate with the in vitro migration 
and invasion capacity of many colorectal tumor cell lines.27d Tumor cells at the invasion front 
of colorectal and gastric carcinomas are found to exhibit stronger CD97 expression than 
other cells within the same tumor.27d, 29 Further, overexpression of CD97 has been shown to 
stimulate single cell motility in vitro and increase invasiveness of the fibrosarcoma cell line 
HT-1080 in scid mice.30 Similarly, CD97 has been shown to promote tumor invasion in 
thyroid cancer as well as glioblastoma.31 All of these observations suggest that CD97 plays a 
role in promoting tumor invasion by stimulating tumor cell migration. Similar functions have 
also been reported for a known target of miR-126, CRK.5a, 32 CRK is a component of the 
focal adhesion network, and decreased CRK expression has been shown to suppress tumor 
cell migration.32 Furthermore, it has been shown that miR-126 inhibited gastric cancer 
metastasis, partially through the downregulation of CRK.26b Our discovery that miR-126 
targets CD97, a key prometastasis factor in gastric cancer, suggests that perhaps miR-126 
suppresses metastasis through downregulation of both CRK and CD97.  
In addition to promoting tumor progression in a cell-autonomous manner, CD97 has also 
been shown to function non-cell-autonomously. CD97 can stimulate the motility and 
invasion of endothelial cells by binding to cell surface integrins to promote angiogenesis,33 
an essential process in cancer metastasis. Previous reports have indicated that miR-126 
represses angiogenesis by restricting VEGF-induced signals through direct targeting of 
Sprout-related EVH1 domain-containing protein 1 (SPRED1), vascular endothelial growth 
factor A (VEGFA), and phosphatidylinositol 3-kinase regulatory beta subunit (PI3KR2).26c, 34 
Since endothelial cell migration is essential to angiogenesis, it is reasonable to hypothesize 
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that downregulation of CD97, a proangiogenic factor that stimulates endothelial cell 
migration and invasion, also contributes to suppression of angiogenesis by miR-126. Similar 
to CD97, three recently revealed miR-126 targets also regulate endothelial recruitment. 
Knockdown of genes coding insulin-like growth factor binding protein 2 (IGFBP2), c-Mer 
tyrosin kinase (MERTK), and phosphatidylinositol transfer protein (PITPNC1) significantly 
suppressed the ability of metastatic breast cancer cells to recruit endothelial cells, leading to 
inhibition of metastatic colonization in vivo.35 This suppressive role of miR-126 in non-cell-
autonomous cancer progression is further illustrated by the discovery that miR-126 also 
inhibits recruitment of mesenchymal stem cells and inflammatory monocytes by targeting 
stromal cell-derived factor-1 alpha (SDF-1α).25  
miR-126 has been shown to regulate genes involved in both cell-autonomous and non-cell-
autonomous cancer progression (Figure 2.6). miR-126 can suppress cell-autonomous cancer 
progression by targeting IRS1 and CRK to inhibit tumor cell proliferation, migration, and 
invasion. miR-126 also inhibits metastasis in a non-cell autonomous manner by down-
regulating IGFBP2, MERTK, PITPNC1, and SDF-1α to limit cell recruitment. In addition, 
we now know that miR-126 targets CD97, a molecule that has been shown to promote 
metastasis both by stimulating tumor cell invasion and by inducing angiogenesis through 
recruitment of endothelial cells. This discovery provides new insight into the mechanism of 
tumor-suppression by miR-126 and identifies a potential therapeutic target for controlling 
both cell-autonomous and non-cell autonomous cancer progression. 
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Materials and Methods 
Cell culture 
Lentivectors and plasmids. SparQTM cumate switch inducible expression constructs, 
pCDH-EF1-CymR-T2A-Puro (QM200PA-2) and pCDH-CuO-MCS-EF1-GFP dual promoter 
lentivector (QM511B-1) were purchased from System Biosciences (SBI). pMIR-REPORTTM 
miRNA expression reporter (AM5795) and pcDNATM3.1(+) vector (V790-20) were from 
Invitrogen. Cd97 3’-UTR was amplified from human genomic DNA using the following 
primers: AAT TAA CTA GTA GGC GCA TGG TTC TGG ACG GCC CAG (forward) and 
ATT TTT CAG TGT TGA CAC TTA AAA TTA AAC ACA TGC ATA CAG AAG AAA 
GCT TTA TA (reverse).  
Lentiviral transduction. MDA-CymR cells stably expressing pCDH-EF1-CymR-T2A-Puro 
were generated by transducing MDA-MB-231 breast cancer cells (ATCC) with pCDH-EF1-
CymR-T2A-Puro virus (SBI, QM200VA-2) followed by a 14-day selection with 10 µg/mL 
puromycin.  To produce lentivirus containing inducible miR-126 constructs, HEK293 cells at 
80% confluency were transiently transfected using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer's instructions. The cells were transfected with either pCDH-
CuO-miR126-EF1-GFP or pCDH-CuO-MCS-EF1-GFP, along with two packaging plasmids 
and a fourth plasmid used to produce VSV-G pseudotyped lentivirus. The cell culture 
medium was collected 24, 48 and 72 h post transfection, filtered through an 0.8 µm filter, 
concentrated using a 30,000 MW cutoff spin column (Millipore), and stored at -80 °C. The 
MDA-CymR cells were infected with a 1:10 dilution of the concentrated lentiviral stocks 
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before further passaging and subdivision by FACS analysis based on the intensity of GFP 
fluorescence in order to obtain populations with similar numbers of transgene integrations. 
Fluorescence activated cell sorting. Cells were detached and pelleted by centrifugation (200 
g, 3 min) and washed once with 1 mL Hank’s balanced salt solution (0.2% BSA, 10 mM 
HEPES), and once with a cushion of FBS added to the bottom of the tube. Finally, cells were 
resuspended in 400 µL Hank’s buffer before filtering through a 50 µm Nytex nylon mesh 
screen (Sefar). Cells were stored on ice until flow cytometry analysis on a FACSAria flow 
cytometer (BD Biosciences Immunocytometry Systems) at the Flow Cytometry Facility of 
the Beckman Institute at Caltech. 
RT-PCR. Cumate solution (SBI) was added to cells carrying inducible miR-126 constructs 
at final concentrations of 0, 30, 150, 300, or 600 µg/mL. At 2, 8, 24, and 72 h post induction, 
cells were washed with PBS, trypsinized, and harvested. Total RNA from these cells was 
isolated with mirVana miRNA isolation kits (Invitrogen, AM1560). Reverse transcriptase 
(RT)-PCR was performed according to manufacturer’s protocols (TaqMan® microRNA 
Assays, Invitrogen, 4427975). Briefly, RNA concentrations were measured and 10 ng of 
RNA was used as template for reverse transcription using TaqMan® microRNA reverse 
transcription kit (Invitrogen, 4366596). Products from the RT reaction served as templates 
for quantitative PCR (qPCR) using a Model 7300 real-time PCR system (Applied 
Biosystems). Reagents used for qPCR include, TaqMan® Universal PCR master mix without 
AmpErase® UNG (Invitrogen, 4324018) and primers from TaqMan® microRNA assays 
(Invitrogen, has-miR-126, ID000450; U6 snRNA control, ID001973). Relative miR-126 
expression was calculated using the ΔΔCt method as previously described.36 
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Cell culture and amino acid incorporation. Cells were maintained in a 37 °C, 5% CO2 
humidified incubator chamber in customized Dulbecco’s modified Eagle’s medium (DMEM) 
(Invitrogen) supplemented with 10% dialyzed fetal bovine serum (Invitrogen), 50 U/mL 
penicillin, 50 µg/mL streptomycin, 0.2 mM methionine, 0.398 mM arginine, and 0.798 mM 
lysine or lys+8 (Cambridge Isotopes) 9. One day prior to cumate addition, cells were 
passaged and seeded at a density of 3×106 in 150 cm2 tissue culture flasks. Cumate was added 
to cells at a final concentration of 300 µg/mL. At 24 h post induction, cells were washed with 
PBS and fresh medium containing 1 mM Aha was added.  
Enrichment of newly synthesized proteins. After incubation with Aha for 4 h, cells were 
washed, detached, and lysed using cold 4% SDS/PBS solution containing protease inhibitors 
(Roche). Lysates were clarified by centrifugation at 14,000 g for 5 min. Supernatant was 
collected and diluted to a final SDS concentration of 0.1%. Total protein concentration in 
each lysate sample was quantified using a BCA protein assay according to the 
manufacturer’s protocol (Pierce). Lysates from light and heavy cultures were mixed at equal 
protein concentration. Affinity probes were attached using published click chemistry 
conditions 37. Excess probes were removed by precipitating proteins with cold acetone at -20 
°C.  
To enrich for newly synthesized proteins, pelleted protein was dissolved in 0.1% SDS/PBS 
solution and allowed to bind Streptavidin Plus UltraLink resin (Pierce) for 1 h at RT. 
Samples were washed thoroughly with 1% SDS/PBS and 0.1% SDS/PBS and bound proteins 
were cleaved by incubation with 5% formic acid for 4 h. Newly synthesized proteins were 
then eluted with 0.1% SDS/PBS and concentrated for further preparation for MS.  
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Sample preparation for MS. Enriched proteins were separated by SDS-PAGE gel 
electrophoresis and each lane was cut into eight equal gel slices. Gel slices containing 
proteins were subjected to reduction with 7 mM DTT solution for 30 min at 50 °C before 
alkylation with 37 mM chloroacetamide for 30 min in the dark. In-gel digestion was carried 
out in 3 ng/µL lysC (Promega) solution at 37 °C overnight. Peptides were extracted from gel 
slices and desalted on C-18 columns prior to MS analysis.  
Mass spectrometry. Mass spectrometry experiments were performed on an EASY-nLC 
(Thermo Scientific) connected to a hybrid LTQ-Orbitrap Classic with a nanoelectrospray ion 
source (Thermo Scientific). Binding and separation of the peptides took place on a 15cm 
silica analytical column (75 µm ID) packed in-house with reversed phase ReproSil-Pur C18AQ 
3 µm resin (Dr Maisch GmbH, Ammerbuch-Entringen, Germany). Samples were run for 60 
min on a 2% to 30% acetonitrile gradient in 0.2% formic acid at a flow rate of 350 nL per 
minute. The mass spectrometer was programmed to acquire data in a data-dependent mode, 
automatically switching between full-scan MS and tandem MS acquisition. Survey full scan 
MS spectra (from m/z 300 to 1,700) were acquired in the Orbitrap after the accumulation of 
500,000 ions, with a resolution of 60,000 at 400 m/z. The ten most intense ions were 
sequentially isolated, and after the accumulation of 5,000 ions, fragmented in the linear ion 
trap by CID (collisional energy 35% and isolation width 2 Da). Precursor ion charge state 
screening was enabled and singly charged and unassigned charge states were rejected. The 
dynamic exclusion list was set for a 90s maximum retention time, a relative mass window of 
10 ppm, and early expiration was enabled.  
26	  
	  
MS data analysis. Thermo raw data files were analyzed by MaxQuant (v 1.2.2.5)38 and were 
searched against the IPI human database (75,710 sequences) and an in-house contaminant 
database (259 sequences) including human keratins and proteases. All default options were 
used except as follows: match between runs was enabled (2 min maximum), variable 
modifications on methionine of Aha (-4.9863), AlST (+835.4300), AlST-X (+93.0868), 
Oxidation (+15.9949), and protein N-terminal acetylation (+42.0106), fixed modification on 
cysteine of Carbamidomethyl (+57.0215) and multiplicity of 2 with heavy label Lys8 
(+8.014199). LysC digest was specified with up to two missed cleavages. Initial precursor 
mass tolerance was 7 ppm; however, MaxQuant calculates tighter individual precursor 
tolerances after recalibration. Fragment ion tolerance was 0.5 Daltons. Peptide, protein, and 
site false discovery rates were fixed at 1% using the target-decoy approach with a reversed 
database.38 The minimum number of peptides for quantification was 1. Further data 
processing was performed to calculate ratios and standard errors of the ratios using in-house 
scripts described previously.39 Briefly, hierarchical models are constructed of the data, where 
the overall ratio for each protein is the geometric mean of the biological replicates and the 
biological replicate ratio is the median of all of the peptide ratios in the replicate. The 
standard error of the overall protein ratio is calculated by estimating the global peptide ratio 
standard error using pooled variance (calculated separately for peptide ratios based on 
requantified isotopic patterns) and using a bootstrapping procedure to resample at each level 
in the hierarchical model. In cases where the protein replicate ratios are inconsistent (i.e. 
upregulated in one sample and downregulated in another), the standard error would be very 
large and the protein would not be considered significantly changed from 1:1. 
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Luciferase reporter assays. HEK293 cells (20,000 per well) were seeded in a 96-well plate 
and grown for 24 h. Cells were transfected with a plasmid cocktail containing 50 ng pRL-
CMV (renilla luciferase control), 50 ng firefly luciferase construct outfitted with the 3’ UTR 
of interest, and either pcDNA3.1+-miR126 or pcDNA3.1+-miRex, using lipofectamine LTX 
(Invitrogen). At 48 h post transfection, the Dual-Glo luciferase assay was performed 
according to the manufacturer’s instructions (Promega).  Luminescence was measured on a 
microplate reader (Tecan).  
Oligonucleotides used in this study. 
CD97 3’UTR PCR primer fwd: 5’-
AATTAACTAGTAGGCGCATGGTTCTGGACGGCCCAG-3’ (restriction sites 
underlined) 
CD97 3’ UTR PCR primer rev: 5’-
TATAAAGCTTTCTTCTGTATGCATGTGTTTAATTTTAAGTGTCAACACTGAAAAA
T-3’ 
CD97-ex PCR1 fwd: 5’- GTGTTTGTGGACGAAGTACCGAAAGGTC-3’ 
CD97-ex PCR1 rev: 5’- GCAGGCCTCTCTCAGGCAGTGGCCCCAAGG-3’ (overlapping 
region in bold italics) 
CD97-ex PCR2 fwd: 5’- ACTGCCTGAGAGAGGCCTGCCCTGCCTG-3’ 
CD97-ex PCR2 rev: 5’- GCAAGGCGATTAAGTTGGGTAACGCC-3’ 
CD97-ex PCR3 fwd: 5’-AATTAACTAGTAGGCGCATGGTTCTGGACGGCCCAG-3’ 
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CD97-ex PCR3 rev: 5’-
TATAAAGCTTTCTTCTGTATGCATGTGTTTAATTTTAAGTGTCAACACTGAAAAA
T-3’ 
CD97-M3-126: 5’-
TGGGGCCACTGCCTGAGGCTCTGCGTACAGAGGCCTGCCCTGCCT-3’ (mutations in 
bolded italics) 
CD97-M3-126*: 5’- 
TCCCTCCACCCTCCCTCCCTGATCCCGTCATCCACCAGGAGGGAGTGGCAGCTAT
AGTCT-3’ 
CD97-M3-R1: 5’- 
GGAGCCACTGGTCCTGCTGCTGGCTGCCAGACTGCTCCACCTTGTGACCCAGGGT
GGGGA-3’ 
CD97-M3-R2: 5’- 
TGGGGCTCAGCTTCCCTCTTAAGCTAAGTGAGATGTCAGAGGCCCCATGGCGAG
GCCCCT-3’ 
miR-126 with flanking region sequence: pre-miR-126 sequence in bolded italics 
5’-
GCTAGCGAATTCGCCCTTGTGGACATTGCCGTGTGGCTGTTAGGCATGGTGGGGG
GCACTGGAATCTGGGCGGAAGGCGGTGGGGACTCCCTCTCCAGGGAGGGAGGAT
GGGGAGGGAGGATAGGTGGGTTCCCGAGAACTGGGGGCAGGTTGCCCGGAGCC
TCATATCAGCCAAGAAGGCAGAAGTGCCCCGTCCCGGGGTCCTGTCTGCATCCA
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GCGCAGCATTCTGGAAGACGCCACGCCTCCGCTGGCGACGGGACATTATTACTTT
TGGTACGCGCTGTGACACTTCAAACTCGTACCGTGAGTAATAATGCGCCGTCCACG
GCACCGCATCGAAAACGCCGCTGAGACCTCAGCCTTGACCTCCCTCAGCGTGGCC
GGGACCCTGAGCCTCTGCGCAGAGCCACCCGCCCCGACGTACTTAGGCGGCATA
GCCCTGAGACCTCTGGCCAGCGCCAGGCAGGCAGCGGGGGCGGCAGAGGCCTG
GGCCTGAGTCTTCTGGCTCTGCCTCGCGGCCGC -3’ 
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Scheme 2.1. A combined proteomic approach of BONCAT and SILAC. 
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Figure 2.1. Fluorescence activated cell sorting (FACS) analysis of transduced MDA-
MB-231 breast cancer cells. MDA-CuO cells (A) containing CymR repressor vector and 
empty SparQ cumate inducible vector and MDA-CuO-miR cells (B) capable of inducible 
expression of miR-126 precursor sequence were sorted according to GFP fluorescence to 
obtain cell populations with similar numbers of transgene integrations. Three cell populations 
with low (turquoise), medium (purple) and high (pink) fluorescence were collected, and cells 
with low fluorescence were used in subsequent studies.  
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Figure 2.2. Cumate-inducible expression of miR-126 in MDA-MB-231 cells. (A) Cumate 
binds to repressor CymR and allows expression of miR-126. (B) RT-PCR analysis of relative 
miR-126 expression at various time points after induction with concentrations of cumate 
ranging from 0 to 600 µg/mL.   
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Table 2.1. Proteins responsive to miR-126 overexpression identified by a combined 
BONCAT-SILAC approach. Listed are proteins quantified using at least 6 independent 
measurements that exhibit consistent regulation of more than 20% in both initial experiments 
and cumate control experiments.  
 
 
 
 
 
Protein Fold change (log2)
SDPR -0.68
KIF4 -0.45
HSP27 -0.45
CNN3 -0.43
CD97 -0.40
EIF4F -0.34
EGFR 0.31
COX6C 0.33
ASPH 0.39
NT5 0.39
PPIL3 0.39
LTB4DH 0.41
ACS3 0.41
CARS 0.43
DIA4 0.43
AARS 0.45
MSN 0.46
ETFA 0.46
CTSL 0.47
LAMB2 0.47
NDUFA4 0.48
ANTXR2 0.49
MMP14 0.52
ASNS 0.55
ETFB 0.56
ORCA 0.57
UGDH 0.63
PSA 0.71
ECH1 0.72
CD49B 0.82
TSC22D1 0.86
HMOX1 1.13
PGDH3 1.16
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Figure 2.3. CD97 is a direct target of miR-126. (A) pMIR-REPORT construct was used for 
luciferase assay, and specific miRNA binding in the 3’-UTR regulates reporter expression. 
(B) Human embryonic kidney (HEK) cells were cotransfected with pMIR-REPORT 
containing the indicated 3’-UTRs and pcDNA3.1+-miR126 or pcDNA3.1+ empty vector 
control. Relative luciferase activity was measured 48 h later. 2miR contains two miR-126 
binding sites and IRS1 is a known target of miR-126. Vector control was taken as 100%. P 
values were obtained using one-sided unpaired Student’s t-tests. *P < 0.01. 
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Figure 2.4. Identification of the binding site of miR-126 in CD97 3’UTR. (A) A 
computationally predicted miR-126 interaction site in CD97 3’UTR and CD97 3’UTR 
mutants used for luciferase assay. (B) Either removing the predicted binding site or mutating 
three nucleotides within the binding site abolished miR-126-dependent suppression of the 
luciferase activity of the CD97 3’UTR construct. Mutations at a random site within the CD97 
3’UTR had no effect on suppression of luciferase activity. miR-ex control was taken as 
100%. P values were obtained using one-sided unpaired Student’s t-tests. *P < 0.01. 
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Figure 2.5. CD97 is a direct target of miR-126, not miR-126*. (A) The most favorable 
miR-126* interaction site in CD97 3’UTR predicted by RNAhybrid algorithm and CD97 
3’UTR mutants used for luciferase assay. (B) Neither mutations at the predicted binding site 
for miR-126* nor at any other random position within CD97 3’UTR rescued suppression of 
luciferase activity. miR-ex control was taken as 100%. P values were obtained using one-
sided unpaired Student’s t-tests. *P < 0.01.  
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Figure 2.6. Direct targets of miR-126 in cancer. CD97, a pro-metastatic GPCR, has been 
reported to promote tumor cell invasion cell-autonomously by increasing tumor cell mobility 
and to induce angiogenesis non-cell-autonomously by recruiting endothelial cells. The 
identification of CD97 as a direct target of miR-126 sheds new light on the tumor 
suppressive roles of miR-126 in both cell-autonomous and non-cell-autonomous cancer 
progression. 
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CHAPTER 3 
Developing Cyclooctyne Fluorophores for Imaging 
Living Cells using Noncanonical Amino Acids 
 
 
 
 
 
 
 
 
 
This chapter was adapted with permission from: Beatty, KE; Fisk, JD; Smart, BP; Lu, YY; 
Szychowski, J; Hangeuer, MJ; Baskin, JM; Bertozzi, CR; Tirrell, DA. Live-cell imaging of 
cellular proteins by a strain-promoted azide-alkyne cycloaddition. ChemBioChem, 2010. 11 
(15): 2092-2095. Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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Abstract 
Circumventing the need for genetic manipulation, residue-specific incorporation of reactive 
amino acids allows labeling of newly synthesized proteins for visualization of cellular events. 
Copper-catalyzed azide-alkyne ligation is highly selective and has been previously used to 
label proteins within cells; however, the toxicity of copper limits its use to imaging fixed 
specimens. Here we report the synthesis of a set of membrane-permeant cyclooctyne 
coumarin dyes and demonstrate labeling of azide-containing proteins in live cells using 
copper-free strain-promoted azide-alkyne cycloaddition. Confocal fluorescence micrographs 
showed specific fluorescence in Rat-1 fibroblasts pre-treated with azidohomoalanine (Aha), 
an azide-containing methionine analogue. Counterstaining using MitoTracker Red showed 
healthy mitochondrial morphology of cells after Aha pulse and dye labeling. Further, we 
identified optimum labeling conditions for the cyclooctynes, providing powerful new tools 
for visualizing dynamic cellular processes in living cells.  
 
Introduction 
Protein synthesis, degradation, and trafficking contribute to the highly dynamic and complex 
nature of many cellular processes. Imaging studies of fixed cells can only provide snapshots 
of these processes. Live cell imaging has allowed scientists to observe internal structures and 
cellular processes in real time, providing invaluable insights to understanding biology. The 
most widely used protein-labeling strategy for live cell imaging is to create a fusion between 
the target protein and a fluorescent protein.1 While this strategy allows tracking of 
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preselected proteins, it requires genetic manipulation and is not suitable for studying global 
protein synthesis and transport in living cells. 
Circumventing the need for genetic manipulation, residue-specific incorporation of reactive 
amino acids allows tagging of newly synthesized proteins for subsequent selective 
modifications.2 Azidohomoalanine (Aha) and homopropargylglycine (Hpg) are reactive 
methionine (Met) analogues that can be incorporated into proteins.3 Proteins containing Aha 
or Hpg can be labeled with fluorophores by highly selective copper-catalyzed azide-alkyne 
ligations.4  This approach has allowed selective labeling of newly synthesized proteins, but 
the toxicity of copper has limited its use in imaging fixed cells.5 
The development of the strain-promoted, copper-free azide-alkyne cycloaddition provides 
excellent chemistry for labeling live cells.6 Further, the reactivity of the cyclooctyne can be 
increased by elevated ring strain or by fluorination adjacent to the alkyne.6b, 6c, 7 Using this 
efficient chemical reaction, glycan trafficking has been monitored in live cells and zebrafish 
embryos using membrane impermeable fluorophores.6c, 7d In order to explore beyond cell-
surface labeling, we need new generations of fluorophores that will enable us to monitor 
dynamic cellular events inside living cells. In this study, we describe the design of a set of 
cell-permeable cyclooctyne coumarin dyes for labeling newly synthesized proteins inside 
living cells. 
 
Results and Discussion 
Designing cell-permeable cyclooctyne fluorophores. In order to create cell-permeant 
fluorophores for rapid labeling of live cells, we focused on two components: the fluorophore 
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and the cycloocytne. We chose coumarin as the fluorophore for its small size, membrane-
permeant property, and two-photon excitation. Two-photon excitation fluorescence imaging 
is particularly advantageous for imaging living cells because it provides deeper penetration 
into the specimen with higher spatial resolution and less photodamage than single-photo 
confocal microscopy.8 For cyclooctyne design, we chose to test several cyclooctyne acids 
with varying degree of fluorination. Commercially available dimethylaminocoumarin 
(DMAC) was conjugated to various differentially-activated cyclooctyne acids via a short 
linker to yield the coumarin-cyclooctyne conjugates 1-3 (Scheme 3.1). The linker was 
designed to improve the solubility of the molecules and to increase the distance between the 
dye and its protein target, which could potentially enhance the fluorescence signal.9 The 
membrane permeability of these probes was assessed by Caco-2 permeability analysis,10 and 
the results confirm their membrane permeability. 
Determination of optimal conditions for labeling live cells. We used flow cytometry to 
optimize labeling conditions as a function of dye concentration, Aha pulse duration, and dye-
labeling time. Rat-1 fibroblasts were pulsed with either Aha or Met for 4 h before reaction 
with each dye at concentrations between 0.5 to 50 µM for 10 min. The mean fluorescence 
increased with increasing dye concentration for all three probes (Figure 3.1a). The 
fluorescence enhancement is the ratio between the mean fluorescence for Aha-treated cells 
and that for Met-treated cells. With increasing concentrations of 1 and 2, fluorescence 
enhancement increased with increasing dye concentrations. However, the fluorescence 
enhancement peaked at 10 µM for 3, and increasing the dye concentration further did not 
improve fluorescence enhancement.  This property of 3 was hypothesized to be due to 
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significant side reactions with cellular nucleophiles. Further investigations confirmed that 3 
can react with cysteines in vitro.11 
Cells pulsed for 0.5-4 h and dye-labeled for 6- 60 min at the optimum concentration of each 
dye were also analyzed using flow cytometry. Longer Aha-pulse duration led to increased 
fluorescence enhancement (Figure 3.1b). A 6 min dye-labeling yielded significant 
fluorescence enhancement for all three dyes and the fluorescence enhancement increased 
with dye-labeling time for probes 1 and 2 (Figure 3.1c). The more reactive 3 exhibited 
different optimum reaction conditions, including a shorter labeling time of 10 min at a lower 
dye concentration of 10 µM. 
Labeling live mammalian cells. To assess the ability of these coumarin-cyclooctyne 
conjugates to label azide-containing proteins inside living cells, Rat-1 fibroblast cells were 
labeled and examined using confocal fluorescence microscopy. Near-confluent fibroblast 
cells were pulsed with 1 mM Aha or Met. Cells that had been pretreated with the protein 
synthesis inhibitor anisomycin were also pulsed with 1 mM Aha as a control for assessing the 
contribution of free Aha to the fluorescence signal. After a 4 h pulse, cells were washed and 
subjected to reaction with each of the coumarin conjugates for 10 min at 37 °C using 
optimized probe concentrations, 50 µM for 1 and 2, and 10 µM for 3. We used MitoTracker 
Red, a fluorescent dye that localizes to functional mitochondria, as a counterstain to assess 
mitochondrial morphology as a measure of cell viability. Following the reaction, cells were 
washed and examined by confocal microscopy (Figure 3.2). For all three dyes, bright 
fluorescence was observed in cells treated with Aha alone, while cells treated with Met or 
Aha plus anisomycin showed a lack of fluorescence. Further, the mitochondrial morphology 
observed by staining with MitoTracker Red suggested that cells were alive and healthy after 
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dye-labeling. Together, these images demonstrate the selective labeling of Aha-containing 
proteins in live cells.  
Labeling patterns of these probes appears to vary depending on the type of cyclooctyne 
attached to DMAC. Fluorescence in Aha-treated cells was brighter in the cytoplasm and dim 
in the nucleus for 1 and 2, while the fluorescence of cells labeled with 3, a difluorinated 
cyclooctyne, appears to be more uniform. This observation could potentially be due to 
differences in reactivity and hydrophobicity attributed to the additional fluorination in 3. 
Evaluating the extent of labeling in cellular compartments. To confirm that labeling by 
these coumarin-cycooctynes is not confined to the cell membrane, we evaluated the extent of 
labeling in different cellular compartments. Rat-1 fibroblasts cells were pulsed with either 1 
mM Aha, Met, or Aha plus anisomycin for 4 h. Cells were then washed and treated with 10 
µM of each probe for 30 min. After dye-labeling, cells were detached, washed, counted, and 
collected by centrifugation. Cells were then lysed and four fractions containing cytoplasmic, 
membrane, nuclear, and cytoskeletal proteins were collected. To confirm efficient 
fractionation, fractionated protein samples were subjected to western blotting analysis using 
antibodies for compartment-specific protein markers, including the cytosolic protein β-
tubulin, the endoplasmic reticulum (ER)-resident glucose-regulated protein (GRP78), and the 
nucleolar protein fibrillarin (Figure 3.3). Each protein marker was specifically detected in the 
expected fractions, indicating efficient separation of cellular compartments.  
Protein concentrations in the fractionated protein samples were determined and fluorescence 
from each fraction was measured using a microplate reader. Raw fluorescence data were 
normalized by either cell number or protein concentration to yield the fluorescence 
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percentage for each fraction (Figure 3.4). Fluorescence was detected in all four cellular 
compartments for all three probes, confirming labeling within cells. Furthermore, although 
cells treated with probes 1 and 2 exhibit little fluorescence in the nucleus by fluorescence 
imaging, this study confirms labeling of nuclear proteins. 
Conclusions 
We synthesized a set of coumarin-cyclooctynes for labeling newly synthesized proteins in 
living cells. Brief exposure of these dyes to Aha-treated cells resulted in specific fluorescence 
in cells pulsed with Aha by both fluorescence microscopy and flow cytometry. Optimal 
labeling conditions were identified for each probe. Further, fluorescence was observed in 
different cellular compartments, confirming that labeling using these probes occurs 
throughout the cell, and is not confined to the cell membrane. The synthesis and 
characterization of these cell-permeant cyclooctyne fluorophores provide researchers with 
new tools to visualize dynamic cellular events by labeling azide-containing proteins in living 
cells. 
 
Material and Methods 
Cell Maintenance. Rat-1 fibroblasts cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Invitrogen) supplemented with 10% (v/v) fetal bovine serum, 50 U/mL 
penicillin, and 50 µg/mL streptomycin. Cells were maintained in a 37 °C, 5% CO2 
humidified incubator chamber. Near confluent cells were passaged with 0.05% trypsin in 
0.52 mM EDTA. 
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Preparation of Cells for Fluorescence Microscopy. Lab-Tek chambered coverglass slides 
(8-well, Nalge Nunc International) were prepared by treatment with fibronectin solution (10 
µg/mL). The wells were rinsed twice with PBS, blocked with a 2 mg/mL solution of heat 
inactivated BSA at room temperature, and rinsed with PBS. 
Near-confluent cells in 100 mm Petri dishes were rinsed twice with warm phosphate-buffered 
saline (PBS). Cells were detached with trypsin in EDTA and added to the appropriate media. 
The cells were pelleted via centrifugation (200 g, 3 min) and counted. Cells were added at a 
density of 1 x 104 cells per well to prepared slides. Cells were grown in media overnight. 
After growth overnight in DMEM++, each well was washed twice (200 µL) with warm PBS. 
Cells were incubated for 5 min in serum-free medium lacking Met [SFM: DMEM, with 1 
mg/mL bovine serum albumin (BSA, fraction V, Sigma-Aldrich), with 2 mM Glutamax I 
(Invitrogen), without Met], followed by 30 min in fresh SFM to deplete intracellular Met 
stores. Anisomycin (40 µM, Sigma-Aldrich) was added to cells during this time to inhibit 
protein synthesis. After incubation, 
either 1 mM Met or 1 mM Aha was added to the medium. After 4 h, wells were rinsed twice 
with DMEM++ before adding the dye-labeling mixture.   
Cells were exposed to coumarin-cyclooctyne in the labeling medium DMEM-Imaging 
[DMEM lacking phenol red, with HEPES (Invitrogen), supplemented with 10% FBS and 1 
mg/mL BSA]. Each coumarin-cyclooctyne was added to the labeling medium as a dilution 
from a 10 mM stock solution in DMSO. Labeling was allowed to proceed for 10 min at 37 
°C in the incubator chamber. After labeling, cells were washed twice before counterstaining. 
Cells were counterstained for 10 min with 300 nM MitoTracker Red CMXRos (Invitrogen). 
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After treatment, cells were washed thrice with DMEM-Imaging and then imaged in DMEM-
Imaging. Cells were kept in an incubator until they could be imaged (up to 3 h). 
For counterstaining with propidium iodide, cells were washed twice with DMEM++ before 
addition of a 1:1000 dilution of propidium iodide (1.0 mg/mL; Invitrogen) in DMEM-
Imaging for 10 min. Cells were washed thrice before imaging. Fixed (3.7% 
paraformaldehyde, 10 min) and permeabilized (0.1% Triton X-100 in PBS, 3 min) cells were 
also imaged as a control. Fixed cells stained with propidium iodide were not treated with 
coumarin-cyclooctyne. 
Live cells were imaged on a confocal microscope (Zeiss LSM 510 Meta NLO) at the 
Biological Imaging Center of the Beckman Institute at Caltech. A heated chamber was placed 
around the microscope to image the cells at ~37 °C. MitoTracker Red or propidium iodide 
fluorescence was obtained by excitation at 543 nm with emission collected between 565 and 
615 nm. Transmitted light images were also collected to differentiate individual cells. 
Coumarin fluorescence was obtained by two-photon excitation at 800 nm (Ti:sapphire laser) 
with emission collected between 376 and 494 nm. The set of images for each dye was 
obtained with identical conditions to capture coumarin fluorescence. Individual optical slices 
of coumarin fluorescence were collected at 0.5 µm intervals in order to create an extended 
focus image (i.e., projection). Images were acquired with a Plan-Apochromat 63x/1.4 oil 
objective (Zeiss) and analyzed with Zeiss LSM and ImageJ1 software. 
Preparation of Cells for Flow Cytometry. Pulse-labeling was performed directly in the 6-
well tissue culture dishes in which cells were grown. Each well was washed twice with warm 
PBS, followed by a 30 min incubation in SFM to deplete intracellular Met stores. Cells were 
55	  
	  
then exposed to 1 mM Aha or 1 mM Met for 4 h. In addition to examining a 4 h pulse length, 
we also examined 0.8, 0.25, 0.5, and 1 h pulses. Then, cells were washed twice with PBS. 
Coumarin-cyclooctyne dye in DMEM-Imaging was added to each well for coumarin-
labeling. Dye concentrations of 0.5 µM to 50 µM were examined. To examine alternative 
dye-labeling times, 10 µM dye was added for 6-60 min in DMEM-Imaging. After labeling, 
cells were washed twice with warm PBS and detached using 250 µL of 0.05% trypsin in 
EDTA. Cells were added to 750 µL DMEM++, and 100 µL FBS was added to the bottom of 
the Eppendorf tube to improve cell pelleting. Cells were pelleted by centrifugation (200 g, 3 
min) and washed once with 1 mL DMEM-Imaging, once with a cushion of FBS added to the 
bottom of the tube. Finally, cells were resuspended in 400 µL DMEM-Imaging before 
filtering through a 50 µm Nytex nylon mesh screen (Sefar). Cells were stored on ice until 
analysis. 
Flow Cytometry. Cells were analyzed on a FACSAria flow cytometer (BD Biosciences 
Immunocytometry Systems) at Caltech’s Flow Cytometry Facility. Coumarin fluorescence 
was excited by a 407 nm laser and detected after passage through a 450/40 bandpass filter. 
Forward- and side-scatter properties were used to exclude doublets, dead cells, and debris 
from analysis. 7- 
aminoactinomycin D (7-AAD; Beckman Coulter) was used to exclude dead cells from 
analysis. 7-AAD was excited by a 488 nm laser and detected after passage through a 695/40 
filter. Unlabeled cells, 7-AAD labeled cells, and coumarin-labeled cells were analyzed to 
ensure minimal cross-over fluorescence in each channel. When necessary, compensation was 
applied to 
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reduce cross-over fluorescence. Data was analyzed using FloJo7 software (Tree Star). 
Preparation of Live Cells for Fractionation. Pulse-labeling was performed directly in the 
10 cm tissue culture dishes in which cells were grown. Each plate was washed twice with 
warm PBS and incubated 30 min in SFM to deplete intracellular Met. Anisomycin, a protein 
synthesis inhibitor, was added at this time. Cells were exposed to 1 mM Aha, 1 mM Aha with 
anisomycin, or 1 mM Met for pulse-labeling (4 h). Then plates were washed twice with 
warm PBS. Coumarin-cyclooctyne dyes (10 μM) in DMEM++ were added to each plate for 
fluorophore labeling. After labeling for 30 min, cells were washed twice with warm PBS and 
detached using 1 mL of 0.05% trypsin in EDTA. Plates were scraped using a cell scraper and 
cells were collected and added to 4 mL DMEM++. Cells were pelleted by centrifugation 
(500g, 10 min) and washed once with 2 mL ice-cold PBS. Cells were transferred to a clean 
eppendorf tube. Cells were then fractionated using the QProteome cell compartment kit 
(Qiagen). Briefly, each cell pellet was gently resuspended in 1 mL ice-cold extraction buffer 
CE1 and incubated at 4°C in a lab rotator for 10 min. The lysates were centrifuged at 1000 g 
for 10 min at 4°C. The supernatants (fraction 1) were carefully collected and saved on ice; 
this fraction should contain primarily cytoplasmic proteins. The pellets were then 
resuspended in ice-cold 1 mL extraction buffer CE2 and incubated at 4°C in a lab rotator for 
30 min. The suspensions were then centrifuged at 6000 g for 10 min at 4°C. The supernatants 
(fraction 2) were carefully collected and put on ice; this fraction should contain primarily 
membrane proteins and proteins from the lumen of organelles. The pellets were then treated 
with Benzonase nuclease for 15 min at room temperature. Then 500 μL of ice-cold extraction 
buffer CE3 was added to each tube. The tubes were incubated at 4°C in a lab rotator for 10 
min. The suspensions were then pelleted by centrifugation (6800 g, 4°C, 10 min). The 
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supernatants were carefully collected (fraction 3); this fraction should primarily contain 
nuclear proteins. The pelleted material was resuspended in 100 μL of room temperature 
buffer CE4 (fraction 4); this final fraction contains the remaining proteins, most of which 
should be cytoskeletal.  
Western Blotting. Fractionated protein samples were separated on a 12% SDS-
polyacrylamide gel and transferred to a nitrocellulose membrane (hybond ECL, GE 
Healthcare) using a semidry transfer system (Amersham Biosciences). After being blocked in 
5% non-fat milk at room temperature for 1 h, the blots were incubated with primary 
antibodies (anti-GRP78, 1:250 and anti-fibrillarin, 1:1000, Abcam) for 2 h at room 
temperature. For β-tubulin detection, the blot was incubated with anti-β-tubulin-HRP 
conjugated antibodies (1:1000, Abcam) for 1 h at room temperature. After incubation in 
secondary HRP-conjugated anti-mouse IgG (1:10000) for 1 h at room temperature, the blots 
were washed with PBST three times prior to signal detection using ECL+ kit (GE 
Healthcare). The blots were imaged using a Typhoon molecular imager (GE Healthcare). 
Preparation for fluorescence measurement. Fractionated protein samples were isolated 
using acetone precipitation and resuspended in RIPA buffer (Sigma). Protein concentrations 
were then determined by BCA assay. Fluorescence from each fraction was measured using a 
Safire II (Tecan) plate reader. Raw fluorescence data were normalized using either cell 
number or protein concentration and analyzed to yield fluorescence percentage in each 
fraction. 
Synthesis of Coumarin-Cyclooctyne Dyes. All chemicals were purchased from Aldrich and 
used as received unless otherwise noted. Dry solvents were obtained from commercial 
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suppliers and used as received. Silica chromatography was performed using 230-400 mesh 
silica gel 60 (EMD). TLC was performed using Baker-flex silica gel IB-F plates; Rf values 
are reported under the same solvent conditions as those used for chromatography unless 
otherwise noted. TLC plates were examined under UV light for fluorescent compounds or 
alternatively stained with KMnO4, ceric ammonium molybdenate, or p-anisaldehyde. NMR 
spectra were recorded on Varian spectrometers (300 MHz for 1H) and processed with NUTS 
NMR software. NMR spectra were referenced to internal standards; proton and carbon 
spectra were referenced to tetramethylsilane. Fluorine spectra were referenced to 
hexafluorobenzene. All coupling constants are reported in hertz. FAB mass spectrometry was 
performed at the California Institute of Technology Mass Spectrometry Facility. 
1-Boc-amino-13-amino-4,7,10-trioxotridecane, 8 (Scheme 3.2). A solution of ditert-
butyldicarbonate (5.0 g, 23 mmol) in 100 mL of CH2Cl2 was added via a dropping funnel to a 
rapidly stirred solution of 1,13-diamino-4,7,10-trioxotridecane (10.1 g, 46 mmol) in 200 mL 
CH2Cl2 over a period of ~1 h. The resulting clear solution was stirred 16 h then transferred to 
a separatory funnel and washed twice with 100 mL of 0.1 M HCl and the aqueous layer was 
back-extracted 5 times with 50 mL of CH2Cl2. The combined organics were dried over 
NaSO4 and evaporated to give 6.6 g (90%) of an opaque viscous oil, which was used without 
further purification. 1H NMR (300 MHz, CDCl3) δ 1.44 (s, 9 H), 1.55 (br s,2H), 1.68-1.84 
(m, 4H), 2.81 (t, 2H, J = 6.8), 3.23 (br q, 2H, J = 6.2), 3.51-3.72 (m, 12H), 5.02-5.29 (2x br t, 
rotomers, 1H); 13C NMR (75 MHz, CDCl3) δ 28.46, 29.61, 33.26, 38.48, 39.62, 69.47, 69.56, 
70.18, 70.22, 70.58, 70.60, 78.80, 156.05, 156.10; FAB MS calc for C15H33N2O5 (M+H)+ 
321.2389, observed 321.2386. 
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Boc-Linker-Coumarin 9 (Scheme 3.2). To a solution of 1-Boc-amino-13-amino-4,7,10-
trioxotridecane, 8, (0.027g, 80 µmol) and triethylamine (0.015 g, 140 µmol) in 2 mL of 
CH2Cl2 in a foil-wrapped flask was added 7-dimethylaminocoumarin-4-acetic acid 
succinimidyl ester (0.025 g, 73 µmol, Anaspec) in 1 mL of CH2Cl2. The reaction was stirred 
for 12 h and then the solvent was removed and the product purified by silica chromatography 
(1:19 ethanol:ethyl acetate, Rf = 0.25) yielding 40 mg ~100%. 1H NMR (300 MHz, CDCl3) 
δ 1.43 (s, 9 H), 1.73 (app quintet, 4 H, J = 6.2), 3.06 (s, 6 H), 3.19 (br q, 2 H, J = 6.3), 3.36 
(q, 2 H, J = 6.0), 3.45-3.65 (m, 14 H), 5.01 (br, t, 1 H), 6.07 (s, 1 H), 6.50 (d, 1 H, J = 2.8), 
6.62 (dd, 1 H, J = 2.5, 9.0), 6.75 (br t, 1 H), 7.53 (d 1 H, J = 9.0 ); 13C NMR (75 MHz, 
CDCl3) δ 28.44, 28.61, 29.66, 38.52, 40.12, 40.62, 69.42, 70.02, 70.08, 70.14, 70.24, 70.39, 
78.89, 98.14, 108.50, 109.13, 110.24, 125.84, 150.18, 153.04, 155.98, 161.86, 168.01; FAB 
MS calc for C28H43N3O8 (M+H)+ 549.3050, observed 549.3027. 
1. Cyclooctyne acid 5  (Scheme 3.2) (0.0245 g, 0.095 mmol) was dissolved in 2 mL of DMF 
in a foil wrapped flask and placed under argon. Pyridine (18 µL, 0.11 mmol) was added, and 
the solution was cooled in an ice bath. Pentafluorophenyl trifluoroacetate (18 µl, 0.11 mmol) 
was added, and the solution was stirred for 2 h. The solvent was diluted with ethyl acetate 
(20 mL), extracted twice with 1 M HCl, extracted once with saturated NaHCO3, dried over 
Na2SO4, and evaporated to give a clear oil that was resuspended in 2 ml of CH2Cl2. This 
solution was added to a solution of 9 (0.043 g, 0.072 mmol) that had been deprotected by 
treatment with 1:1 TFA:CH2Cl2 for 2 h, followed by solvent removal and resuspension in 2 
mL CH2Cl2 and 22 µL (0.160 mmol) triethylamine. The combined solution was stirred under 
argon and monitored by TLC. After 6 h, the reaction mixture was applied directly to a silica 
column and eluted with 2:9:9 ethanol:CH2Cl2:ethyl acetate (Rf = 0.24 in 1:19 
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ethanol:CH2Cl2) to give 0.044 g (0.064 mmol, 88%) of a yellow-white solid. 1H NMR (300 
MHz, CDCl3) δ 1.46 (m, 1 H), 1.59-1.76 (m, 4 H), 
1.79-1.93 (m, 5 H), 1.93-2.39 (m, 4 H), 3.04 (s, 6 H), 3.27 (app q, 2 H, J = 5.9), 3.41-3.47 
(m, 4 H), 3.51-3.66 (m, 12 H), 4.22 (m, 1 H), 4.16 (d, 1 H, J = 12.5), 4.69 (d, 1 H, J = 12.5), 
6.06 (s, 1 H), 6.46 (d, 1 H, J = 2.4), 6.59 (dd, 1 H, J = 9.1, 2.5), 6.79 (br t, 1 H), 7.27 (br t, 1 
H), 7.38 (d, 2 H, J = 8.1), 7.49 (d, 1 H, J = 9.1), 7.77 (d, 2 H, J = 8.1);13C NMR (75 MHz, 
CDCl3) δ 20.70, 26.37, 28.53, 28.85, 29.72, 34.30, 38.63, 38.89, 40.09, 40.49, 42.32, 53.46, 
69.92, 70.06, 70.17, 70.28, 70.42, 70.46, 72.04, 92.50, 98.04, 100.66, 108.38, 109.20, 110.06, 
125.76, 127.11, 127.70, 133.53, 141.81, 150.19, 153.07, 155.94, 162.12, 167.58, 168.39; 
FAB MS calculated for C39H51N3O8 (M+H)+ 690.3754, observed 690.3720. 
2. Cyclooctyne acid 6 (Scheme 3.2) (0.005 g, 0.019 mmol) was dissolved in 0.2 mL of DMF 
in a foil wrapped flask and placed under argon. Pyridine (6 µL, 0.08 mmol) was added, and 
the solution was cooled in an ice bath. Pentafluorophenyl trifluoroacetate (4 µL, 0.02 mmol) 
was added, and the solution was stirred for 3 h. The solvent was diluted with ethyl acetate 
(20 mL), extracted twice with 1 M HCl, extracted once with saturated NaHCO3, dried over 
Na2SO4, and evaporated to give a clear oil that was resuspended in 2 mL of CH2Cl2. This 
solution was added to a solution of 9 (0.020 g, 0.04 mmol) that had been deprotected by 
treatment with 2 mL of 1:1 TFA:CH2Cl2 for 2 h, followed by solvent removal and 
resuspension in 2 mL CH2Cl2 and 22 µL (0.160 mmol) triethylamine. The combined solution 
was stirred under argon and monitored by TLC. After 8 h the reaction mixture was applied 
directly to a silica column and eluted with 1:19 ethanol:CH2Cl2 (Rf = 0.24) to give 0.006 g 
(0.009 mmol, 45%) of oily yellow product. 1H NMR (300 MHz, CDCl3) δ 1.29-1.45 (m, 1H), 
1.60-1.76 (m, 4 H), 1.77-2.10 (m, 6 H), 2.13-2.36 (m, 3 H), 3.03 (s, 1 H), 3.04 (s, 6H) 3.07 
61	  
	  
(d, 1H), 3.25, 3.37 (app q, 2 H), 3.38-3.46 (m, 4 H), 3.52-3.68 (m, 12 H), 6.06 (s, 1 H), 6.49 
(d, 1 H, J = 2.5), 6.60 (dd, 1 H, J = 2.5, 9.0), 6.64 (br t, 1 H), 7.16 (br t, 1H), 7.34 (d, 2 H, J = 
7.9), 7.51 (d, 1H, J = 9.0), 7.74 (d, 2 H, J = 8.4); FAB MS calculated for C39H51N3O7F 
(M+H)+ 692.3711, observed 692.3726. 
3. Cyclooctyne acid 7 (Scheme 3.2) (0.0028 g, 0.014 mmol) was dissolved in 200 mL of 
CH2Cl2 in a foil-wrapped flask and placed under argon. Triethylamine (8 µL, 0.06 mmol) 
was added, and the solution was cooled in an ice bath. Pentafluorophenyl trifluoroacetate (3 
µL, 0.02 mmol) was added, and the solution was stirred for 1 h. The solvent was removed 
under reduced pressure, and the resulting oil was resuspended in 3 mL of 1:1 ethyl 
acetate:hexane and passed through a short plug of silica (in a pasteur pipette). The solvent 
was removed under reduced pressure, and the material was resuspended in 1 mL of CH2Cl2. 
This solution was added to a solution of 9 (0.0125 g, 0.023 mmol) that had been deprotected 
by treatment with 1.5 mL of 1:1 TFA:CH2Cl2 for 2 h, followed by solvent removal, 
azeotropic removal of TFA with toluene and resuspension in 0.2 mL CH2Cl2 and 30 µL (0.21 
mmol) triethylamine. The combined solution was stirred under argon and monitored by TLC. 
After 3 h the reaction mixture was applied directly to a silica column and eluted with 1:19 
ethanol:CH2Cl2 (Rf = 0.22) to give 5.3 mg (0.0082 mmol, 64%) of a yellow glassy solid. 1H 
NMR (300 MHz, CDCl3) δ 1.68-1.87 (m, 4H), 1.98-2.08 (m, 2H), 2.13-2.31 (m, 3H), 2.39-
2.63 (m, 3H), 3.06 (s, 6H), 3.31-3.45 (m, 4H), 3.45-3.69 (m, 15H), 3.92 (s, 2H), 6.07 (s, 1H), 
6.48 (d, 1H, J = 2.6), 6.61 (dd, 1H, J = 2.9, 8.8), 6.79 (br t, 1H), 6.98 (br t, 1H), 7.51 (d, 2H, 
J = 9.3); FAB MS calculated for C33H46N3O8F2 (M+H)+ 650.3253, observed 650.3233. 
Caco-2 Permeability Analysis. Each of the three coumarin cyclooctynes 1-3 was submitted 
to Apredica (Watertown, MA) for Caco-2 (human colon carcinoma cell) permeability 
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analysis. Briefly, each probe was supplied as a 10 mM stock solution in DMSO. A test 
concentration of 10 µM probe was applied to the apical side of a monolayer of differentiated 
Caco-2 cells. Each probe was applied in transport buffer (1.98 g/L glucose in 10 mM 
HEPES, 1x Hank’s Balanced Salt Solution, pH 6.5) supplemented with 100 µM of the 
impermeable dye Lucifer Yellow. For comparison, low permeability controls (Ranitidine, 
Vinblastine), Quinidine, and a high permeability control (Warfarin) were also applied to the 
cells. 
After 2 h, the amount of permeation for each probe was determined by LC/MS/MS analysis 
of the transport buffer removed from the basolateral side of the monolayer. The value 
obtained is the permeability of each compound (Papp), which is defined as:  
𝑃𝑎𝑝𝑝 = 𝑑𝑄𝑑𝑡𝐶𝑜𝐴  
where dQ/dt is the rate of permeation, C0 is the initial concentration of the test agent, and A 
is the area of the monolayer. The Papp value for 1-3 and the standards are given in Table 1. 
From the Papp values, we conclude that each of the probes is membrane permeable and able 
to pass through the Caco-2 monolayer, although the assay also predicts that the 
bioavailability would be low. 
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Scheme 3.1. Chemical structures of coumarin-cyclooctynes.  
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Figure 3.1. Identifying optimum labeling conditions by flow cytometry. (A) Mean 
fluorescence enhancement as a function of dye concentration for cells pulsed for 4 h and dye-
labeled for 10 min; (B) Fluorescence enhancement as a function of pulse duration for cells 
dye-labeled with 10 µM 3 or 50 µM 2 for 10 min; (C) Fluorescence enhancement as a 
function of dye-labeling duration for cells labeled with 10 µM 1, 2, or 3 after a 4 h pulse.	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Figure 3.2. Labeling live cells using coumarin-cyclooctynes. Confocal fluorescence 
imaging of Rat-1 firbroblasts pulsed for 4 h with 1 mM Met, 1 mM Aha pre-treated with the 
protein synthesis inhibitor anisomycin, or 1 mM Aha with or without counterstaining with 
MitoTracker Red. Cells were dye-labeled for 10 min with 50 µM 1, 50 µM 2, or 10 µM 3 
before imaging.	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Figure 3.3. Western blot analysis of cellular fractions. Cells were fractionated into four 
portions containing cytoplasmic (F1), membrane (F2), nuclear (F3), and cytoskeletal (F4) 
proteins. An sample of 5 µg total protein was loaded from each fraction, separated by gel 
electrophoresis, and subjected to western blotting using antibodies for cytosolic protein β-
tubulin, membrane-bound protein GRP78, and nucleolar protein fibrillarin.  
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Figure 3.4. Fluorescence labeling in different cellular compartments. Fibroblasts cells 
were pulsed with either Aha or Met for 4 h, dye-labeled for 10 min with 50 µM 1, 50 µM 2, 
or 10 µM 3 before fractionation to separate proteins from different cellular compartments. 
Fluorescence was measured on a microplate reader and percent fluorescence was calculated 
by either normalizing for protein concentration (A) or cell number (B).   
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Scheme 3.2. Chemical structures of intermediates for coumarin-cyclooctyne synthesis. 
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CHAPTER 4 
An Approach to Multisite PEGylation of Proteins  
at Glutamine Positions 
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Abstract 
Residue-specific incorporation of noncanonical amino acids (ncAAs) has greatly expanded 
the toolbox for engineering proteins with novel chemical and physical properties. To further 
expand this chemical toolbox, here we report the first demonstration of global replacement of 
a polar amino acid, glutamine, by its reactive noncanonical analogue, L-glutamic acid γ-
hydrazide (Gah). Using an E. coli strain that is deficient in glutamine synthesis (a glutamine 
auxotroph), we achieved near-quantitative incorporation of Gah at glutamine sites of a 
reporter protein, dihydrofolate reductase (mDHFR). Incorporation of Gah decorates proteins 
with bioorthogonal hydrazide groups that can undergo selective reaction with ketones under 
physiological conditions. To demonstrate the novel reactivity of Gah-containing proteins, we 
synthesized a ketone tag for western blot analysis and showed specific detection of Gah-
containing mDHFR. We also designed a ketone-modified fluorophore and demonstrated 
selective labeling of live bacterial cells. In addition, using the surface accessibility of 
glutamine residues, we are exploring an alternative strategy for PEGylating therapeutic 
proteins at multiple sites using Gah.  
 
Introduction 
Protein engineering has relied on mutagenesis to produce proteins with new sequences. 
While changing the primary sequence can create proteins with desired properties, the 
diversity of engineered proteins is limited by the intrinsic properties of the 20 canonical 
amino acids. Residue-specific incorporation of noncanonical amino acids (ncAA) has 
expanded the possibilities of modifying protein structures and functions. For example, global 
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replacement of leucine by trifluoroleucine has created a more thermally stable variant of 
leucine zipper structure.1 Proteins can also be evolved to tolerate ncAAs and recover wild-
type properties.2 Aside from physical properties, incorporation of ncAAs can also create 
proteins with novel chemical reactivity by introducing various functional groups, such as 
azides, alkynes, alkenes, and ketones.3 So far, many nonpolar residues have been replaced 
with ncAAs; however, incorporation of ncAAs at polar amino acid positions has been 
investigated to a lesser extent. Replacing polar amino acids with ncAAs is attractive for 
several reasons. Polar residues typically occupy solvent exposed positions on protein 
surfaces,4 and incorporation of ncAAs at these positions should cause less structural and 
functional perturbation. Further, reactive ncAAs at surface positions will allow chemical 
modifications under native conditions.  
L-glutamic acid-γ-hydrazide (Gah) (Scheme 4.1), an analogue of the polar amino acid 
glutamine, is known to support protein synthesis in vivo5 and has also been shown to be 
tolerated by the Escherichia coli (E. coli) glutaminyl-tRNA synthetase (GlnRS) using in vitro 
assays.6 Furthermore, hydrazides react with ketones selectively under physiological 
conditions (Scheme 4.1),7 making the incorporation of Gah particularly attractive for protein 
modification. In this work, we demonstrate the residue-specific incorporation of Gah into 
newly synthesized proteins in E. coli and its applications in protein labeling, live-cell 
imaging, and modifying therapeutic proteins.  
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Results and Discussion 
Residue-specific incorporation of Gah. We first assessed the ability of Gah to support 
protein synthesis using bacterial cells harboring an inducible expression vector. The 
expression vector pQE-80L encodes a common reporter protein, mouse dihydrofolate 
reductase (mDHFR), under control of a bacteriophage T5 promoter, and an N-terminal 
hexahistidine sequence for purification. Glutamine auxotrophic E. coli strain M5004, 
obtained from the Coli Genetic Stock Center at Yale University, was transformed with the 
pQE-80L construct and grown to an OD600 of 1 before a medium shift was performed. Cells 
were pelleted from complete medium, washed with cold saline solution, and resuspended in 
medium supplemented with 19 amino acids (lacking Gln), 19 amino acids plus 4 mM Gah, or 
19 amino acids plus 4 mM Gln. DHFR expression was induced by addition of isopropyl-β-D-
thiogalactopyranoside (IPTG) at a concentration of 1 mM. After 4 h, cells were harvested by 
centrifugation, washed twice, and subjected to lysis. Cell lysates were analyzed using 
polyacrylamide gel electrophoresis (Figure 4.1). A band at the expected molecular weight of 
DHFR (24 kDa) is present in samples prepared from cultures supplemented with either Gln 
or Gah after IPTG induction. In contrast, the DHFR band is absent in samples containing 
only 19 amino acids because these auxotrophic cells cannot support protein synthesis without 
Gln or its analogues. Taken together, these data suggest that Gah exhibits sufficient 
translational activity to support protein synthesis in the absence of Gln. 
Incorporation of Gah into mDHFR was confirmed by matrix-assisted laser desorption 
ionization mass spectrometry (MALDI-MS) and liquid chromatography mass spectrometry 
(LC-MS).  mDHFR was purified using immobilized chelate affinity chromatography. Tryptic 
peptides of mDHFR from the Gah-treated culture were analyzed by MALDI-MS. The peak 
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of a Gln-containing peptide with sequence LLPEYPGVLSEVQEEK (amino acid position 
173-188) is absent at its expected mass of 1830 Da, while a new peptide peak emerged at 
1845 Da, consistent with the 15 Da mass difference between Gah and L-glutamine (Figure 
4.2). These MALDI data suggests near-quantitative incorporation of Gah at Gln positions. By 
comparing the integrated areas of the corresponding signals in the chromatogram from LC-
MS, the extent of replacement was determined to be ~93%, and the identity of each peptide 
was confirmed by tandem mass spectrometry (Figure 4.3).  
Selective detection of Gah-containing proteins. Next, we investigated the chemical 
properties of Gah-containing proteins.  To selectively label proteins containing Gah, a biotin 
tag with a ketone moiety was designed and synthesized (scheme 4.2). mDHFR was purified 
from cultures grown in the presence of Gln or Gah. These mDHFR samples (40 µM) were 
treated with 400 µM ketone biotin tag in aqueous solution, pH 6.5, at RT, for 12 h. Proteins 
were separated using gel electrophoresis, transferred to a nitrocellulose membrane, and 
detected using a fluorescent streptavidin conjugate. Strong fluorescence signal was observed 
for the sample prepared from the Gah-treated culture; minimal signal was present in the 
sample prepared from the culture supplemented with Gln, suggesting selective biotinylation 
of Gah-labeled mDHFR. Positive anti-His signals, providing a loading control, indicate 
similar amounts of protein were present in both lanes.  
Using the western blotting analysis, we investigated the timing of Gah incorporation into 
proteins.  After the medium shift, aliquots of Gah and Gln cultures were collected every 10 
min over a total of 2 h. Cultures were lysed, normalized by OD600, treated with ketone biotin 
tag, and analyzed by western blotting (Figure 4.4a). In the sample prepared from the Gah-
treated culture, a significant biotin signal was observed just 5 min post medium shift; the 
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signal accumulated with increasing expression time. In the Gln-treated culture, no significant 
biotin signal was observed. These observations suggest Gah is rapidly taken up by bacterial 
cells and incorporated into newly synthesized proteins.  
Imaging live cells in Gah-treated cultures. Gah is particularly attractive as a Gln analogue 
because it provides a biocompatible labeling strategy via hydrazide ketone reaction. Here we 
demonstrate selective fluorescence labeling of live bacterial cells by metabolically 
incorporating Gah and subsequent reaction with a ketone coumarin dye (Scheme 4.2). After 4 
h expression in the presence of Gah or Gln, cells were washed to remove excess free amino 
acids before dye-labeling in M9 medium, pH 6.5, for 3 h at 4 °C. Post dye reaction, cells 
were washed, stained by cell viability markers, and imaged using fluorescence microscopy 
(Figure 4.4b). Gah-treated cells showed strong coumarin fluorescence while cells grown in 
Gln culture exhibited little fluorescence. In addition, only very few cells were dead as shown 
by propidium iodide staining. Taken together, these results demonstrate selective 
fluorescence labeling of live Gah-treated cells using hydrazide ketone chemistry.  
Multisite PEGylation using Gahs at Gln sites. By populating Gln sites with its reactive 
analog, we can develop a new approach to modifying therapeutic proteins at multiple sites. 
The covalent attachment of polyethylene glycol (PEG) to proteins, PEGylation, is a well-
established and widely employed method to improve properties of therapeutic proteins.8 Its 
main advantages include improved solubility, increased stability and in vivo circulation time, 
and decreased immunogenicity.9 Many FDA-approved therapeutic proteins are PEGylated 
randomly at lysine residues using amine chemistry. Such a method, even at defined 
stoichiometric ratios, will  result in complex mixtures of mono-, di-, tri-, and numerous 
higher-PEGylated species, requiring stringent downstream purification.8 Furthermore, 
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because multiple lysines can participate in reactions, even mono-PEGylation leads to 
positional isomers that can differ substantially in biological and biomedical properties.8 As a 
result, a major drawback of the classical PEGylation approach is significantly reduced 
biological activity.10  
L-Asparaginase II (ASNase) is currently used to treat acute lymphoblastic leukemia because 
it kills leukemic cells by depriving them of their essential growth factor, asparagine.11 The 
native E. coli ASNase has shown limited effects in delaying intensification phases of 
leukemia due to the development of neutralizing antibodies in patients and often requires 
high dosage due to a short in vivo circulation period.12 A 5 kDa PEG chain was coupled using 
random PEGylation at lysine residues to improve immune tolerance and circulation duration; 
however, the modified enzyme retains only 8% of its original in vitro biological activity.13 
ASNase contains a lysine residue at its catalytic site,14 and undesired PEGylation at this 
lysine could account for the loss in catalytic activity. Herein we explore multisite PEGylation 
of E. coli ASNase using hydrazide-ketone chemistry provided by incorporation of Gah at Gln 
sites. 
To express the Gah-containing enzyme, E. coli ASNase with a C-terminal His tag was cloned 
into the multiple cloning site (MCS) of the pQE-80L vector for inducible expression by 
IPTG. Gln-auxotrophic E. coli cells harboring this construct were grown and subjected to a 
medium shift. ASNase expression was induced in the presence of 4 mM Gah and allowed to 
proceed for 2 h. Because previous reports have shown expression and transport of E. coli 
ASNase to the periplasmic region,15 we obtained three lysis fractions, periplasmic, 
cytoplasmic, and inclusion bodies, and analyzed them using gel electrophoresis and western 
blotting (Figure 4.5). The expression of ASNase is evident by the appearance of a band at the 
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expected molecular weight of 38 kDa in anti-His as well as anti-ASNase western blots. The 
majority of the protein is present in the periplasmic fraction as expected in both Gah and Gln-
treated samples, whereas no protein is detected in the culture supplemented with 19 amino 
acids, consistent with Gah incorporation into ASNase, which was further confirmed by 
MALDI-MS. 
ASNase was purified by metal chelate chromatography followed by size exclusion 
chromatography (SEC). SEC fractions were analyzed using a colorimetric activity assay 
(Figure 4.6).  As a negative control, ASNase with a single threonine to alanine mutation 
(T12A) showed little activity as previously published.16 Canonical ASNase exhibited 0.9 
U/mg activity, which was improved by SEC isolation of the active tetrameric form of the 
enzyme. Although Gah-containing ASNase showed significant activity, it is 10-fold lower 
than that of wt ASNase.  
 
Ongoing Work 
Several studies are currently underway to improve the catalytic activity of Gah-containing 
ASNase. Global replacement of Gln by Gah would likely cause structural and functional 
perturbation. Initial calculations for solvent accessibility of all Gln residues suggest that 
some may be buried.17 Moreover, these calculations correspond to the crystal structure, 
which also shows several Gln residues solvent inaccessible and near the inter-subunit 
interface of the tetramer.14 These Gln residues could be important for proper folding and 
formation of the catalytically active tetramer and will be mutated to other canonical amino 
acids. Asparagine is a good candidate since it may be able to form the same hydrogen bond 
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interactions as Gln. Histidine and glutamic acid have been shown to be structural homologs 
of Gln with the ability to mimic secondary structural motifs.18 Finally, comparative studies 
on the sequence homology within the ASNase family have yielded several additional 
candidates such as alanine, methionine, and glutamic acid. After recovering the enzymatic 
activity of Gah-containing ASNase, we will subject the enzyme to reaction with ketone 
modified PEGs of various sizes. The PEGylated ASNase will be purified and assayed for in 
vitro biological activity prior to efficacy assessment in vivo.  
 
Conclusions 
In this work, we have demonstrated the first example of global replacement of a polar amino 
acid by its noncanonical analogue. Using a Gln-auxotrophic E. coli strain, we have shown 
near-quantitative incorporation of Gah at Gln positions. To demonstrate the novel chemical 
property of Gah-containing proteins, we designed ketone-containing probes for protein 
modifications using hydrazide-ketone chemistry. We synthesized a ketone biotin tag and 
showed selective labeling of Gah-containing mDHFR using western blotting. We dye-labeled 
live bacterial cells using ketone-modified coumarin and observed highly specific 
fluorescence in cells cultured with Gah. Residue-specific incorporation of Gah introduces 
novel reactivity to cellular proteins and can be applied to monitor cellular events via live-cell 
imaging and to produce novel engineered proteins. As an example, we are currently using 
this method to explore PEGylating therapeutic proteins at multiple sites.  
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Materials and Methods 
Materials. All 20 natural amino acids and L-glutamic acid γ-hydrazide (Gah) were obtained 
from Sigma and Santa Cruz Biotechnology. Gln-auxotrophic E. coli strain M5004 was 
obtained from the Yale E. coli Genetic Stock Center.  
In vivo incorporation assays. Glutamine auxotrophic strain M5004 was grown in M9 
minimal medium supplemented with 0.8% D-glucose, 35 mg/L thiamin, 1 mM MgSO4, 0.1 
mM CaCl2, 20 amino acids (4 mM L-glutamine and 40 mg/L for other amino acids), and 200 
mg/L ampcillin. The overnight culture was diluted 50-fold in fresh M9 minimal medium. The 
cells were grown to an OD600 between 0.8 and 1.0, sedimented by centrifugation, and washed 
twice with ice-cold 0.9% NaCl. The cell pellet was resuspended in fresh M9 minimal 
medium containing either 19 amino acids (40 mg/L), 19 amino acids plus 4 mM L-glutamine, 
or 19 amino acids plus 4 mM Gah. After 10 min, 1 mM isopropyl β-D-thiogalactopyranoside 
(IPTG) was added to induce mDHFR expression. After 4 h, cells were pelleted and kept at -
80 °C. Whole cell lysates were analyzed by SDS-PAGE. 
Quantification of incorporation using mass spectrometry. mDHFR was purified on a Ni-
NTA column under denaturing conditions according to the supplier’s instructions (Qiagen). 
After purification, mDHFR concentration was determined by UV absorbance at 280 nm 
using a calculated extinction coefficient of 30,940 M-1cm-1.19 After concentration of the 
protein by ultrafiltration (Millipore), 10 µL of protein solution was diluted into 90 µL of 75 
mM (NH4)2CO3 for trypsin digestion. Modified trypsin (2 µL, Promega, 0.2 µg/µL) was 
added, and the mixture was incubated for 4 h at 37°C. The reaction was quenched by addition 
of 20 µL of 5% trifluoroacetic acid (TFA) solution and the mixture was subjected to LC-MS. 
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LC-MS analysis of protease-digested peptides was performed using a Premier XE LC-MS 
coupled with an Acquity UPLC chromotography system (Waters Co.). Peptides were 
separated on an Acquity UPLCTM BEH C18 column (1.7 µm, 300 Å, 2.1 × 100 mm) and 
eluted at a flow rate of 0.3 mL/min using a gradient of 0-50% of solvent B (89% 
acetonitrile/10% H2O/0.02% TFA/1% formic acid) and solvent A (2% acetonitrile/97% 
H2O/0.02% TFA/1% formic acid) in 55 min.  
Live cell fluorescence microscopy. After expressing mDHFR in the presence of either L-
glutamine or Gah for 1-4 h, bacterial cells were collected by centrifugation at 6000 g for 5 
min at 4 °C. For dye labeling, 2.5 mL of bacterial culture with OD600 of 1 was used per 
reaction. Cells were washed twice using 19 aa M9 to remove excess Gah in the medium 
before treatment with 500 µM coumarin ketone dye in 20aa M9, pH 6.5 for 3 h at 4 °C. After 
coumarin labeling, cells were washed three times with 19 aa M9 to remove excess dye. 
Viability of the cells was assessed using a Live/dead BacLight Bacterial viability Kit 
(Molecular Probes, L13152). Briefly, dry powder of live stain SYTO 9 and dead stain 
propidium iodide was dissolved in 5 mL ddH2O to make 2 × solution. Equal volumes of the 2 
× solution and coumarin-labeled culture were mixed at RT and kept in the dark for 45 min. 
Cells were washed once and resuspended in imaging solution (20% glycerol in 20 aa M9, pH 
7). Live cells were imaged on a confocal microscope (Zeiss LSM 510 upr) at the Biological 
Imaging Center of the Beckman Institute at Caltech. Propidium iodide fluorescence was 
obtained by excitation at 543 nm with emission collected between 565 and 615 nm. SYTO 9 
fluorescence was obtained by excitation at 488 nm with emission collected between 500 and 
530 nm. Transmitted light images were also collected to differentiate individual cells. 
Coumarin fluorescence was obtained by two-photon excitation at 800 nm (Ti: sapphire laser) 
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with emission collected between 376 and 494 nm. Cells treated with Gln or Gah were imaged 
using identical parameters in order to compare coumarin fluorescence. Images were acquired 
with a Plan-Apochromat 100 ×/1.4 oil DIC objective (Zeiss) and analyzed with Zeiss LSM 
and ImageJ software. 
Biotinylation and western blot detection. After expressing mDHFR in the presence of Gln 
or Gah, cells were collected and resuspended in lysis buffer (8 M urea, 10 mM Na2PO4, 300 
mM NaCl, pH 6.5). Cell suspension was subjected to a freeze-thaw cycle to achieve 
sufficient lysis. Cell lysate was biotinylated using 400 µM biotin ketone in urea solution, pH 
6.5, for 12 h at RT. For western blot analysis, equal amounts of protein samples were 
separated on a 12% SDS-PAGE. The gel was transferred to a nitrocellulose membrane 
(Hybond ECL, GE Healthcare) using a semi-dry transfer system (Amersham Biosciences). 
The membrane was blocked with 5% milk at RT for 1 h. The membrane was washed three 
times using 0.1% tween/PBS before incubation with antibodies for 1 h at RT [streptavidin 
TexasRed-conjugated (Abcam), 1:5000 and anti-pentahis Alexa488-conjugated (Invitrogen), 
1:5000]. Washed membrane was imaged on a Typhoon molecular imager (GE Healthcare).  
ASNase expression, purification, and detection. The gene encoding for E. coli ASNase 
was amplified from E. coli genomic DNA using forward and reverse primers to include a C-
terminal histidine tag for ease of purification and two restriction sites flanking the ends 
(EcoR1, Sal1) through PCR amplification (Stratagene, Agilent Technologies). Standard 
cloning protocols were used to construct the pQE80L-msig-ansB-his expression plasmid 
through restriction enzyme digestion and ligation of the digested PCR product and pQE80L 
plasmid backbone at EcoR1 and Sal1 sites. Mutant ASNase (T12A) was constructed using 
Quikchange mutagenesis of the pQE80L-msig-ansB-his plasmid (Stratagene, Agilent 
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Technologies). Incorporation of Gah into ASNase was done as previously described for 
mDHFR. After expression for 3 h at 37°C, cells were pelleted (15 min at 5000 g, 4°C) and 
gently resuspended in 20 mL per liter culture volume x cell OD600 of ice-cold 0.75 M 
sucrose, 0.1M Tris (Tris/sucrose buffer). The periplasmic fraction was extracted as 
previously described20 and dialyzed for 36 h against a solution of Ni-NTA binding buffer 
(0.3M NaCl, 0.05M NaH2PO4, pH 8.0) using 6-8 kilodalton molecular weight cutoff 
(MWCO) dialysis tubing (Spectrum Labs). ASNase was purified on a Ni-NTA column under 
native conditions according to the supplier’s instructions (Qiagen) with one change, the 
addition of 10% glycerol to all Ni-NTA purification buffers, which has been used as a protein 
stabilizer to prevent aggregation.21 Ni-NTA fractions containing ASNase was then further 
purified using size-exclusion chromatography (SEC) on an AktaPrime FPLC (GE 
Healthcare). All purification steps were assessed by SDS-PAGE analysis and identity of 
ASNase was confirmed via western blotting with asparaginase- and histidine-tag specific 
antibodies. Further, SEC fractions containing ASNase were then assayed for activity using an 
asparaginase activity assay kit (Sigma MAK007), which colorimetrically detects the 
appearance of aspartic acid using a microplate reader (Tecan). 
Synthesis of ketone probes. Coumarin ketone. 1-Amino-2-propanol (12 µL, 0.155 mmol) 
was added to a solution of coumarin NHS ester (50 mg, 0.145 mmol) in anhydrous CH2Cl2 (5 
mL).  The resulting solution was stirred overnight at RT to generate the coumarin alcohol 
intermediate.  Dess-Martin periodinane (86 mg, 0.202 mmol) was added, and the suspension 
was stirred for 18 h.  Isopropanol (100 µL) was added, and the mixture was stirred for 1 h, 
transferred to a separatory funnel, and washed 3 times with 1M HCl, 3 times with saturated 
NaHCO3, and once with brine.  The organic layer was dried over sodium sulfate, filtered, and 
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concentrated on a rotary evaporator.  Purification by column chromatography 
(MeOH/CH2Cl2) gave ketone 1c (29 mg, 66%). 1H NMR (600 MHz, methanol-d4) δ 7.59 (d, 
J = 9.0 Hz, 1H), 6.75 (dd, J = 9.0, 2.6 Hz, 1H), 6.54 (d, J = 2.6 Hz, 1H), 6.09 (s, 1H), 4.09 – 
4.04 (m, 2H), 3.78 – 3.74 (m, 2H), 3.05 (s, 6H), 2.12 (s, 3H). 13C NMR (151 MHz, methanol-
d4) δ 202.38, 167.60, 161.19, 156.00, 153.11, 149.33, 125.50, 110.28, 108.88, 104.99, 97.96, 
49.80, 45.00, 39.90, 27.02. 
Biotin ketone. 1-Amino-2-propanol (6.3 µL, 81.6 µmol) was added to a solution of biotin 
NHS ester (1a, 50 mg, 77.7 µmol) in anhydrous CH2Cl2 (5 mL).  The resulting solution was 
stirred overnight at RT to generate the biotin alcohol intermediate.  Dess-Martin periodinane 
(46 mg, 0.11 mmol) was added, and the suspension was stirred for 18 h.  Isopropanol (100 
µL) was added, and the mixture was stirred for 1 h, transferred to a separatory funnel, and 
washed 3 times with 1M HCl, 3 times with saturated NaHCO3, and once with brine.  The 
organic layer was dried over sodium sulfate, filtered, and concentrated on a rotary 
evaporator.  Purification by preparatory-HPLC (H2O/MeCN) gave ketone 2c (15 mg, 32%). 
1H NMR (600 MHz, Methanol-d4) δ 4.51 (dd, J = 7.8, 5.0 Hz, 1H), 4.32 (dd, J = 7.8, 4.4 Hz, 
1H), 4.04 (s, 2H), 3.67 – 3.64 (m, 4H), 3.61 (dt, J = 5.9, 2.8 Hz, 4H), 3.54 (td, J = 6.2, 3.5 
Hz, 4H), 3.28 (td, J = 6.6, 3.3 Hz, 4H), 3.26 – 3.20 (m, 1H), 2.95 (dd, J = 12.8, 5.0 Hz, 1H), 
2.76 – 2.68 (m, 1H), 2.58 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 6.9 Hz, 2H), 2.22 (t, J = 7.5 Hz, 
2H), 2.16 (s, 3H), 1.77 (td, J = 6.5, 4.2 Hz, 4H), 1.73 – 1.58 (m, 4H), 1.50 – 1.43 (m, 2H). 
13C NMR (151 MHz, Methanol-d4) δ 204.48, 174.51, 173.53, 173.00, 70.11, 69.81, 69.79, 
68.51, 68.45, 61.95, 60.19, 55.57, 48.94, 45.01, 39.60, 36.45, 36.40, 35.42, 30.80, 30.55, 
28.99, 28.95, 28.37, 28.08, 25.54, 25.45. 
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Primers used: 
For PCR ampfilication of ASNase: 
FWD: 5’-AATAGAATTCATTAAAGAGGAGAAATTAACTATGGAGTTTTTCAAAAA-
3’ 
REV: 5’-  
TAATTGTCGACTTAACCATGATGATGATGATGATGACCGTACTGATTGAAGATC-
3’ 
For T12A Mutant: 
Fwd: 5’-CCATTTTAGCAACCGGCGGGGCCATTGCCGGTGGTGGTGAC-3' 
Rev: 5’-GTCACCACCACCGGCAATGGCCCCGCCGGTTGCTAAAATGG-3’ 
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Scheme 4.1. Chemical structures of Gln and Gah. The hydrazide group on Gah reacts with 
ketones under physiological conditions to form a stable hydrazone linkage.  
+ 
Physiological 
conditions 
Gln Gah 
hydrazide ketone hydrazone 
92	  
	  
                        
  
 
Figure 4.1. Gel electrophoresis analysis of mDHFR expression. Protein expression was 
induced in cultures containing 19 amino acids, 19 amino acids plus 4 mM Gln, or 19 amino 
acids plus 4 mM Gah. mDHFR expression is evident by the appearance of a band at the 
expected molecular weight of 24 kDa in cultures containing Gln or Gah.  
IPTG             –             +                –              +               –              +                 
19 aa Gln Gah  
mDHFR 
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Figure 4.2. MALDI-MS analysis of tryptic digested peptides of mDHFR. The protein was 
expressed in medium containing 19 amino acids plus either Gln or Gah, purified, and 
subjected to trypsin digestion. A peptide fragment of sequence LLPEYPGVLSEVQEEK 
(amino acids 173-188, expected mass 1830.79 Da) yields the spectra shown. Replacement of 
Gln by Gah results in a 15 Da mass increase. The disappearance of the original peptide signal 
and the emergence of a new signal in the Gah sample suggest near-quantitative replacement 
of Gln by Gah.  
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Figure 4.3. Quantitative analysis of Gah incorporation by LC-MS. (A) Chromatography 
peak 1 corresponds to peptide LLPEYPGVLSEVZEEK (amino acids 173-188) with Gah at 
the Z position. Its relative integrated area is 267. (B) Chromatograph peak 2 corresponds to 
the peptide with natural amino acids; its relative integrated area is 19. (C) Mass spectrum of 
peak 1, shown as doubly-charged ions for the peptide with calculated mass of 1845 Da. A 
mass shift of 15 Da, corresponding to the mass difference between Gah and Gln, confirms 
incorporation of Gah. (D) Mass spectrum of peak 2, doubly-charged ions for peptide with 
calculated mass of 1830 Da.  Peak 3 corresponds to an irrelevant peak that has an isotope 
mass at 915 Da. 
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Scheme 4.2. Synthetic scheme for preparation of ketone probes. 
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Figure 4.4. Selective labeling of Gah-containing proteins using ketone probes. (A) Gah 
and Gln-containing mDHFR was subjected to reaction with biotin ketone in PBS, pH 6.5, at 
RT, for 12 h. Specific biotin signal in Gah sample was detected using a fluorescent 
streptavidin conjugate. (B) Bacterial cells grown in the presence of either Gah or Gln were 
treated with coumarin ketone in minimal medium containing 20 amino acids, pH 6.5, at 4 °C 
for 3 h prior to cell viability staining. Syto9 (green) is a cell-permeant dye and stains all cells 
while propidium iodide (red) only stains dead cells. Gah-treated cells exhibit strong 
fluorescence while cells cultured in 20 aa are not fluorescent. 
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Figure 4.5. Western blotting analysis of asparaginase expression. Using both anti-His and 
anti-ASNase antibodies, expression of asparaginase was confirmed in cultures supplemented 
either with Gah or with Gln. Peri = periplasmic space; cyto = cytosolic soluble fraction; IB = 
inclusion bodies. 
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Figure 4.6. ASNase activity assay. Absorbance at 570 nm was measured at 30 second 
intervals for 25 min for protein samples before (Gah, Gln, T12A) and after SEC-FPLC 
(SEC22). Asparaginase activity values for Gah sample were found to be 15-fold less than 
Gln. The T12A mutant was found to have no activity, indicating that there was minimal 
noise.   
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CHAPTER 5 
Selective Metabolic Labeling of Cancer Cells by the 
Glutamine Analogue L-Glutamic Acid-γ-Hydrazide 
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Abstract 
Our understanding of cancer has been shifted dramatically by the discovery that the tumor 
microenvironment plays an important role in tumorigenesis. As a result, there has been a 
growing interest in interrogation of tumors and their microenvironments using both in vitro 
and in vivo models; however, the selective labeling of a particular cell type in the complex 
microenvironment of many cell types presents a technological challenge. In this study, we 
explore the possibility of using a reactive glutamine analogue L-glutamic γ-hydrazide (Gah) 
for selective labeling of tumor cells by taking advantage of the difference in glutamine 
metabolism between cancer and normal cells.  We treated cervical cancer HeLa cells and 
normal human dermal fibroblasts (NHDF) with Gah and found that Gah exhibited specific 
toxicity towards HeLa cells (IC50 = 80 µM) and had little effect on NHDF (IC50 > 2 mM), 
indicating a preferential uptake of Gah by HeLa cells. Further, we demonstrated selective 
fluorescent labeling of Gah-treated tumor cells using an aldehyde-containing fluorophore.  
 
Introduction 
In the course of tumor progression, the tumor microenvironment emerges as a result of 
interactions between tumor cells and tumor stroma, blood vessels, infiltrating inflammatory 
cells, and associated tissue cells.1 The microenvironment has been considered the “soil” for 
carcinogenesis, and studying the immediate microenvironment within a developing tumor 
has become as important as studying the dysfunctional cells within that tumor.2 Recently, 
much effort has been focused on interrogating both in vitro and in vivo models of tumor 
microenvironments; however, selective monitoring of one cell type in such a complex 
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mixture of many cell types is challenging. Fluorescent proteins are commonly used for cell 
tracking; however, this approach requires genetic manipulation of tumor cells prior to 
formation of the microenvironment, which limits its use to in vitro studies. Since in vitro 
models of tumor microenvironment do not replicate the original structural milieu such as 
relative cell populations, and do not reflect the heterogeneity that is characteristic of solid 
tumors,3 there is a growing interest in ex vivo culture models that incorporate human tumor 
tissue in its native 3D state and enable dynamic manipulation of the system.4 A simple 
approach that circumvents the requirement for genetic manipulation is needed to selectively 
label tumor cells for investigations of these tumor microenvironment models.  
Metabolic differences between cancer cells and normal cells have been established since the 
1920s when it was observed that tumor cells predominantly produce energy by an 
unexpectedly high rate of glycolysis in the presence of oxygen (the Warburg effect).5 Cancer 
cells have had major modifications in their metabolic pathways in order to provide energy 
and macromolecules to sustain their increased proliferation.6 Recent studies have suggested 
that activating mutations in phosphoinositol 3-kinase (PI3K) and its downstream effectors 
induce the conversion of mitochondria within the transformed cells into synthetic organelles 
that support glucose-dependent lipid synthesis and non-essential amino acid production.7 
This metabolic phenotype is also the basis for tumor imaging using 18F-labeled glucose 
analogues for positron emission tomography (PET) and has become an important diagnostic 
tool for cancer detection and management.8  
In addition to glucose, glutamine (Gln) is another essential nutrient for cell growth and 
viability.9 Glutamine is the major source of nitrogen for nucleotide and amino acid 
synthesis.10 Further, Gln can replenish intermediates of the citric acid (TCA) cycle to 
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generate energy for maintaining cellular homeostasis through the process of glutaminolysis, 
whereby glutamine is converted to glutamate.11 In cancer cells, fewer glucose-derived 
metabolites feed into the TCA cycle as a result of the Warburg effect, and cancer cells 
typically have an increased reliance on alternative metabolites such as glutamine.12 Gln 
metabolism in cancer cells has been reported to far exceed the use of any other amino acid.9b, 
13 In cancer patients, some tumors have been reported to consume such an abundance of 
glutamine that they depress plasma glutamine levels.14 Although glutamine is considered a 
non-essential amino acid in normal cells, certain cancer cells cannot survive without 
exogenous glutamine, exhibiting a glutamine addiction phenotype.9b, 15 Taking advantage of 
this difference in glutamine metabolism, in this work, we demonstrate the selective labeling 
of tumor cells using a reactive glutamine analogue, L-glutamic acid-γ-hydrazide (Gah) 
(Scheme 5.1).  
 
Results and Discussion 
Incorporation of Gah into auxotrophic bacterial cells. Gah has been shown to exhibit 
translational activity 70% of that of Gln in an in vitro assay using reconstituted E. coli 
translational components.16 The in vivo incorporation of Gah using a glutamine auxotrophic 
E. coli strain and a medium shift procedure was demonstrated and discussed in Chapter 4. 
We also attempted to incorporate Gah without performing a medium shift to remove residual 
glutamine, and found no evidence of incorporation by matrix-assisted laser desorption 
ionization mass spectrometry (MALDI-MS) (Figure 1). These observations suggest that Gah 
does not compete successfully with endogenous levels of glutamine. Thus, Gah is not 
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expected to be incorporated into mammalian cells, which can typically synthesize glutamine; 
however, we hypothesized that Gah might be selectively incorporated into tumor cells that 
rely on exogenous supplies of glutamine.  
Preferential uptake of Gah by tumor cells. To test our hypothesis, we first compared the in 
vitro cytotoxicity of Gah in normal and tumor cells. The human cervical cancer cell line 
(HeLa) and normal human dermal fibroblasts (NHDF) were chosen for this study for two 
reasons: 1) HeLa cells have been shown to exhibit the glutamine addiction phenotype;15 2) 
HeLa and fibroblasts cells are widely used model cell lines for studying interactions between 
tumor and stroma.17 Cells were seeded at a density of 10,000 cells per well in 96-well plates 
and grown for 24 h. The culture medium was replaced with serum-free medium (SFM) 
lacking Gln. Gah was then added to final concentrations ranging from 0 to 4 mM. After a 96-
h incubation, cells were washed with phosphate buffered saline (PBS) prior to cell viability 
evaluation by the MTT assay (Figure 2).18 The viability of HeLa cells was dramatically 
reduced at low concentrations of Gah (IC50 = 80 ± 8.6 µM); whereas NHDF cells were 
affected by Gah only at high concentrations (IC50 > 2 mM). This specific cytotoxicity of 
Gah towards HeLa cells, evident by the 25-fold difference in IC50 values, could be a result 
of inhibition of macromolecular synthesis by Gah.  
Selective labeling of tumor cells. After demonstrating the specific cytotoxicity of Gah, we 
evaluated the possibility of selectively labeling tumor cells using Gah and subsequent 
reaction with a fluorescent dye (1, Scheme 5.1). The Gah side chain provides hydrazide 
groups that selectively react with ketones or aldehydes in aqueous solution.19 Proteins and 
live bacterial cells containing Gah have been selectively modified using ketone probes as 
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discussed in Chapter 4. Herein, we describe dye-labeling of mammalian cells using Gah and 
an aldehyde derivative of fluorescein, 1. 
To identify optimum conditions for selective labeling of cancer cells, we screened various 
pulse durations and concentrations of Gah. HeLa and NHDF cells were grown for 24 h on 8-
well chamber slides pretreated with fibronectin to promote cell adhesion and growth. Cells 
were washed with PBS and the culture medium was replaced with SFM lacking Gln. Gah 
was added to each well to a final concentration of 0, 1, 5, or 10 mM. After an incubation 
period of either 2 or 6 h, cells were washed with PBS to remove free Gah, fixed with 
paraformaldehyde, blocked with bovine serum albumin (BSA) before reaction with 10 µM of 
1 in PBS, pH 6.5, for 2 h at room temperature.  
Cells were washed with PBS after dye labeling and examined by fluorescence microscopy. 
Fluorescence images were acquired with identical acquisition settings for all samples, and 
mean fluorescence intensities were compared (Figure 3). At 2 h, HeLa and NHDF cells 
exhibited similar levels of fluorescence that were close to the background fluorescence 
observed for samples without Gah, indicating that little Gah was incorporated by either cell 
type. However, at 6 h, HeLa cells exhibited an elevated mean fluorescence signal, compared 
to that of NHDF at Gah concentrations of 1 and 5 mM; in contrast, fluorescence from NHDF 
cells showed no dependence on either pulse length or Gah concentration. Although the 
fluorescence enhancement was moderate, the selectivity of dye-labeling is evident in images 
acquired with identical instrument settings (Figure 4). The fluorescence images show bright 
fluorescence in HeLa cells and a lack of fluorescence from NHDF cells after 6-h pulses with 
either 1 mM or 5 mM Gah. At 10 mM, Gah did not enhance the fluorescence of HeLa cells; 
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this result could be caused by the inhibitory effects of Gah on protein synthesis and cell 
growth at high concentrations.  
 
Conclusions 
The differences between cancer and normal cells in metabolism of basic nutrients have been 
known for several decades.20 Based on the difference in glutamine metabolism, we 
hypothesized that a reactive glutamine analogue, Gah, might be preferentially incorporated 
into tumor cells. Gah exhibits highly specific cytotoxicity toward HeLa cells compared to 
NHDF cells, suggesting a difference in its rate of consumption by the two cell types. We 
utilized this difference in uptake and demonstrated selective labeling of HeLa cells using an 
aldehyde-fluorescein dye. By taking advantage of the distinct metabolic differences between 
cancer and normal cells, this approach circumvents the need for genetic manipulation and 
provides a facile strategy to selectively label cancer cells in complex tumor 
microenvironment models.  
 
Future Work 
To improve the fluorescence enhancement in HeLa cells, background fluorescence will need 
to be reduced. A basal level of fluorescence was observed in samples without Gah, perhaps 
due to an undesired reaction between aldehyde-fluorescein and  reactive lysines on cellular 
proteins.21 Ketone dyes could potentially reduce the background fluorescence because they 
are less reactive towards amines22 and should exhibit more selective reactivity toward 
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hydrazides. Having optimized dye-labeling in separate cultures of HeLa and NHDF, we will 
assess the selectivity of labeling in co-culture systems.  
 
  
Materials and Methods 
 Cell culture. HeLa and NHDF cells (ATCC) were cultured at 37°C under a humidified 
atmosphere of 5% CO2. Cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% (v/v) fetal bovine serum (Invitrogen), 50 U/mL penicillin, 
and 50 µg/mL streptomycin. Near-confluent cells were passaged with 0.05% trypsin in 0.52 
mM EDTA (Invitrogen).  The cells were continuously maintained in the culture medium and 
subcultured every 3-4 days. 
MTT cell viability assay. Cells were seeded at a density of 10,000 cells/well in a 96-well 
plate and grown for 20 h. Prior to Gah exposure, the culture medium was removed and the 
cells were washed once with warm PBS. Fresh media containing Gah at concentrations 
ranging from 0 to 4 mM, was added to appropriate wells. Cells were subsequently incubated 
at 37 °C for 96 h. The Gah-supplemented medium was then removed and the cells were 
washed twice with warm PBS before being subjected to the MTT cell proliferation assay 
according to the manufacturer’s instructions (ATCC). Cells were incubated with fresh 
medium containing MTT reagent for 3 h at 37 °C before detergent was added to solubilize 
purple formazan crystals formed by proliferating cells. Absorbance at 570 nm was then 
measured on a Safire II (Tecan) plate reader. 
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Preparation of cells for fluorescence microscopy. Near-confluent cells were washed twice 
with 5 mL warm PBS. Cells were detached with trypsin in EDTA and treated with 3 mL of 
complete DMEM. The cells were pelleted via centrifugation (200 g, 3 min), resuspended in 1 
mL of serum-free medium (DMEM lacking glutamine and FBS), and counted. Cells were 
seeded at a density of 2.5 × 104 per well to prepared slides. 
Eight-well Lab-Tek II chamber slides (Nalge Nunc International) were prepared by treatment 
with fibronectin solution (10 µg/mL) at 4°C overnight. The wells were rinsed three times 
with PBS, blocked with a 2 mg/mL solution of heat-inactivated BSA for 30 min at RT, and 
washed with PBS.  
Cells were incubated for 30 min in SFM to deplete residual glutamine. After incubation, Gah 
was added to appropriate wells at final concentrations of 0, 1, 5, or 10 mM. After either 2 or 
6 h, cells were rinsed three times with warm PBS, fixed with 3.7% paraformaldehyde 
solution for 15 min, and rinsed twice with PBS. Cells were permeabilized with 0.1% Triton 
X-100 for 3 min and treated with a blocking solution containing 10% (v/v) FBS, 50 mg/mL 
sucrose, and 20 mg/mL BSA for 30 min at RT. Cells were washed twice with PBS and 
treated with 10 µM 1 in PBS, pH 6.5 for 2 h at RT, in the dark. After reaction, cells were 
washed four times with 1% Tween 20 in PBS at 10 min intervals with agitation to remove 
excess dye. Cells were rinsed once with PBS. Chamber walls were removed and slides were 
mounted for visualization. 
Fluorescence microscopy. Fixed cells were imaged on an inverted epifluorescence 
microscope (Olympus) in the laboratory of Professor Chin-Lin Guo at Caltech. Each set of 
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images was obtained with identical settings. All images were acquired with a 10X objective 
and analyzed with imageJ. 
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Scheme 5.1. Chemical structures of amino acids and fluorophore.   
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Figure 5.1. Gah cannot be incorporated into proteins in the presence of glutamine. 
Glutamine auxotrophic cells were grown in medium supplemented with 20 aa (0.27 mM Gln) 
for 5 h prior to DHFR induction in the presence of 4 mM Gah for 4 h.  Tryptic digested 
mDHFR peptides were analyzed by MALDI-MS. A Gln-containing peptide with sequence 
LLPEYPGVLSEVQEEK (amino acids 173-188, expected mass 1830.79 Da) yields the 
spectra shown. Replacement of Gln by Gah should give rise to a new peptide peak that is 15 
Da away. The absence of new peaks indicates no replacement of Gln by Gah  
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Figure 5.2. Gah is toxic to HeLa cells. HeLa and NHDF cells were grown in glutamine-free 
medium supplemented with Gah concentrations ranging from 0 to 4 mM. Cell viability was 
assessed 96 h later by measuring cellular metabolic activities using the MTT assay. Gah 
exhibits specific toxicity to HeLa cells with an IC50 of 80 µM, 25-fold lower than in NHDF 
cells. 
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Figure 5.3. Mean fluorescence comparison of dye-labeled cells. Cells were grown in 
media containing Gah at concentrations ranging from 0 to 10 mM for either 2 or 6 h. Cells 
were fixed, permeabilized, and labeled with 1 for 2 h. Cells were then imaged and mean 
fluorescence was calculated using ImageJ software.  
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Figure 5.4. Gah enables selective visualization of tumor cells. Bright fluorescence was 
observed in HeLa cells treated with 1 mM and 5 mM Gah, while NHDF cells exhibited little 
fluorescence under any conditions.   
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Abstract: The combination of highly efficient polymerizations with modular “click” coupling reactions has
enabled the synthesis of a wide variety of novel nanoscopic structures. Here we demonstrate the facile
synthesis of a new class of clickable, branched nanostructures, polyethylene glycol (PEG)-branch-azide
bivalent-brush polymers, facilitated by “graft-through” ring-opening metathesis polymerization of a branched
norbornene-PEG-chloride macromonomer followed by halide-azide exchange. The resulting bivalent-brush
polymers possess azide groups at the core near a polynorbornene backbone with PEG chains extended
into solution; the structure resembles a unimolecular micelle. We demonstrate copper-catalyzed azide-alkyne
cycloaddition (CuAAC) “click-to” coupling of a photocleavable doxorubicin (DOX)-alkyne derivative to the
azide core. The CuAAC coupling was quantitative across a wide range of nanoscopic sizes (∼6-∼50
nm); UV photolysis of the resulting DOX-loaded materials yielded free DOX that was therapeutically effective
against human cancer cells.
Introduction
The explosion of nanoscience is fuelled by problems that
require nanoscale solutions and by the inherent challenges of
nanoscale synthesis.1-3 In drug delivery, for example, plasma
clearance time of a polymer-drug conjugate is closely linked
to its nanoscopic size; materials smaller than 10 nm are excreted
rapidly whereas larger materials often display significantly
longer retention times.3-9 Nanoscopic architecture also plays
an important role in determining in vivo retention time.10-12
Branched polymeric structures such as dendrimers, star poly-
mers, bottle-brush polymers, and hyperbranched polymers
generally display longer in vivo retention times compared to
their linear polymer analogues.11,13 A wealth of research
attention has focused on synthetic approaches to branched,
stimuli-responsive, nanoscopic materials that possess orthogonal
functionality for incorporation of therapeutic, imaging, and
targeting molecules.14-25
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The most widely studied branched macromolecules for drug
delivery are dendrimers; their nanoscale, monodisperse, mul-
tivalent structures provide functional handles for elaboration with
bioactive groups of interest.26-28 One factor that limits wide-
spread application of dendrimers is synthetic difficulty. Though
recent synthetic advances are impressive,16,29-32 it remains a
challenge to prepare functionally diverse dendrimers of variable
sizes. To overcome this challenge, researchers have appended
linear polymers to dendrimers33-36 or prepared linear polymers
with dendritic fragments attached to their side chains. The latter
“dendronized linear polymers” have attracted attention as
nanoscopic building blocks; their cylindrical shapes can provide
important advantages in nanoscale fabrication when compared
to spherical dendrimers.37-43 Similar nanoscale structures can
be formed from bottle-brush-polymers that carry long chains
grafted at high density to linear polymer backbones.44-63 Bottle-
brush polymers are prepared by graft-to, graft-from, or graft-
through methodologies. The graft-to strategy requires an efficient
coupling reaction to attach a functional molecule to every
monomer unit of a linear polymer; “click”64 reactions such as
the copper-catalyzed azide-alkyne cycloaddition65,66 (CuAAC)
and thiol-ene coupling have proven useful in this regard.43,46,67-70
Graft-from and graft-through methodologies require highly
efficient polymerization reactions capable of initiation and
propagation in sterically demanding environments.48,51-53,71
Recent developments in efficient, controlled polymerization
coupled with new click reactions provide materials chemists
with the tools to generate novel functional nanoscopic
materials.72-77
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strain provides the driving force for high conversion in these
systems. Although catalyst 1 is incompatible with azides and
alkynes, its functional group tolerance enables use of monomers
bearing azide and alkyne precursors that are easily converted
to the requisite click groups after polymerization. Binder and
co-workers used ROMP combined with CuAAC to append
various small molecules to clickable linear polymers.84,85 We
have used ROMP in conjunction with CuAAC to generate cyclic
polymers by end-to-end coupling.86 To our knowledge, there
are no examples of water-soluble brush polymers prepared by
graft-through ROMP that are subsequently functionalized via
click reactions. Such a strategy combines the benefits of ROMP
for graft-through brush polymer synthesis with the modularity
and efficiency of CuAAC for clicking-to; branched nanoscopic
polymers with easily addressable functional groups can be
rapidly prepared over a wide range of sizes simply by altering
the ratio of catalyst to MM.
In this report, we demonstrate the sequential combination of
graft-through- and click-to synthetic strategies to generate a
clickable polyethylene glycol (PEG)-azide branched polymer
material: a bivalent-bottle-brush polymer (Figure 1). Graft-
through ROMP of a PEG-chloride macromonomer (Figure 1,
Scheme 1, 6) gave bivalent-brush polymers of varying nano-
scopic sizes. These materials resemble first-generation den-
dronized polymers with branch points located near the linear
polymer backbone (Figure 1); attached on one side of the branch
point is a linear polymer and on the other side a small molecule
(e.g., a drug). This design incorporates a water-soluble PEG
domain that extends into solvent and a hydrophobic alkyl
chloride near the core. We hypothesize that PEG attachment to
one branch of these bivalent-brush polymers will confer the
biocompatibility widely observed for PEGylated systems.6,87
Core-functionalized nanomaterials have been elaborated with
functional small molecules by click chemistry;88-92 in this work,
we convert the core alkyl chlorides to azides by treatment with
sodium azide. Then, we utilize CuAAC to couple doxorubicin
(DOX), to the core via a photocleavable nitrobenzyloxylcarbonyl
(NBOC) linker. The latter enables controlled release of free
DOX in response to long-wavelength (∼365 nm) ultraviolet
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Figure 1. Schematic depiction of the “graft-through and click-to” approach described in this work. A: We start with a bivalent macromonomer (2) and
perform “graft-through” ROMP with catalyst 1 followed by in situ chloride-azide exchange. B: The resulting azido-bivalent-brush polymer is then functionalized
with an alkyne by click chemistry in a “click-to” step. If the alkyne partner is a drug molecule linked via a cleavable linker, then the resulting brush polymer
can release the drug in response to an external stimulus. In this work, we demonstrate controlled release of the anticancer agent doxorubicin (DOX) in
response to 365 nm UV light.
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(UV) light; we demonstrate that released DOX is therapeutically
active against human cancer cells in culture.
Results and Discussion
Synthesis of MM 6. Clickable bivalent PEG brush polymers
can be generated from an MM containing a strained norbornene
derivative for ROMP, a PEG chain, and a functional group
suitable for CuAAC (Figure 1, Scheme 1). Since neither azides
nor alkynes are compatible with catalyst 1, we designed MM 6
to carry an alkyl chloride for facile conversion to an azide in a
post-ROMP modification step. We incorporated a 6-carbon
spacer between the strained norbornene moiety and the tertiary
amide branch point to reduce steric hindrance between the
growing polymer chain end and the branched side-chains. This
spacer may also facilitate subsequent side chain modification
reactions, such as chloride to azide conversion and CuAAC.
MM 6 was obtained in five steps from exo-N-(6-hydroxyhexyl)-
5-norbornene-2,3-dicarboximide (norb-C6OH, Scheme 1). The
synthesis commenced with Swern oxidation of norb-C6OH to
give aldehyde 2. Reductive amination using 2 and 3-chloro-
propylamine hydrochloride gave secondary amine 3, which was
readily converted to acid 4 by treatment with succinic anhydride.
Reaction of 4 with N-hydroxysuccinimide (NHS) in the presence
of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochlo-
ride (EDC) and catalytic 4-(dimethylamino)pyridine (DMAP)
gave NHS ester 5. We have prepared 5 on a multigram scale
and expect it to be useful for the preparation of a variety of
multifunctional ROMP monomers. In this work, commercially
available 3 kDa PEG-NH2 was treated with a slight excess of 5
to give MM 6. Excess 5 was used to ensure complete conversion
of every PEG-amine to amide 6; the only polymeric species in
the final reaction mixture was 6 and it was easily purified via
repeated precipitation in diethyl ether. The 1H NMR, 13C NMR,
and MALDI spectra for MM 6 are provided in the Supporting
Information.
Graft-Through ROMP of 6 and Halide-Azide Exchange to
Generate nN3 Bivalent-Brush Polymers. We pursued a one-pot
synthetic strategy to rapidly generate a library of azide-functional
brush polymers (nN3) with variable number-average degrees of
polymerization (DP) and hydrodynamic radii. A strength of this
approach is the ease of generating branched functional materials
of variable sizes rapidly and efficiently; each of the polymers
described here was prepared by adding an aliquot of catalyst 1
to a vial containing MM 6, allowing 60 min for ROMP to
proceed, quenching the polymerization by addition of ethyl vinyl
ether, solvent exchange, and finally treatment with sodium azide
(Scheme 2). The first several steps were performed within a
few hours, whereas the final step, attaching azides to the polymer
side chains, was left for 48 h to ensure high conversion.
The polymer characterization data in Table 1 demonstrate
that ROMP of 6 is well-controlled up to the highest DP tested;
a small amount of catalyst deactivation and/or experimental error
may explain the larger-than-expected DP for the 400N3 samples.
In general, polymers with low polydispersities and molecular
weights defined by the ratio of 6:1 were obtained. The GPC
traces for all samples (Figure 2A) show monomodal molecular
weight distributions and very high (>95%) MM conversions.
All of the polymers were highly soluble (>100 mg/mL) in water;
Scheme 1. Synthesis of PEG-Norbornene-Chloride MM 6
Scheme 2. Synthesis of Azido-Bivalent-Brush Polymers (nN3) by
ROMP and Chloride-Azide Exchange
Table 1. Characterization of nN3 Bivalent Brush Polymers by GPC(room temp., 0.2 M LiBr in DMF, 1 mL/min) and DLS (aqueous)
n (theo.)a DPb Mn (GPC, kDa) PDI Rhc/nm
10 10 34.1 1.11 3.1 (0.3)
30 32 109 1.04 6.3 (0.8)
50 53 180 1.07 6.9 (0.9)
70 70 238 1.14 7.3 (0.3)
80 80 272 1.14 7.5 (0.8)
100 101 343 1.06 11 (1)
300 295 1,000 1.11 15 (1)
400 575 1,960 1.27 25 (2)
a Ratio of MM to catalyst (i.e., theoretical DP). This number is used
to identify nN3 and nDOX samples throughout the text. b DP observed
derived from Mn(GPC)/Mn(MM). c Hydrodynamic radii measured by
dynamic light scattering (DLS). DLS correlation functions were fit using
the CONTIN algorithm.
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aqueous DLS measurements (Table 1, Figure 2B) confirm that
their nanoscopic dimensions increased with DP and were tunable
over a broad range (radii from 3-25 nm) of relevant sizes for
drug delivery applications. Furthermore, DLS (Figure 2B) shows
that the particle size distributions are monomodal.
Graft-through ROMP ensures that every side chain unit
possesses both a PEG chain and an alkyl chloride; the weight
percentage of chloride is independent of DP. It follows that if
every chloride is converted to an azide then the weight
percentage of azide is also independent of DP. One may expect
side chain modification reactions with bivalent-brush polymers
to display DP-dependent conversion; perhaps increased DP
would lead to lower reaction yields because of increased steric
hindrance. We have found that for both chloride-azide exchange
and CuAAC reactions there is no apparent difference in reaction
yield across the DP values studied here. Figure 3 shows the
FTIR spectra for a subset of nN3 polymers normalized to the
PEG ether (C-O-C antisymmetric stretch) absorbance at
∼1100 cm-1. The intensities of the characteristic azide anti-
symmetric stretch (∼2100 cm-1) are the same for each DP,
which suggests that the azide:PEG ratio is the same for each
sample and that the chloride-azide exchange reaction occurred
with equal efficiency for each DP value.
Click Chemistry Using DOX-NBOC-Alkyne 9. The ultimate
application of these nN3 bivalent-brush polymers is defined by
how they are decorated with functional groups. For drug delivery
applications, one can imagine clicking a drug-alkyne derivative
attached via a cleavable linker group (Figure 1). The resulting
polymer would undergo controlled drug release in response to
an external stimulus leaving the brush polymer scaffold intact.
In this work, we designed 9 for controlled release of DOX in
response to UV light after click coupling to the nN3 polymer
scaffold (Scheme 3). Photoinitiated release from macromolecules
provides a means for site-specific, controlled drug delivery and
could potentially complement traditional phototherapeutic
methods.93-103 Though placement of azide groups near the core
of these bivalent-brush polymers should allow PEG to extend
into solution and increase the biocompatibility of these materials,
a buried location may make them difficult to functionalize with
subsequent reactions. Anticipating this challenge was one reason
we chose two highly efficient reactions, halide-azide exchange
and CuAAC, as the modification reactions; as described above,
CuAAC has proven useful for quantitative attachment of small
molecules to the side chains of ROMP polymers84,85 and we
expected that it would provide the best opportunity for high-
yield coupling of sterically demanding alkyne reagents to
bivalent-branch polymers. There are a variety of CuAAC
conditions throughout the literature and the catalyst/ligand/
solvent system depends on the application;104-107 perhaps the
most impressive applications of CuAAC are in the field of
(93) Dolmans, D. E. J. G. J.; Fukumura, D.; Jain, R. K. Nat. ReV. Cancer
2003, 3, 380–387.
(94) Bethea, D.; Fullmer, B.; Syed, S.; Seltzer, G.; Tiano, J.; Rischko,
C.; Gillespie, L.; Brown, D.; Gasparro, F. P. J. Dermatol. Sci. 1999,
19, 78–88.
(95) Mal, N. K.; Fujiwara, M.; Tanaka, Y. Nature 2003, 421, 350–353.
(96) Skwarczynski, M.; Noguchi, M.; Hirota, S.; Sohma, Y.; Kimura, T.;
Hayashi, Y.; Kiso, Y. Bioorg. Med. Chem. Lett. 2006, 16, 4492–
4496.
(97) McCoy, C. P.; Rooney, C.; Edwards, C. R.; Jones, D. S.; Gorman,
S. P. J. Am. Chem. Soc. 2007, 129, 9572–9573.
(98) Jiang, M. Y.; Dolphin, D. J. Am. Chem. Soc. 2008, 130, 4236–4237.
(99) Agasti, S. S.; Chompoosor, A.; You, C.-C.; Ghosh, P.; Kim, C. K.;
Rotello, V. M. J. Am. Chem. Soc. 2009, 131, 5728–5729.
(100) Lee, H.-i.; Wu, W.; Oh, J. K.; Mueller, L.; Sherwood, G.; Peteanu,
L.; Kowalewski, T.; Matyjaszewski, K. Angew. Chem., Int. Ed. 2007,
46, 2453–2457.
(101) Pastine, S. J.; Okawa, D.; Zettl, A.; Frechet, J. M. J. J. Am. Chem.
Soc. 2009, 131, 13586–13587.
(102) Kim, H.-C.; Hartner, S.; Behe, M.; Behr Thomas, M.; Hampp Norbert,
A. J. Biomed. Opt. 2006, 11, 34024.
(103) Haertner, S.; Kim, H.-C.; Hampp, N. J. Polym. Sci., Part A: Polym.
Chem. 2007, 45, 2443–2452.
(104) Lewis, W. G.; Magallon, F. G.; Fokin, V. V.; Finn, M. G. J. Am.
Chem. Soc. 2004, 126, 9152–9153.
(105) Rodionov, V. O.; Fokin, V. V.; Finn, M. G. Angew. Chem., Int. Ed.
2005, 44, 2210–2215.
(106) Rodionov, V. O.; Presolski, S. I.; Diaz, D. D.; Fokin, V. V.; Finn,
M. G. J. Am. Chem. Soc. 2007, 129, 12705–12712.
(107) Rodionov, V. O.; Presolski, S. I.; Gardinier, S.; Lim, Y.-H.; Finn,
M. G. J. Am. Chem. Soc. 2007, 129, 12696–12704.
Figure 2. A: Representative GPC traces for nN3 bivalent-brush polymer samples show monomodal molecular weight distributions, low polydispersities,
and high conversions. B: Hydrodynamic diameter histograms for selected nN3 polymers obtained from DLS measurements using the CONTIN fitting algorithm.
The particle sizes increase with increasing DP and are varied over a wide range by adjusting the ratio of MM to catalyst (6:1) before graft-through ROMP.
Figure 3. FTIR spectra of nN3 bivalent-brush polymers normalized to the
strong PEG ether (C-O-C) antisymmetric stretch absorbance. The relative
amount of azide is approximately the same for each n value which suggests
that chloride-azide exchange is not sterically limited with increased DP.
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bioconjugation where the requisite azide and alkyne functional
groups are present in very low concentration among a number
of other reactive groups.108-111 The Finn laboratory recently
reported optimized CuAAC conditions for bioconjugation which
utilize a new accelerating ligand THPTA (Scheme 4).112
Aqueous CuAAC was found to proceed orders of magnitude
faster with THPTA than in the absence of a ligand. Since these
nN3 bivalent-brush polymers are nanoscopic, narrowly dis-
persed, water-soluble materials with buried functional groups,
we envisioned CuAAC reactions to them as similar to biocon-
jugation reactions to proteins bearing multiple azide or alkyne
groups. After initial attempts without accelerating ligand, which
led to <20% conversion after several days, we were pleased to
find that addition of THPTA to the reaction mixture gave
quantitative conversions. In a typical reaction, the polymer,
THPTA (20 equiv. to azide), and alkyne 9 (1.05 equiv. to azide)
were dissolved in 95% H2O/5% DMSO such that the concentra-
tion of alkyne 9 was 2 mM. Aqueous sodium ascorbate (1.0
M) was added followed by copper(II) sulfate (1.0 M); two more
aliquots of aqueous copper sulfate and sodium ascorbate were
added over 2 days such that their final amounts were 10 and 50
equiv., respectively, relative to azide. The reactions were
performed at 40 °C to achieve the maximum rate possible
without inducing potential azide-olefin cycloaddition side reac-
tions.84
Figure 4A (inset) depicts the CuAAC coupling of 9 to 100N3
as monitored by liquid-chromatography mass-spectrometry (LC-
MS). Compound 9 eluted at ∼4.2 min while DOX-loaded
polymer eluted from ∼3.5 - ∼4 min. The unique absorbance
of DOX (∼500 nm) enables facile monitoring of the CuAAC
reaction; the 100N3 polymer does not absorb at 500 nm and
therefore the growth of a new, broad polymer peak is attributed
to CuAAC coupling of 9 to the polymer. The time-dependent
LC-MS traces (Figure 4A, inset) show an increasing polymer
absorbance at the expense of the alkyne 9 absorbance until a
final, very high (>97%) conversion is reached. As for the case
with chloride-azide exchange, one may expect the CuAAC
reaction progress to depend on DP. Figure 4A shows preparatory
high-performance liquid chromatography (prep-HPLC) 500 nm
absorbance traces for several crude nDOX polymers; the total
ratio of nDOX:9 is the same for each DP which again suggests
that DP has little effect on the efficiency of reactions to these
structures. The retention times for the nDOX polymers increase
slightly for each DP indicating that polymer-column interactions
are dependent on DP. The pure polymer fractions were collected
and either lyophilized to dryness or concentrated before use in
subsequent experiments. Figure 4B shows the FTIR spectrum
of purified 50DOX compared to that of 50N3. The azide
antisymmetric stretch at ∼2100 cm-1, present in the spectrum
of 50N3, is completely absent from the 50DOX spectrum which
suggests very high consumption of the azide group. Integration
of the broad aromatic resonances in the 1H NMR spectrum of
50DOX compared to the PEG methylene groups is in close
agreement to that expected for fully DOX-functionalized
polymer (Figure S5). The final DOX weight percentage for the
(108) Ngo, J. T.; Champion, J. A.; Mahdavi, A.; Tanrikulu, I. C.; Beatty,
K. E.; Connor, R. E.; Yoo, T. H.; Dieterich, D. C.; Schuman, E. M.;
Tirrell, D. A. Nat. Chem. Biol. 2009, 5, 715–717.
(109) Dieterich, D. C.; Link, A. J.; Graumann, J.; Tirrell, D. A.; Schuman,
E. M. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 9482–9487.
(110) Speers, A. E.; Cravatt, B. F. Chem. Biol. 2004, 11, 535–546.
(111) Prescher, J. A.; Bertozzi, C. R. Nat. Chem. Biol. 2005, 1, 13–21.
(112) Hong, V.; Presolski, S. I.; Ma, C.; Finn, M. G. Angew. Chem., Int.
Ed. 2009, 48, 9879–9883.
Scheme 3. Synthesis of DOX-Nitrobenzyloxycarbonyl (NBOC)-Alkyne Derivative 9 for Click Chemistry and Photorelease of DOX
Scheme 4. CuAAC Coupling of 9 to nN3 Brush Using
Tris(hydroxypropyltriazolylmethyl)amine (THPTA) Ligand,
Copper(II) Sulfate, and Sodium Ascorbate As an in Situ Reductant
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functionalized polymers is 12.6%. As mentioned above, this
value is independent of DP; it could be adjusted by varying the
PEG length or the degree of branching in the MM precursor.
Photorelease of DOX and Cell Culture Studies. Having
successfully coupled 9 to nN3 we next studied the release of
free DOX from the brush polymer in response to UV light
(∼365 nm). An aqueous solution of purified nDOX polymer
was irradiated at 365 nm for a given time and subjected to
LC-MS analysis. The progress of photorelease was monitored
over 10 min by repeated irradiation and LC-MS; the data for
100DOX are shown in Figure 5A. As irradiation time increased,
we observed a new peak at ∼3 min that increased in intensity
at the expense of the 100DOX polymer peak. The new peak
corresponds to the retention time and mass of free DOX. We
also observed a small side product at ∼3.8 min with a mass of
569 Da (labeled “*” in Figure 5A), which is likely the result of
intramolecular trapping of carbamic acid 10 to give cyclic
carbamate 11 (Scheme 5). Nevertheless, the major product of
UV photolysis was free DOX; the photolysis yield after 10 min
irradiation was ∼70% for all nDOX polymers which led us to
examine the effectiveness of these materials against human
cancer cells in cell culture.
We performed cell viability experiments using MCF-7 human
breast cancer cells. Cells were treated with aqueous solutions
of either free DOX or the corresponding nDOX polymer at
various concentrations and irradiated for 10 min using 365 nm
light or kept in the dark. The cells were then incubated in the
dark for 24 h, washed twice, and incubated for another 24 h in
fresh, drug-free growth medium. Cell viability was assessed
using the MTT assay (see Methods and Materials for details).
Data for n ) 100 polymers (100N3 and 100DOX) are shown
in Figure 5B (cell viability data for other n values is given in
the Supporting Information). Free DOX, with and without UV
irradiation, effectively killed the cells at 3-5 µM while azide
polymer 100N3 was nontoxic with and without light up to 100
µM; these data taken together suggest that under our conditions
10 min of 365 nm UV irradiation has no adverse affect on cell
viability nor does it interrupt the cellular toxicity of DOX. None
of the nDOX bivalent-brush polymers studied were toxic up to
50 µM in the absence of UV irradiation; irradiation for 10 min
yielded IC50 values ∼7-10 µM which confirms that free DOX
generated by photorelease is therapeutically active. The IC50
values were not DP-dependent. This observation suggests that
the nDOX polymers remain in the extracellular environment
Figure 4. A: Prep-HPLC traces of crude CuAAC mixtures which depict similar conversion for each n value. A (inset): Progress of CuAAC coupling of
9 to 100N3 monitored by LC-MS. B: FTIR spectra of 50N3 and 50DOX confirming complete loss of azide after CuAAC.
Figure 5. A: Time-dependent UV photolysis of 100DOX monitored by LC-MS; after 10 min irradiation ∼70% of free DOX was released. A minor
product (labeled “*”, see Scheme 5) was also observed at longer irradiation times. B: Viability of MCF-7 human breast cancer cells treated with free DOX,
100N3 bivalent-brush polymer, and drug-loaded 100DOX polymer both with and without UV irradiation. Data points were fit to a sigmoidal function and
the half-maximum inhibitory concentrations (IC50) are shown for DOX and the photocleaved 100DOX. The x-axis labels refer to the concentration of both
free and polymer-conjugated drug.
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and upon photolysis free DOX is released and diffuses into the
cell nucleus where it induces apopotosis. Although in vitro
experiments do not show DP-dependent cytotoxicity, we expect
that DP will affect in vivo trafficking and thus the overall utility
of these materials in drug delivery. Targeting groups could be
appended to the periphery of these materials to promote
trafficking into the cell.113
Conclusions
Here we have demonstrated the utility of a combined graft-
through/click-to strategy for the synthesis of a new class of
clickable, branched nanostructures: PEG-branch-azide biva-
lent-brush polymers. This approach makes use of the remark-
able efficiency of ROMP for graft-through polymerization
and the modular coupling power of click chemistry for
polymer functionalization. A wide range of nanoscale sizes
is accessible which will enable detailed structure/function
correlation in biological settings. We are currently exploring
applications for these materials in drug delivery. Design and
synthesis of novel clickable linkers (e.g., longer wavelength-,
pH-, and redox-cleavable), attachment of targeting moieties
at the PEG periphery, incorporation of degradable units within
the polymer backbone, and use of chain-transfer agents to
append orthogonal groups selectively to the ends of these
polymers are being studied. Furthermore, copolymerization
of MMs like 6 with other monomers (such as a norbornene-
alkyl halide small molecule) will provide access to new
multiblock polymer structures with the potential for higher
drug loadings.
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Scheme 5. Photolysis of nDOX Polymers Gives Carbamic Acid 10a
a Decarboxylation of 10 yields free DOX as the major product while intramolecular trapping provides DOX-carbamate derivative 11 as a minor product.
Reactive nitrosobenzaldehyde photoproducts remain bound to the polymer core after photolysis.
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ABSTRACT: Graft-through ring-opening metathesis polymerization (ROMP) using ruthenium N-hetero-
cyclic carbene catalysts has enabled the synthesis of bottle-brushpolymerswithunprecedented ease and control.
Here we report the first bivalent-brush polymers; these materials were prepared by graft-through ROMP of
drug-loaded poly(ethylene glycol) (PEG) based macromonomers (MMs). Anticancer drugs doxorubicin (DOX)
andcamptothecin (CT) were attached toanorbornene-alkyne-PEGMMvia aphotocleavable linker.ROMPof
either or both drug-loadedMMs generated brush homo- and copolymers with low polydispersities and defined
molecular weights. Release of freeDOX andCT from thesematerials was initiated by exposure to 365 nm light.
All of the CT andDOX polymers were at least 10-fold more toxic to human cancer cells after photoinitiated
drug release while a copolymer carrying both CT and DOX displayed 30-fold increased toxicity upon irra-
diation.Graft-throughROMPof drug-loadedmacromonomers provides a generalmethod for the systematic
study of structure-function relationships for stimuli-responsive polymers in biological systems.
Introduction
Recent advances in catalysis and polymer synthesis have
allowed the preparation of new materials with unprecedented
functional and structural diversity and blurred the line between
small-molecule and polymer synthesis.1,2 Ring-opening metath-
esis polymerization (ROMP) using fast-initiating ruthenium
catalysts (e.g., 1, Figure 1) is particularly suited for the synthesis
of diverse side-chain functional polymers with controllable mo-
lecular weights (Mn) and low polydispersities (PDI).
3-6
Discrete bottle-brush polymers (brush polymers) are typically
comprised of a linear polymer backbone connected at each
monomer unit to a polymeric side chain. Brush polymers with
two polymer side-chains attached to each monomer unit of a
polymer backbone (centipede-brushes) have been reported; these
materials can possess disparate polymer domains within the same
polymer structure.7-9 Synthetic approaches to all types of brush
polymers fall into “graft-to,” “graft-from,” or “graft-through”
categories; each approach has advantages and disadvantages.10
For example, graft-to and graft-from strategies, whereby linear
polymers are coupled to the backbone of a linear polymer or are
grown from the backbone of a linear macroinitiator respectively,
are suited to most polymerization methods but suffer from
sterically limited grafting densities for even the most efficient
coupling and polymerization reactions.11-20 The alternative
graft-through approach, which involves polymerization of well-
defined monofunctional macromonomers (MMs), ensures quan-
titative grafting density but requires a polymerization method
capable of propagation under conditions of very low monomer
concentration and high steric hindrance.21-26 Thus, most brush
polymers made by graft-through approaches have significant
amounts of MM impurities due to incomplete conversion; few
examples of functional systems of high degree of polymerization
(DPn) have been reported.
27,28
Recently, our group and others have shown the utility of
ROMP using catalyst 1 for the graft-through polymerization of a
variety of norbornene-terminated MMs to yield brush homo-
and copolymers that have high DPns and low PDIs.
27-31 These
studies have set a benchmark for efficiency in brush polymer
synthesis and led us to explore the application of graft-through
ROMPto the synthesis of novel bivalent-brushpolymers (Figure 1)
with one branch comprised of a hydrophilic solubilizing polymer
and the other a drug molecule covalently attached through a
degradable linker. Brush polymers and other branched polymeric
architectures (dendrimers, hyperbranched polymers, dendro-
nized polymers, etc.) possess features, such as multivalency and
nanoscopic size, which make them attractive for in vivo drug
delivery applications.32-34 Branched structures of sufficient size
display extended in vivo circulation times in comparison to their
linear analogues-an advantageous feature for passive tumor
targeting via the enhanced permeation and retention effect
(EPR effect).35,36 Dendrimers are the most extensively studied
branched polymers in this regard; their monodisperse, globular
structures resemble those of proteins and render them attractive
for biological applications.37,38 Despite the promise of dendri-
mers, synthetic challenges limit their utility in therapeutic appli-
cations. It is difficult to prepare dendrimers larger than ∼10 nm
due to the steric hindrance which must be overcome when
functionalizing the periphery of a high-generation dendritic
structure. To overcome this limitation, the Frechet group has
appended linear poly(ethylene glycol) (PEG) chains to dendri-
mers to increase their size, water solubility, and biocompatibility
while retaining their inherentmultivalency.39-41 These “PEGylated”
dendrimers have proven remarkably effective for treatment of
cancer in mice via controlled delivery of doxorubicin (DOX)39
and camptothecin (CT).41 Though large polymers may be pre-
ferable in certain applications, several reports suggest that non-
degradable polymers for drug delivery applications must be no
larger than ∼10 nm to ensure complete renal clearance.35,42 A
synthetic approach capable of rapidly generating branched poly-
meric structures of easily variable sizes is highly desirable.
Here we introduce a new bivalent-brush polymer structure for
use in chemotherapy delivery. Figure 1 depicts a schematic of our*Corresponding authors.
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design; a water-soluble PEG side chain and a drug molecule are
attached to a polynorbornene backbone via a branch point. The
drug is attached via a degradable linker that allows controlled
release in response to an appropriate stimulus.We expect thePEG
chains to extend into solution effectively shielding the hydropho-
bic drugþ polynorbornene core; the structure resembles that of a
unimolecularmicelle.We reasoned that these bivalent-brush poly-
mers might exhibit similar drug-delivery attributes when com-
pared to PEGylated dendrimers but may be easier to synthesize,
especially over a wide range of nanoscale sizes and with greater
functional diversity, using graft-through ROMP of a PEGylated-
norbornene MM. Here we demonstrate the power of this ap-
proach for the preparation of water-soluble polynorbornene-
g-PEG brush polymers and copolymers that have DOX and CT
covalently bound near the core through a photocleavable linker.
Brief ultraviolet (UV, 365 nm) irradiation of these brush polymers
releases the respective drug molecules in unmodified form; we
demonstrate the utility of these systems for photoregulated che-
motherapy delivery in human cancer cell culture.
Materials and Methods
All reagents and solvents were purchased from Aldrich or
VWR chemical companies and were used as supplied unless
otherwise noted. Ruthenium catalyst 1,43 3-azidopropyl-1-amine
(note: caremust be takenwhenworkingwith small-molecule,<6
carbons per azide, azides. In this work, 3-azidopropyl-1-amine is
used as a ∼1 M solution in toluene and never isolated),44 and
3-(tert-butyldimethylsilyloxymethyl)-2-nitrobenzoic acid 845 were
prepared according to literature procedures. Degassed dichloro-
methane (DCM), tetrahydrofuran (THF), and dimethyl sulfoxide
(DMSO) solvents were passed through solvent purification col-
umns prior to use.46 Doxorubicin hydrochloride (DOX-HCl) was
purchased from Axxora LLC.
Gel permeation chromatography (GPC) was performed using
two I-series Mixed Bed Low MW ViscoGel columns (Viscotek)
connected in series with a DAWN EOS multiangle laser light
scattering (MALLS) detector (Wyatt Technology) and an Opti-
lab DSP differential refractometer (Wyatt Technology). Experi-
ments were performed at room temperature using 0.2 M LiBr in
N,N-dimethylformamide (DMF) eluant at a flow rate of 1 mL/
min. Molecular weights were calculated from dn/dc values that
were obtained assuming 100% mass elution from the columns.
Dynamic light scattering (DLS) measurements were made at
room temperature using a Brookhaven ZetaPALS DLS instru-
ment. Samples were dissolved in nanopure water at a concentra-
tionof∼1mg/mL.A fresh, clean, polystyrene cuvettewaswashed
with compressed air to remove dust. The sample solution was
passed through a 0.4 μm Teflon syringe filter directly into the
cuvette; the cuvettewas capped andplaced in theDLS for particle
sizing. At least three measurements were made per sample and
average hydrodynamic diameters were calculated by fitting the
DLS correlation function using the CONTIN routine (ISDA
software package from Brookhaven instruments). Nuclear mag-
netic resonance (NMR) experiments were performed on either a
Mercury 300MHz spectrometer, an INOVA500MHz spectrom-
eter, or an INOVA 600 MHz spectrometer. Varian VNMRJ
and MestReNove NMR 5.3.2 software were used to obtain and
analyze the NMR spectra, respectively. Analytical high-perfor-
mance liquid chromatography mass spectrometry (HPLC-MS
or LC-MS) data was obtained using an Agilent 1100 series
HPLC system equipped with a variable wavelength ultraviolet-
visible (UV-vis) detector andanAgilent 1100VLLC/MSDmass
spectrometer. Separation was achieved using a 9.4  50 mm
AgilentZorbaxXDB-C18 columnwithmobile phase gradients of
0.1% acetic acid in water and acetonitrile. Experiments were per-
formed at room temperature with a flow rate of 1.0mL/min. Pre-
paratory HPLC was performed on an Agilent 1100 series HPLC
system with an Agilent 1200 series automated fraction collector
and an 1100 series variable wavelength detector. Separation was
achieved using a 9.4 250 mmAgilent Eclipse XDB-C18 column
with 0.1% acetic acid in water and acetonitrile mobile phase.
Experiments were performed at room temperature with a flow
rate of 5 mL/min. High-resolution mass spectrometry data was
obtained on an Agilent 6200 series accurate-mass time-of-flight
(TOF) LC/MS. Matrix assisted laser desorption ionization mass
spectrometry (MALDI) measurements were performed by the
California Institute ofTechnologymass spectrometry facility using
a Voyager De_Pro TOF mass spectrometer (Applied Biosystems)
fitted with a 355 nm YAG laser from Blue Ion Technologies. In
a typical experiment, 1.0 mg of polymer sample was dissolved in
100 μL of THF and diluted 10-fold with the MALDI matrix,
dithranol (10 mg/mL in THF). To each sample was added 0.1 μL
of saturated NaI in ethanol and 0.35 μL of the sample-matrix
mixture was spotted on aMALDI plate for analysis. The Voyager
De_Pro was operated in linear mode with an accelerating voltage
of 20000 V, grid voltage of 95.2%, guide wire 0.03%, extraction
delay time 250 ns, acquisition mass range 800-5000 Da, and laser
rep rate 20 Hz. The instrument was calibrated externally using a
Sequazyme Mass Standard Kit supplied by Applied Biosystems.
Brush polymer purificationwas performedby centrifugal filtration
through 30 kDa molecular-weight cut off (MWCO) Amicon
Ultra-15 centrifugal filter units (Millipore Inc.). Photolysis experi-
ments were performed using a Multiple Ray Lamp (UVP) fitted
with an 8 W, longwave, filtered blacklight bulb (365 nm). Sample
Figure 1. Schematic depiction of bivalent macromonomer (MM) and bivalent-brush polymer described in this work. Mes = mesityl.
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vials were placed as close as possible to the light source and
irradiated for the desired time before analysis by LC-MS.
Norbornene-Hexanol (2). A solution of 6-amino-1-hexanol
(3.0 g, 25.6 mmol) and cis-5-norbornene-exo-2,3,-dicarboxylic
anhydride (4.0 g, 24.4 mmol) in toluene (50 mL) was added to a
dried, 150 mL round-bottom flask fitted with a Dean-Stark trap
andplaced in anoil bathpreset to 140 Cfor 24hwhile stirring.The
reactionmixturewas transferred to a silica gel columnprimedusing
10% ethyl acetate in hexanes (10% EtOAc/hexane). A 300 mL
portion of 10%EtOAc/hexanes was flushed through the column
before elution of the product using 50% EtOAc/hexanes (TLC
Rf=0.3, 50% EtOAc/hexanes, KMnO4 stain). Removal of sol-
vent by rotary evaporation yielded 6.0 g of 2 as a colorless oil
(94%). 1H NMR (300MHz, CDCl3): δ 6.00 (s, 2H), 3.26 (t, J=
6.4Hz, 2H), 3.13 (t, J=7.3, 2H), 2.93 (s, 2H), 2.38 (s, 2H), 1.31-
1.15 (m, 5H), 1.14-0.95 (m, 4H), 0.92 (t, J = 7.4 Hz, 1H). 13C
NMR (300 MHz, CDCl3): δ 177.9, 137.5, 61.8, 47.5, 44.8, 42.4,
38.3, 32.2, 27.4, 26.4, 25.0. TOF HRMS: calcd for C15H22NO3
[M þ H]þ, 264.1600; found, 264.1612.
Norbornene-aldehyde (3). A three-neck round-bottom flask
containing a stir bar was equipped with a vacuum adaptor and
two 150mL addition funnels each capped with a rubber septum.
The flask was flame-dried under vacuum, cooled to room tem-
perature, and backfilled with argon. A positive argon pressure
(using amercury bubbler) wasmaintained through the course of
the reaction. DCM (58 mL) was added to the flask via cannula
followed by oxalyl chloride (3.21mL, 37.36mmol). The solution
was cooled to -76 C using an acetone/dry ice bath. One of the
addition funnels was charged with DCM (7.3 mL) and DMSO
(5.31 mL, 74.72 mmol) while alcohol 2 (6.60 g, 24.90 mmol)
dissolved in DCM (43mL) was added to the other. The DMSO/
DCM solution was added dropwise to the flask containing
oxalyl chloride over 15 min while stirring. After the addition,
the solution was stirred for 15 min at -76 C. The solution of 2
in DCM was then added dropwise over 20 min while stirring.
The addition funnel was washed twice with 5 mL of DCM and
the reaction mixture was stirred for 30 min at -76 C. Triethy-
lamine (20.83 mL, 149.4 mmol) and DCM (3.7 mL) were com-
bined in the washed addition funnel that previously held 2 and
this solution was added dropwise over 15min to the flask during
which time a thick white precipitate formed. After the addition
the mixture was stirred for 10 min before warming to room tem-
perature and transferring to a separatory funnel. The mixture
was washed twice with 50 mL of 1 M HCl and once with brine,
dried over Na2SO4 and concentrated on a rotary evaporator.
The crude product was purified by silica gel column chroma-
tography (30%EtOAc/hexanes, TLCRf=0.25, stain with ani-
saldehyde solution) to yield 3 (5.83 g, 89%) as a colorless oil. 1H
NMR (300MHz, CDCl3): δ 9.52 (s, 1H), 6.08 (s, 2H) 3.23 (t, J=
7.3 Hz, 2H), 3.02 (s, 2H), 2.46 (s, 2H), 2.22 (td, J= 7.2, 1.4 Hz,
2H), 1.52-1.22 (m, 5H), 1.21-1.05 (m, 2H), 0.99 (d, J=9.8Hz,
1H). 13C NMR (300 MHz, CDCl3): δ 202.0, 177.7, 137.6, 47.6,
44.9, 43.3, 42.5, 38.1, 27.3, 26.2, 21.3. TOF HRMS: calcd for
C15H19NO3 [M þ H]þ, 262.1443; found, 262.1438.
Norbornene-Alkyne-Amine (4). Aldehyde 3 (1.0 g, 3.83
mmol) and propargyl amine (258 μL, 4.0 mmol) were dissolved
in methanol (10 mL) in a round-bottom flask. The mixture was
stirred at room temperature under argon atmosphere for 30min
to form an imine intermediate (reaction monitored by TOF-
LC/MS: calcd for imineC18H22N2O2 [MþH]þ, 299.1754; found,
299.1856). The reaction mixture was cooled to 0 C using an
ice bath; NaBH4 (232 mg, 6.13 mmol) was carefully added. The
ice bathwas removed and themixturewas stirred for 3minbefore
quenching with 100 mL of saturated NaHCO3(aq.). The mixture
was transferred to a separatory funnel andwashed five timeswith
DCM (100 mL). The organic fractions were combined and dried
overNa2SO4, filtered, and concentrated on a rotary evaporator.
The resulting oil was purified by silica gel chromatography (2%
MeOH/CH2Cl2, TLC Rf = 0.2, stain with ninhydrin solution)
to yield 4 as a colorless oil (836 mg, 73%). 1H NMR (300MHz,
CDCl3): δ 6.18 (s, 2H), 3.33 (t, J=7.3 Hz, 2H), 3.29 (d, J=2.4
Hz, 2H), 3.14 (s, 2H), 2.62-2.46 (m, 4H), 2.12 (t, J = 2.4 Hz,
1H), 1.53-1.30 (m, 5H), 1.30-1.14 (m, 5H), 1.10 (d, J=9.8Hz,
1H). 13C NMR (300 MHz, CDCl3): δ 177.9, 137.7, 82.2, 71.2,
48.3, 47.7, 45.0, 42.6, 38.5, 38.0, 29.5, 27.6, 26.7, 26.6. TOF
HRMS: calcd for C18H24N2O2 [M þ H]þ, 301.1911; found,
301.1951.
Norbornene-Acid-Alkyne (5). Succinic anhydride (134 mg,
1.34 mmol) was combined with amine 4 (382 mg, 1.28 mmol) in
DCM (13 mL) and the resulting solution was stirred for 1 h at
room temperature before transferring to a silica gel column.
Elution with 60% EtOAc/hexanes (TLC Rf = 0.2, stain with
bromocresol green solution) gave the purified acid 5 (364 mg,
71%) as a mixture of amide rotamers after concentration on a
rotary evaporator. 1HNMR (300MHz, CDCl3): δ 9.25 (b, 1H),
6.24 (s, 2H), 4.15 (d, J = 2.4 Hz, 1.2H), 4.01 (d, J = 2.3 Hz,
0.8H), 3.50-3.31 (m, 4H), 3.22 (s, 2H), 2.82-2.50 (m, 6H), 2.29
(t, J= 2.3 Hz, 0.3H), 2.17 (t, J= 2.5 Hz, 0.7H), 1.68-1.40 (m,
5H), 1.39-1.21 (m, 5H), 1.16 (d, J = 9.8 Hz, 1H). 13C NMR
(300 MHz, CDCl3): δ 178.2, 177.0, 171.6, 171.1, 137.8, 78.9,
78.4, 72.8, 71.8, 47.8, 47.1, 46.6, 45.1, 42.7, 38.5, 38.4, 37.5, 34.6,
29.4, 29.3, 28.1, 28.0, 27.9, 27.5, 27.2, 26.5, 26.2. TOF HRMS:
calcd for C22H27N2O5 [M - H]-, 399.1920; found, 399.1941.
Norbornene-Alkyne-N-Hydroxysuccinimidyl (NHS)-Ester
(6). DCM (10 mL) was added to a flask containing N-(3-
(dimethylamino)propyl)-N0-ethylcarbodiimide hydrochloride
(EDCI, 262 mg, 1.36 mmol), N-hydroxysuccinimide (157 mg,
1.36 mmol), 4-(dimethylamino)pyridine (DMAP, 11.1 mg, 0.091
mmol), and 5 (364 mg, 0.91 mmol). The resulting solution was
stirred under argon at room temperature for 20 h. The mixture
was transferred to a silica gel column. Elution with 70% EtOAc/
hexanes (TLC Rf= 0.2, stain with anisaldehyde solution and/or
visualize under UV light) gave norbornene 6 (339 mg, 75%) after
concentration on a rotary evaporator. 1H NMR (300 MHz,
CDCl3): δ 6.23 (s, 2H), 4.16 (d, J = 2.4 Hz, 1.2 H), 3.98 (d,
J= 2.2 Hz, 0.8 H), 3.49-3.26 (m, 4H), 6.23 (s, 2H), 2.95 (t, J=
6.9 Hz, 2H), 2.79 (s, 4H), 2.70 (t, J= 6.9 Hz, 2H), 2.62 (s, 2H),
2.29 (t, J= 2.4 Hz, 0.3H), 2.17 (t, J= 2.5 Hz, 0.7H), 1.68-1.40
(m, 5H), 1.39-1.20 (m, 5H). 13C NMR (300 MHz, CDCl3): δ
178.0, 169.6, 169.3, 169.0, 168.4, 137.8, 78.9, 78.4, 77.5, 76.7, 72.9,
71.8, 47.7, 46.9, 46.6, 45.1, 42.7, 38.5, 38.3, 37.4, 34.4, 28.1, 28.0,
27.8, 27.6, 27.5, 27.3, 26.5, 26.2, 25.6. TOF HRMS: calcd for
C26H32N3O7 [M þ H]þ, 498.2241; found, 498.2203.
Norbornene-Alkyne-PEG(3000) Macromonomer (7). O-(2-
Aminoethyl)poly(ethylene glycol) (100 mg, 33.3 μmol) and 6
(17.4 mg, 35 μmol) were dissolved in anhydrous DMF (1 mL)
and the resulting solution was stirred at room temperature for
4 h. The reaction mixture was added dropwise to diethyl ether
(20 mL) to precipitate 7 as a white solid which was collected by
centrifugation and decanting of the ether before redissolving in
DCM (1 mL). This process of precipitation, centrifugation, and
redissolving was repeated five times. On the fifth iteration, the
precipitate was dried under vacuum to afford macromonomer
7 as a white powder (78.1 mg, 69%). GPC (0.2MLiBr in DMF)
3300Da, PDI 1.10.MALDImass spectrumandNMRare shown
in the Supporting Information (Figures S1-S3).
N-(3-Azidopropyl)-3-(tert-butyldimethylsilyloxymethyl)-2-ni-
trobenzamide (9). EDC (92.4 mg, 0.48 mmol) was added to a
suspension of acid 8 (100 mg, 0.32 mmol) and DMAP (3.9 mg,
0.032 mmol) in DCM (4.0 mL). The suspension became a clear
solution within 2 min indicating formation of a soluble acyli-
sourea intermediate. At this time, 3-azidopropyl-1-amine (1.0M
in toluene, 482 μL, 0.48 mmol) was added dropwise to the reac-
tion mixture. The resulting solution was stirred overnight at
room temperature under an argon atmosphere. The reaction
mixture was diluted with 100mLEtOAc andwashed three times
with 1.0MHCl (50mL), three times with sat. NaHCO3 (50mL),
and once with brine (50 mL). The organic layer was then dried
over MgSO4, filtered, and concentrated on a rotary evaporator.
The resulting white solid was passed through a silica plug using
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50%EtOAc/hexanes and evaporated todryness to give 9 (101mg,
80%) as a white crystalline solid (128 mg, 80%). 1H NMR (300
MHz,CDCl3):δ7.75 (d, J=6.4Hz, 1H), 7.52 (t, J=7.7Hz, 1H),
7.41 (d, J=6.2Hz, 1H), 6.46 (b, 1H), 4.78 (s, 2H), 3.65-3.15 (m,
4H), 1.84 (p, J=6.6Hz, 2H), 0.92 (s, 9H), 0.09 (s, 6H). 13CNMR
(300 MHz, CDCl3): δ 165.8, 146.4, 135.4, 131.2, 130.7, 129.9,
126.5, 60.8, 49.3, 37.8, 28.4, 25.0, 18.3, 5.6. TOFHRMS: calcd for
C17H28N5O4Si [M þ H]þ, 394.1911; found, 394.1900.
N-(3-Azidopropyl)-3-(hydroxymethyl)-2-nitrobenzamide (10).
Compound 9 (101 mg, 0.26 mmol) was dissolved in tetrahydro-
furan (3 mL) in a round-bottom flask which was subsequently
cooled to 0 C. Tetrabutylammonium fluoride (1.0 M in THF,
0.385 mL, 0.39 mmol) was added dropwise and the mixture was
stirred for 15min. The solutionwas diluted with EtOAc (50mL)
and washed three times with 1.0 M HCl (25 mL) and once with
brine (50mL). The organic layer was dried overMgSO4, filtered,
and passed through a silica plug to give pure 10 (56 mg, 78%) as
a white solid. 1HNMR (300MHz, acetone): δ 7.98 (b, 1H), 7.82
(d, J=4.6 Hz, 1H), 7.69-7.56 (m, 2H), 4.71 (s, 2H), 3.63-3.28
(m, 4H), 1.88 (p, J=6.8Hz, 2H). 13CNMR(300MHz, acetone):
δ 205.4, 165.2, 135.3, 130.8, 130.1, 126.9, 59.4, 48.8, 36.9. TOF
HRMS: calcd for C11H13N5O4 [M þ H]þ, 280.1046; found,
280.1067.
CT-NBOC-N3. The following reaction (see Scheme 2) was
a modified literature procedure for the preparation of 20-
O-acylcamptothecins.47 (S)-(þ)-Camptothecin (CT, 62.7 mg,
0.18 mmol) and DMAP (70.1 mg, 0.57 mmol) were suspended
inDCM(5mL) under argon atmosphere. Triphosgene (19.6mg,
0.066mmol) was added and themixturewas stirred for 30min at
room temperature. Alcohol 10 (55.2 mg, 0.2 mmol, in 2 mL
THF) was added dropwise via a rubber septum using a gastight
syringe. The reaction was stirred overnight during which time
a white precipitate formed. The reaction mixture was diluted
with EtOAc (100 mL) and washed once with water (50 mL),
twice with 1.0MHCl (25mL), and once with brine (50mL). The
organic layer was dried over MgSO4, filtered, and concentrated
on a rotary evaporator. The solid residue was purified by col-
umn chromatography (100% EtOAc, TLC Rf = 0.2, visualize
under UV light) to give CT-NBOC-N3 as a white solid (106 mg,
90%). 1H NMR (600MHz, CDCl3): δ 8.41 (s, 1H), 8.26 (d, J=
8.6Hz, 1H), 7.95 (d, J=7.8Hz, 1H), 7.86 (ddd, J=8.4, 6.9, 1.4
Hz, 1H), 7.72-7.68 (m, 2H), 7.56 (t, J= 7.7 Hz, 1H), 7.43 (dd,
J=7.6, 1.3 Hz, 1H), 7.34 (s, 1H), 6.33 (t, J=5.8 Hz, 1H), 5.59
(d, J= 17.1 Hz, 1H), 5.34 (d, J= 17.1 Hz, 1H), 5.32-5.19 (m,
4H), 3.46 (q, J=6.5 Hz, 2H), 3.42 (t, J=6.5 Hz, 2H), 2.27 (dt,
J= 14.9, 7.5 Hz, 1H), 2.21-2.11 (m, 1H), 1.85 (p, J= 6.5 Hz,
2H), 1.01 (t, J= 7.5 Hz, 3H). 13C NMR (300 MHz, CDCl3): δ
167.1, 165.5, 157.2, 153.0, 151.9, 148.5, 146.9, 146.3, 145.4,
131.9, 131.8, 131.5, 131.0, 130.4, 129.5, 129.3, 128.5, 128.3,
128.2,128.1, 120.3, 96.1, 78.5, 67.0, 65.3, 50.0, 49.2, 45.0, 37.8,
31.8, 28.4, 7.6; TOF HRMS: calcd for C32H28N7O9 [M þ H]þ,
654.1949; found, 654.2010.
DOX-NBOC-N3. A suspension of 10 (45 mg, 0.16 mmol) in
THF (2 mL) and triethylamine (25 μL, 0.18 mmol) was treated
with 4-nitrophenyl chloroformate (35mg, 0.18mmol). TLC and
1HNMR confirmed complete conversion to carbonate 11 with-
in 15 min. The reaction mixture was transferred to a short silica
gel column and eluted with 70% EtOAc. UV active fractions
with Rf=0.4 were combined and dried on a rotary evaporator.
The resulting white solid, 11 (40 mg, 90 μmol), was immediately
Scheme 1. Synthesis of PEG-Norbornene-Alkyne Macromoner 7
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dissolved in anhydrous DMF (1 mL). DOX-HCl (53 mg,
91 μmol) and anhydrous N,N-diisopropylethylamine (DIPEA,
17 μL, 99 μmol) were added and the resulting solution was stirred
overnight at room temperature. The reaction mixture was diluted
with 50 mL EtOAc and washed twice with 0.1 M HCl (20 mL),
oncewithH2O (20mL), andoncewith brine (20mL) before drying
over magnesium sulfate, filtration, and concentration on a rotary
evaporator. The resulting red solid was purified by column chro-
matography. The columnwas eluted firstwith 3%MeOH/CH2Cl2
and then with 5% MeOH/CH2Cl2 to give DOX-NBOC-N3 as a
red solid (73mg, 95%). 1HNMR(600MHz,DMSO-d6): δ 8.77 (t,
J=5.6Hz, 1H), 7.96-7.87 (m, 2H), 7.67-7.61 (m, 3H), 7.57 (dd,
J=6.9, 2.1Hz, 1H), 7.00 (d, J=8.0Hz, 1H), 5.42 (s, 1H), 5.20 (s,
1H), 5.01 (dd, J=37.8, 13.7Hz, 2H), 4.92 (m, 1H), 4.81 (t, J=6.0
Hz, 1H), 4.69 (d, J = 5.7 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H),
4.14-4.09 (m, 1H), 3.98 (s, 3H), 3.71-3.60 (m, 1H), 3.42-3.39 (m,
1H), 3.38-3.35 (m, 2H), 3.24-3.19 (m, 2H), 2.96 (q, J=18.3Hz,
2H), 2.12 (dt, J= 14.5, 9.0 Hz, 2H), 1.83 (dd, J= 12.8, 9.2 Hz,
1H), 1.69 (p, J=6.7Hz, 2H), 1.09 (d, J=6.5Hz, 4H). 13CNMR
(500 MHz, CD2Cl2): δ 213.1, 186.1, 164.5, 160.4, 155.3, 154.7,
154.0, 146.7, 135.0, 134.6, 132.8, 132.7, 130.6, 130.5, 130.4, 130.1,
126.7, 120.0, 118.7, 117.9, 110.8, 110.7, 99.8, 75.9, 68.7, 68.6,
66.6, 64.7, 61.2, 55.8, 48.6, 46.4, 37.0, 34.8, 33.2, 28.9, 27.7, 15.8.
TOFHRMS: calcd for C39H40N6O16 [M-H]-, 847.2423; found,
847.2418.
General Macromonomer Synthesis by Copper-Catalyzed Azi-
de-Alkyne Cycloaddition (CuAAC) Click Chemistry. Drug
azide,CT-NBOC-N3 orDOX-NBOC-N3, (1.01 equiv to alkyne)
was combined with norbornene-PEG-alkyne 7 (100 mg,
29.4 μmol) in a 2 mL HPLC vial and THF (0.5 mL) was added.
A spatula tip of sodium ascorbate was added followed by a 1.0 M
solution of CuSO4 in H2O (88 μL, 3 equiv to alkyne). The mixture
was flushed with argon, sealed with a septum, and stirred until
completion (as monitored by LC-MS) which was typically ∼1 h.
After the required time, the drug-loaded macromonomer was
purifiedbypreparativeHPLC(linear gradientof 95:5water-0.1%
AcOH:MeCN to 5:95 water-0.1%AcOH-MeCN over 12 min).
The fractions containing pure MM were combined and concen-
trated on a rotary evaporator. The resulting residue was dissolved
in DCM, dried over Na2SO4, filtered, and dried under vacuum
to give pure macromonomer CT-MM or DOX-MM (typical
yield∼75mg,∼70%).MALDI and 1HNMRspectra are shown
Scheme 2. Synthesis of Clickable, Photocleavable Drugs CT-NBOC-N3 and DOX-NBOC-N3
Scheme 3. Click Coupling of 7 to Photocleavable Drug Derivatives
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in the Supporting Information (Figures S4-S7). The synthesis is
depiced in Scheme 3.
General ROMP Polymerization.MacromonomerDOX-MM
orCT-MM (20 mg,∼5 μmol), or a combination of the two, was
added to a 2 mL vial containing a stir bar. The vial was capped
with a septum and placed under vacuum for 5min and then pur-
ged with argon. DCM was added followed by a freshly prepared
solution of catalyst 1 in DCM (1 mg 1/mL DCM, amount added
to give the desired MM:1) such that the total concentration of
MM was 0.05 M. The mixture was stirred at room tempera-
ture under argon for 90 min after which time the reaction became
noticeably viscous. One drop of ethyl vinyl ether was added to
quench the polymerization and the vial was placed under vacuum
to remove volatiles. The resulting polymer film was dissolved in
deionized water (15 mL) and transferred to a centrifugal filter
tube (30 kDa MWCO). The tube was spun at 4000 rpm until
all of the solvent had passed through the filter except for∼1 mL
(typically ∼45 min). More water was added (14 mL) and this
processwas repeated at least 5 times to remove any remainingMM.
After the last centrifugation, the 1mL solution of brush polymer in
water was transferred to a weighed glass vial and lyophilized to
dryness. Typical yields after purification were ∼15 mg (75%).
Representative 1H NMR spectra are shown in the Supporting
Information (Figures S8 and S9).
LC-MS Methods. Two methods were used for analytical
LC-MS experiments; acetonitrile (MeCN) percentage was varied.
MethodAwas a linear gradient of 5%MeCN to 95%MeCNover
5min followed by a 2min hold at 95%MeCN to flush the column.
MethodBbeganat5%MeCNandran to70%MeCNlinearlyover
5min followedbya2min flush at 95%MeCN.MethodAwasused
for the DOX loaded polymers (pDOX02 and the copolymer) and
method B for pCT03. The concentration of CT and/or DOX in
photolyzed samples was estimated from freeCT andDOX calibra-
tion curves, respectively. The calibration curves were generated as
follows. A 1mMsolution ofCT inDMSOwas serially dilutedwith
DMSO to generate 100 μM, 10 μM, and 1 μM solutions. In a
similar fashion, a 1mM solution ofDOX-HCl inwater was serially
diluted with water to generate solutions of known concentration.
Each of these samples was analyzed by LC-MS with wavelength
detection set at 368 and 500 nm for CT and DOX respectively.
Method A was used in both cases. The area under the absorbance
curve for each run was calculated and plotted against the concen-
trationofdrug (Supporting Information,FigureS10).Linear fitting
of the resulting calibration curve gave an extinction coefficient that
was used to estimate the concentration of drug released in photo-
lysis experiments.
Cell Culture. Human breast cancer cell line MCF-7 (ATCC,
HTB-22) was cultured at 37 C under a humidified atmosphere
of 5% CO2. The cells were grown in Eagle’s minimum essential
medium (EMEM, ATCC, 30-2003) supplemented with 10%
fetal bovine serum (Gibco, 10437028), 1% antibiotics (100U/mL
penicillin and 100 μg/mL streptomycin, Gibco, 105140122), and
10 μg/mL bovine insulin (Sigma, I0516). The cells were continu-
ously maintained in the culture medium and subcultured every
3-4 days.
Drug Treatment and Cell Viability Assay. MCF-7 cells were
seeded at 10,000 cells/well in a 96-well plate and allowed to
attach for 20 h before drug treatment. Prior to drug exposure,
the culturemediumwas removed and the cells were washed once
with warm phosphate-buffered saline (PBS). Then, fresh media
with drug concentrations ranging from 0 to 100 μM (based on
dry weight of polymer dissolved in H2O) were added to the ap-
propriate wells. After recovering for 10 min at 37 C, one plate
of cells was submitted to UV light (Multiple Ray Lamp with
filtered blacklight bulb, 365 nm) for 10minwhile the control plate
was kept in the dark. The cells were subsequently incubated in a
cell culture incubator for 24 h. Themediumwas removed and the
cells were washed twice with warm PBS before fresh drug-free
medium was added to each well. The cells were incubated for
another 24 h before analysis by the MTT cell proliferation assay
(ATCC, 30-1010K).CellswerewashedoncewithwarmPBSand
incubated with fresh medium containing MTT reagent for 3 h at
37 C. Detergent was added to solubilize the purple formazan
crystals formed by proliferating cells. Absorbance at 570 nm was
measured on a Safire II (Tecan) plate reader. Data were fit to a
sigmoidal function to determine the half-maximum inhibitory
concentration (IC50).
Results and Discussion
Synthesis of Norbornene-PEG-Alkyne MM. Graft-
through ROMP reduces the problem of brush polymer
synthesis to design of an appropriate, strained alkene MM;
a bivalent-brush is derived from a bivalent norbornene MM
(Figure 1). Using a branched MM avoids the need for copo-
lymerization of two different monomers, one PEG-MM
and one drug-loaded monomer; a high drug loading is main-
tained and issues arising from different propagation rates be-
tweenMMand small-molecule monomers are negated. Toward
this end, we prepared norbornene-imide derivative 6 (Schemes 1
and 4) which carries two orthogonally addressable functional
groups, anN-hydroxysuccinimidyl (NHS) ester and an alkyne.
Scheme 4. Synthesis and Structure of Poly(norbornene)-PEG Brush Polymers with DOX or CT Attached via a Photocleavable NBOC Linker.
Pyr = pyridine.
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The NHS-ester of 6 was efficiently coupled to water-soluble
PEG-NH2 (Mn = 3 kDa) to give PEG-MM 7 (Figure 2).
We independently prepared DOX- and CT- nitrobenzyloxy-
carbonyl-azide analogues (DOX-NBOC-N3 and CT-NBOC-
N3, Scheme 2 and Figure 2) that allow for drug attachment via
copper-catalyzed azide-alkyne cycloaddition (CuAAC) click
chemistry48-50 and controlled drug release in response to long
wavelength UV irradiation (∼365 nm). CuAAC coupling of 7
to either drug-azide proceeded in high yield to give the desired
drug-loaded PEG-MMs (DOX-MM and CT-MM). The
MALDI spectra of CT-MM and its alkyne precursor 7
confirmed the expected mass increase after CuAAC coupling
(Figure 2).
ROMP of Drug-Loaded, PEGylated MMs. Treatment of
either MM with 1 in methylene chloride (DCM) for 90 min
under N2 yielded polymers (pDOX and pCT) with low PDIs
and Mn dependent on the ratio of MM to 1 (Table 1). The
pDOX brushes were characterized by PDIs on the order
of 1.1 as previously reported for graft-through ROMP poly-
merizations using catalyst 1.27,28 The PDI values for pCT
samples were low for DPn below ∼30 but higher at high
DPn and the overall attainable DPn was limited to∼150. For
in vivo delivery of nondegradable polymers, hydrodynamic
radii of <5-10 nm are often desirable;35,42 graft-through
ROMP of either MM is highly controlled within this size
domain (Table 1). For the higher DPn CT-MM polymeriza-
tions, we hypothesize that the presence of potential chelating
moieties (quinoline and pyrrole) in CT may interfere with
catalyst initiation and propagation especially at high DPn.
Nevertheless, the success of the graft-through ROMP poly-
merizations forbothMMsattests to the remarkable functional-
group tolerance of catalyst 1. Figure 2 shows gel-permeation
chromatography (GPC) traces of brush polymer samples
pCT03andpDOX02withoutpurification, confirmingamono-
modal MW distribution and a very high conversion (>95%).
All of the polymer samples were highly soluble in water (>100
mg/mL); trace MM was removed by passage of an aqueous
solution of polymer through a 30 kDa cutoff centrifuge filter
to give pure brush polymer (Figure 3, red trace). The purified
samples were lyophilized to dryness and redissolved in water
prior to subsequent experiments.
As demonstrated above, graft-through ROMP allows
for rapid access to brush polymers of controlled, variable
molecularweights.We envisioned thismethodology also being
useful for preparing multiple-drug-loaded brush polymers via
copolymerization of appropriate MMs. For example, treat-
ment of equimolar mixtures of DOX-MM and CT-MM with
catalyst 1 in DCM yielded copolymer pDOX50-pCT50 which
exhibited a narrow, monomodal MW distribution (Table 1,
Figure 3). Combination of a variety of therapeutic moieties
within the same polymer system and controlled release using
external, and perhaps different, stimuli will enable study and
discovery of synergistic drug effects and design of synchro-
nized drug releasing systems.
UV Photolysis Experiments. To demonstrate controlled
release of DOX and CT from these brush polymer scaffolds in
response to 365 nmUV light we irradiated aqueous solutions of
the polymers for various times from 30 s to 10 min and moni-
tored the progress of photorelease by high-performance liquid
chromatography connected in series to a single wavelength UV
detector and an electrospray mass spectrometer (LC-MS).
The resulting chromatograms for brush polymer pDOX02
(∼1.1 μMof boundDOX in H2O) before and after irradiation
are shown in Figure 4a. With increasing irradiation time, the
polymer absorbance at 500 nm is diminished and a new peak is
observed at∼3.1 min; the mass of the species giving rise to this
new peak is 542.30Dawhich corresponds to that of freeDOX-
Hþ. The yield for photocleavage in this time was∼50% based
on integration of the polymer and free DOX peaks.
Figure 2. MALDI spectra for PEG-norbornene 7 before (black trace)
and after (red trace) CuAAC click coupling of CT-NBOC-N3 to give
CT-MM. The observed mass shift of 653 Da agrees with the calculated
mass of CT-NBOC-N3 and confirms successful attachment of the
photocleavable drug moiety.
Table 1. GPC Characterization of pDOX and pCT Brush Polymer
Samples and Random Copolymer pDOX50-pCT50
sample MM:1a DPn
b Mn (GPC, kDa) PDI Dh
c
pDOX01 10 9 33.7 1.07 6.2 (0.5)
pDOX02 50 58 227 1.05 12 (2)
pDOX03 100 96 352 1.04 15 (2)
pCT01 15 15 55.4 1.09 7.1 (0.5)
pCT02 25 30 111 1.17 8.7 (0.9)
pCT03 100 75 276 1.38 n.d.e
pCT04 150 107 394 1.61 n.d.
pCT05 200 135 499 1.70 n.d.
pDOX50-pCT50
d 100 101 393 1.13 15 (1)
aRatio of MM to catalyst (i.e., theoretical DPn).
bDPn observed
derived fromMn(GPC)/Mn(MM).
cHydrodynamic diameter measured
by dynamic light scattering (DLS) using the CONTIN fitting algorithm.
Reported values are the average of three experiments with error shown
in parentheses. d pDOX50-pCT50 carries approximately 50 DOX and
50 CT based on MM stoichiometry prior to ROMP. eDh values not
determined for these samples due to high polydispersity.
Figure 3. Representative GPC traces for brush polymer samples. Black
and red chromatograms correspond to crudeROMP reactionmixtures.
The brush polymers display narrowly dispersed, monomodal molecular
weight distributions. The GPC trace for purified pDOX02 is shown in
orange, indicating that it is possible to remove trace MM impurity.
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Similar data for pCT03 (∼2.6 μM bound CT in H2O) are
shown inFigure 4b.After 10min irradiationweobserved∼64%
release of free CT along with two minor peaks labeled “/” in
Figure 4b.CT is a common target for drug delivery because it
is highly active against cancer cells but insoluble and un-
stable in neutral, aqueous solution.47 We believe that these
two peaks may represent degradation products of CT that
result from hydrolysis (open lactone form) or photochemical
degradation; however we have been unable to generate the
same chromatogram by simply photolyzing free CT in solu-
tion due to its insolubility andwe did not observe amolecular
ion in the LC-MS that corresponds to the mass of the open
lactone form (the major peak at ∼4.1 min corresponds to
the therapeutically active lactone form ofCT). These experi-
ments show that the pCT brush polymers effectively solubi-
lize their CT payload and allow for drug release even in
aqueous solution where the CT cargo is insoluble.
We recorded theUV-vis absorption spectra for pDOX01,
pCT01, and pDOX50-pCT50 in water to verify that CT and
DOX were present (Figure 5a). The spectra of pCT01 and
pDOX01 display broad absorption bands at wavelengths
above 300 nm that result from bound CT or DOX, respec-
tively. The spectrum of the copolymer shows both bands.
This information, along with the monomodal GPC trace
(Figure 3) and photolysis data (Figure 5b) suggests that
copolymer pDOX50-pCT50 does indeed carry both drug
molecules bound to the same polymer chain (rather than a
mixture of two homopolymers which would likely result in
broadening of the GPC trace). LC-MS traces for the copoly-
mer (∼1.5 μM in H2O) both before and after irradiation are
shown in Figure 5b. Absorptionwasmonitored at twowave-
lengths, 368 and 500 nm, to detect CT and DOX respectively.
As expected, UV irradiation induced release of both drugs
from the copolymer; to our knowledge, this is the first example
of a polymer system capable of releasing two covalently bound
anticancer drugs (DOX and CT) in response to a controlled
external stimulus. A recent report by Shen and co-workers
suggests thatmaterials capable of releasing bothDOX andCT
will display synergistic cytotoxicity when compared to either
drug alone.51
Cell Culture Studies. To confirm that these drug-bound,
PEG-based brush polymers were inherently nontoxic, and
that photoinitiated drug release did indeed yield sufficient
amounts of chemotherapeutic agent to kill cancer cells, we
performed cell viability experiments using MCF-7 human
breast cancer cells. Cells were treated with aqueous solutions
of either free drug or the corresponding drug-loaded brush
polymer at various concentrations and irradiated for 10 min
using 365 nm light or kept in the dark. The cells were then
incubated in the dark for 24 h, washed twice, and incubated for
another 24h in fresh, drug-free growthmedium.After this time,
cell viability was assessed using the MTT assay (see Methods
and Materials for details). Representative data are shown in
Figure 6a-c. In parts a and b of Figure 6, both free CT and
DOX controls, with and without UV irradiation, gave simi-
lar dose-response curves with IC50 values of ∼1.2 μM and
∼4.9μM, respectively. These data suggest thatUV irradiation
at 365 nm for 10 min is not by itself toxic to the cells nor is it
detrimental to the drug toxicity. On the other hand, polymer
samples pCT01 and pDOX02 without UV irradiation were
nontoxic to cells at concentrations greater than 10 times
those of the free drugs (39μMand105μM, respectively) indi-
cating that the PEG brush polymers effectively shield the
toxic effects of CT and DOX prior to drug release. We were
pleased to find that irradiation of the drug-bound polymers
led to greatly increased cytotoxicity (IC50=2.2 μM and
8.7 μM for pCT01 and pDOX02, respectively) compared
to the nonirradiated samples suggesting that photoreleased
Figure 4. HPLC-MS traces of aqueous brush polymer solutions be-
fore and after 365 nm UV irradiation for various times. pDOX02 and
pCT03 yield free DOX and CT, respectively. LC-MS method A (see
Methods and Materials) was used for pDOX02 while method B was
used for pCT03. Inset mass spectra, obtained from the free DOX and
CT peaks, show strong signals at m:z ratios that correspond to the
molecular ions of DOX and CT.
Figure 5. (A) UV-vis absorption of pDOX01, pCT01, and copolymer pDOX50-pCT50. (B) HPLC traces of an aqueous solution of pDOX50-pCT50
before and after 365 nm UV irradiation for 10 min.
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CT and DOX were therapeutically effective. Figure 6c com-
pares the toxicity of copolymer pDOX50-pCT50 with a 1:1
mixture of pDOX02 and pCT01 before and after irradiation.
The copolymer was nontoxic prior to irradiation at concen-
trations less than 100 μMwhereas the mixture of both poly-
mers appeared to be toxic at lower concentration (29 μM).
UV induced drug release, however, led to a similar IC50 for
both systems (3.2 μM for pDOX50-pCT50 and 2.2 μM for
the mixture). Figure 6d shows the therapeutic factors (X )
for these materials: a measure of the increase in cytotox-
icity after photoinduced drug release. All of the polymers
studied showed at least a 12X increase in toxicity upon drug
release; these results are encouraging and suggest the utility
of these brush polymer systems for in vivo drug delivery
applications.
Conclusions
To our knowledge, this report is the first example of simul-
taneous photoregulated release of DOX and CT and the first
example of bivalent-brush polymers capable of controlled
release of anticancer drugs (for other examples of photorelease
of anticancer drugs see refs 52-54). The graft-through approach
ensures that the weight percentage of drug loaded onto the brush
polymers is the same as the weight percentage of drug on theMM
(because of 100% grafting density) and is independent of DPn
and conversion. Thus, pCT and pDOX polymers carry 8.5% CT
and 12.6% DOX by weight, respectively. These values could
be increased by shortening the length of the PEG side chain
prior to ROMP or designing an MM linked to more than one
drug molecule. The synthesis of these materials was facilitated
by the graft-through ROMP paradigm and we expect this ap-
proach to prove useful for the synthesis of a range of other func-
tional multivalent-brush polymer systems. We are also develop-
ing clickable linkers with alternate drug release mechanisms; one
limitation of this system is the requirement forUV light to initiate
drug release. Though long-wavelength UV (UVA) is used for
photochemotherapeutic treatment of various cancers and skin
disorders,55-61 there is need for new photocleavable groups with
longer absorption wavelengths and high two-photon cross sec-
tions to increase tissue penetration.62,63 The modularity of this
system combinedwith the versatility of graft-throughROMPwill
enable incorporation of new cleavable linkers into bivalent-brush
polymers.
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ABSTRACT: Described herein is the efficient synthesis and evaluation of bioactive arginine-glycine-aspartic acid (RGD)
functionalized polynorbornene-based materials for cell adhesion and spreading. Polynorbornenes containing either linear or
cyclic RGD peptides were synthesized by ring-opening metathesis polymerization (ROMP) using the well-defined ruthenium
initiator [(H2IMes)(pyr)2(Cl)2RuCHPh]. The random copolymerization of three separate norbornene monomers allowed for
the incorporation of water-soluble polyethylene glycol (PEG) moieties, RGD cell recognition motifs, and primary amines for
postpolymerization cross-linking. Following polymer synthesis, thin-film hydrogels were formed by cross-linking with
bis(sulfosuccinimidyl) suberate (BS3), and the ability of these materials to support human umbilical vein endothelial cell
(HUVEC) adhesion and spreading was evaluated and quantified. When compared to control polymers containing either no
peptide or a scrambled RDG peptide, polymers with linear or cyclic RGD at varying concentrations displayed excellent cell
adhesive properties in both serum-supplemented and serum-free media. Polymers with cyclic RGD side chains maintained cell
adhesion and exhibited comparable integrin binding at a 100-fold lower concentration than those carrying linear RGD peptides.
The precise control of monomer incorporation enabled by ROMP allows for quantification of the impact of RGD structure and
concentration on cell adhesion and spreading. The results presented here will serve to guide future efforts for the design of RGD
functionalized materials with applications in surgery, tissue engineering, and regenerative medicine.
■ INTRODUCTION
Synthetic polymers are important as materials for biomedical
applications including uses in implants, tissue engineering, and
regenerative medicine.1−3 Many of these materials have the
desired mechanical properties, stability, and elasticity, while
remaining nontoxic. Nevertheless, inadequate in vivo inter-
action remains a problem, often leading to foreign body
responses that prevent the clinical use of these materials.1 Cell
adhesion, migration, and intracellular signaling in vivo are
mediated by integrins, a class of heterodimeric transmembrane
receptors that bind extracellular matrix proteins such as
fibronectin.4 One approach to promote biological recognition
of synthetic materials is the incorporation of cell adhesive
proteins or peptides, thereby promoting cell recognition via
interactions with integrins.1−4
The use of small peptides has significant benefits relative to
coating synthetic surfaces with matrix proteins such as
fibronectin, which suffer from susceptibility to enzymatic
degradation, immunogenicity, and high cost.1−3 The arginine-
glycine-aspartic (RGD) sequence is the minimal binding
domain of fibronectin necessary to recognize cell surface
integrins,5−7 and materials modified with RGD peptides have
been shown to facilitate cell adhesion, spreading, and wound
healing via enhanced rates of migration of individual cells.8−10
In a similar fashion, materials formed from cross-linked artificial
extracellular matrix proteins presenting the RGD sequence
promote cell spreading and adhesion in a manner that can be
modulated by varying the density of the RGD ligand.11−14
Significant work has been reported regarding the interaction
of structurally varied RGD peptides with αvβ3 and α5β1 integrin
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receptors due to their central roles in homeostasis and
disease.15−17 In particular, cyclic RGD peptides have been
shown to exhibit improved affinity, receptor selectivity, and
enzymatic stability relative to linear peptides.18−21 Kessler and
co-workers have developed a class of cyclic RGD peptides that
have been reported to demonstrate subnanomolar affinity for
the αvβ3 receptor and low nanomolar affinity for the α5β1
receptor.16,22,23 The functionalization of surfaces with
cyclo(RGDfK) peptides was found to stimulate osteoblast
adhesion and proliferation, while the soluble peptide
cyclo(RGDf(NMe)V) is currently in phase III trials for
treatment of glioblastoma.22,23 Few efficient methods for the
incorporation of cyclic RGD peptides in synthetic materials
have been described with applications for promoting cell
adhesion and spreading.1,23
Synthetic polymers covalently modified with RGD peptides
can be formed by blending, copolymerization, or postpolyme-
rization modification, methods that do not ensure maximal
incorporation of the bioactive peptide and often provide little
control over polymer molecular weights.1,24 Ring-opening
metathesis polymerization (ROMP) is an ideal method for
polymer synthesis because of its high functional group
tolerance, excellent control of molecular weight, and ability to
provide narrow PDIs.25−27 Notably, ROMP polymers contain-
ing polynorbornene backbones have been demonstrated to be
nontoxic in a variety of systems including mammalian cell
lines.25,28−30 Methods for the postpolymerization modification
of ROMP polymers with cyclo(RGDfK) have recently been
described with applications for tumor imaging.31,32 Seminal
studies reported ROMP of norbornene monomers covalently
modified with bioactive peptides, including the RGD motif, for
the synthesis of oligomers as multivalent ligands for inhibition
of cell adhesion.33−35 These early studies examined only soluble
materials and employed a linear variant of the RGD peptide.
Since these initial reports, significant improvements in
ruthenium-based catalysts for ROMP have been reported
allowing for rapid initiation at room temperature and greater
catalyst lifetimes. These improved catalysts provide increased
stability to the polar functional groups found in peptides, and
therefore, they give longer polymer chains, uniform incorpo-
ration of peptides, and low polydispersity indices (PDIs) with
monomodal distributions.36,37
We sought to efficiently access a new class of RGD-
functionalized materials that are amenable to postpolymeriza-
tion cross-linking and that exhibit cell adhesive properties. To
this end, we synthesized linear and cyclic RGD conjugated
norbornenes that were copolymerized using ROMP. This work
constitutes the first application of a recently reported bis-
pyridine ruthenium catalyst for ROMP of complex RGD-
conjugated norbornenes, providing copolymers with precise
control of monomer incorporation and excellent control of
molecular weights and PDIs. The synthesis of RGD-containing
polymers described here is a vast improvement from previous
reports using ROMP. Following polymer cross-linking, the
resulting thin-film hydrogels were quantitatively evaluated to
study the impact of RGD structure and content on HUVEC
adhesion and spreading. Strikingly, cross-linked polynorbor-
nene thin films containing cyclic RGD were observed to be
effective at a 100-fold lower concentration than those
containing the linear peptide at supporting cell adhesion and
spreading under serum-free conditions.
■ EXPERIMENTAL SECTION
Polymer Synthesis General Procedure. The random copoly-
mers were synthesized via ROMP with catalyst [(H2IMes)-
(pyr)2(Cl)2RuCHPh] (7) at [M]0/[C]0 = 99 (Scheme 2). For all
polymerizations, the protected amine monomer 2 (Nor-Amine) was
held constant at 20 mol %, and the percentage of RGD (3 or 4) or
control RDG peptides (5 or 6) was varied from 0 to 10 mol %. The
norbornene-polyethylene glycol (PEG) monomer 1 (Nor-PEG) was
added as needed to keep the ratio of monomers to catalyst constant.
The polymerization reactions were run for 35 min, and complete
incorporation of monomers was confirmed by 1H NMR. Reactions
were terminated upon addition of ethyl vinyl ether38 followed by
treatment with tris(hydroxymethyl)phosphine (THMP) for removal
of ruthenium.39 The polymers were precipitated into diethyl ether
(Et2O), and the side chains were deprotected with a mixture of
trifluoroacetic acid (TFA), triisopropylsilane (TIPS), and water
(95:2.5:2.5). Precipitation into Et2O, followed by purification via
dialysis (molecular weight cut-off (MWCO) = 25 000), and
lyophilization of the aqueous solutions provided the pure polymers
for biological evaluation. Polymers were stored as 10 wt % solutions in
Nanopure water at −20 °C. Polymers with a range of molecular
weights were synthesized by varying catalyst loadings from 0.5 to 4%
while keeping the Nor-cycRGD monomer 4 constant at 1%. The PDIs
and average molecular weights (Mn) were calculated by gel permeation
chromatography (GPC) following polymerization reactions. Complete
side-chain deprotection of all polymers was confirmed by 1H NMR.
The synthetic details and characterization of monomers and
copolymers, including a representative polymerization procedure, are
provided in the Supporting Information.
Kinetic Analysis. A stock solution (1 mL) of the specified
monomer at 0.02 M in CD2Cl2/CD3OD (4:1) was added to an oven-
dried septum screw cap NMR tube under an inert atmosphere. The
ruthenium initiator 7 (10 μL of a 0.02 M solution in CD2Cl2) was then
added to the NMR tube through the septum cap and inverted quickly
to mix the solution. The tube was quickly placed in the NMR
spectrometer (Varian Mercury 500 MHz) making note of the time
before the first acquisition. Spectra were acquired at 26 s intervals
(eight scans) using a 0.5 s interval between scans for proton relaxation.
The polymerization was monitored until complete consumption of
starting monomers. The percent conversion was calculated from
integrations of [polymer]/[polymer + monomer] over time (see
Supporting Information).
Preparation of Thin-Film Hydrogels. Samples for biological
evaluation were prepared on 12 mm (Deckglaser) cover glasses that
were functionalized with (3-aminopropyl)triethoxysilane.40,41 Amine
functionalization was performed by soaking coverslips in saturated
KOH in EtOH for 5 min. The coverslips were then rinsed with
Nanopure water, treated with 6N aq. NaOH for 5 min, rinsed again
with water, and allowed to dry under a stream of air. The coverslips
were added to a 95% EtOH/H2O solution containing 2% (3-
aminopropyl)triethoxysilane and allowed to soak for 2 min. The
coverslips were then transferred to a MeOH bath, removed, and
allowed to dry in air.
A 2.5 wt % solution of desired polymer in Nanopure water was
added to 1 equiv of bis(sulfosuccinimidyl) suberate (BS3) relative to
the primary amine in the polymer. An amine functionalized coverslip
was placed on the spin coater (Specialty Coating Systems, 6800 Spin
Coater Series). Approximately 70 μL of the 2.5 wt % polymer/BS3
solution was carefully added covering the entire glass surface. The
sample was then allowed to coat the surface at 2500 rpm for 30 s. All
coated samples were allowed to dry overnight to provide thin-film
hydrogels for subsequent cell adhesion, viability, and spreading studies.
Atomic force microscopy (AFM) analyses of representative thin films
are included in the Supporting Information.
Cell Culture. Human umbilical vein endothelial cells (HUVECs)
(Lonza, CC-2519) were cultured at 37 °C under a humidified
atmosphere of 5% CO2. The cells were grown in endothelial cell
growth medium (Cell Applications, 211-500) supplemented with 1%
penicillin/streptomycin (Gibco, 105140122). The cells were con-
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tinuously maintained in the culture medium and subcultured every 3−
4 days up to 10 passages. Cells from passages 6−10 were used in
studies of adhesion, viability, and spreading.
Cell Adhesion Studies. Cells at 70−80% confluence were washed
with warm PBS, detached, and resuspended in either regular growth
medium or serum-free medium (Cell Applications, 113−500). An
aliquot of 5 × 104 cells was seeded per well in a 24-well plate
containing polymer-coated coverslips. Cells were allowed to attach for
24 h in the incubator before examination by phase contrast
microscopy.
Cell Viability. Cell viability on thin-film hydrogels was assessed
using a Live/Dead Viability kit (Invitrogen, L3224). HUVECs were
seeded at a density of 5 × 104 cells per well in a 24-well plate
containing coated coverslips. Cells were allowed to grow for 24 h in
serum-supplemented or serum-free media in an incubator prior to
staining according to the manufacturer’s protocol. Cells were then
imaged on an inverted epifluorescence microscope (IX71, Olympus)
with a humidified chamber and temperature control at 37 °C. Images
were taken with identical acquisition settings and processed using
ImageJ 1.45s (National Institutes of Health, USA). Cell viability
experiments were run in triplicate.
Cell Spreading. HUVECs were seeded at a concentration of 5 ×
104 cells per well in a 24-well plate in serum-free medium. Cells were
imaged on thin-film hydrogels at 15, 30, 45, 60, 90, 120, 180, 240, and
300 min. Images were taken using a 10× phase contrast objective on a
Nikon Eclipse TE300 inverted microscope. Images were manually
scored for the number of spread versus nonspread (rounded) cells.
Spreading experiments were run in triplicate.
■ RESULTS AND DISCUSSION
Monomer and Polymer Design and Synthesis. The
random copolymers were designed to incorporate three
separate monomers: a water-soluble PEG unit (1), the RGD
cell recognition motif (3 or 4), and a reactive amine functional
group (2) for postpolymerization cross-linking (Figure 1).
Monomers 1 and 2 were synthesized readily using previously
reported condensation reactions of cis-5-norbornene-exo-2,3-
dicarboxylic anhydride with the corresponding amines.37,42
Peptide substituted norbornene monomers (3−6) were
synthesized via Fmoc solid phase peptide synthesis (SPPS)
on 2-chlorotrityl chloride resin. Notably, monomers 3−6 were
designed to incorporate a linker between the highly function-
alized peptide and the ROMP reactive norbornene unit,
thereby ensuring good reactivity in polymerizations. For
monomers Nor-linRGD (3) or Nor-linRDG (5), N-(hexanoic
acid)-cis-5-norbornene-exo-dicarboximide was coupled to the
amino terminus of the peptides on resin. The monomers were
then cleaved from the resin using mild acidic conditions
providing side-chain protected, norbornene-conjugated pep-
tides 3 and 5, which were used in polymerization reactions
without further purification.
The structure of monomer Nor-cycRGD (4) was designed
based on the tumor targeting αvβ3 antagonist cyclo(RGDfK)
and its more potent dimer.43,44 Therefore, the synthesis of
monomer Nor-cycRGD (4) was initiated by SPPS of the side-
Figure 1. Ruthenium-catalyzed ROMP of norbornene monomers (top) for the synthesis of random copolymers incorporating water-soluble PEGs,
RGD peptides, and amines for postpolymerization cross-linking (bottom).
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chain protected linear sequence NH2−Asp(OtBu)-DPhe-Lys-
(Nor)-Arg(Pbf)-Gly-CO2H (8), where the lysine side chain
incorporates the norbornene functionality (Scheme 1).
Cyclization of 8 with propylphosphonic anhydride (T3P),
following the procedure of Liu et al.,45 provided Nor-cycRGD
(4) in excellent yields (85%). The control monomer Nor-
cycRDG (6) was synthesized by a similar method with simple
transposition of the Asp(OtBu) and Gly residues during SPPS
of the linear peptide prior to cyclization.
Polymers were synthesized readily from norbornene
monomers 1−6 by initiation with ruthenium catalyst 7
(Scheme 2). Ruthenium catalysts containing bis-pyridine
ligands have been demonstrated to initiate rapidly at room
temperature, and therefore, provide good molecular weight
control of the resulting polymers.36,46 All copolymerizations
were run for 35 min assuring complete reaction of all
monomers, and terminated with the addition of ethyl vinyl
ether.38 The RGD content in the polymers was controlled by
varying the percentage of the desired RGD monomer (3 or 4)
in the monomer feed prior to initiation with 7. For all
polymerizations, 20% of the Nor-Amine (2) was incorporated
with variable amounts of Nor-PEG (1) in order to keep the
monomer to catalyst ratio constant. Polymers containing linear
RGD peptides were synthesized with a range of 0−10% Nor-
linRGD (3) in the monomer feed. Polymers with no peptide or
10% of the scrambled sequence lin-RDG were also made as
negative controls for biological evaluation. Polymers with cyclic
peptide were synthesized with a range of 0−2.5% Nor-cycRGD
(4) in the polymerization reactions. A negative control polymer
containing 2.5% scrambled cyc-RDG was prepared for biological
studies. Polymers containing cyclic RGD were prepared with
lower peptide concentrations due to the enhanced binding
affinity of the cyclic peptide for cell surface integrins.15−21
Because of the complexity of peptide substituted norbornene
monomers (3−6), we examined whether polymerization
reactions were characterized by a linear dependence of average
molecular weight (Mn) on monomer-to-catalyst ratio ([M]0/
[C]0) thereby indicating a living polymerization.
25−27,47
Polymers with 1% cyc-RGD were synthesized at varying
monomer-to-catalyst ratios ([M]0/[C]0 = 199, 99, 49, and
24, Table 1 entries 7, 3, 8, and 9, respectively), and the
molecular weights (Mn) of these polymers were found to
increase linearly with increased [M]0/[C]0 (see Supporting
Information). Consistent with the living nature of these
polymerizations, all protected polymers were isolated in
excellent yields (95−100%) and gave narrow PDIs (1.04−
1.11). GPC analysis for all polymers showed good control of
molecular weight as well as monomodal distributions for all
polymers (see Table 1 for representative GPC data). Precise
control of molecular weight and low PDI values are important
factors for the use of ROMP as a general method for the
synthesis of polymers. Additionally, since soluble polymers
would inhibit cell adhesion,33,34 narrow PDIs ensure consistent
cross-linking of polymers. Following polymerization, the side-
chain protecting groups were cleaved with TFA and purified by
dialysis. The aqueous solutions were lyophilized to provide
white foams in good yields (60−78%) and were characterized
Scheme 1. Synthesis of Nor-cycRGD (4)
Scheme 2. Random Copolymerizations of Norbornene
Monomers via ROMP
Table 1. GPC Data for Random Copolymers Incorporating
Linear or Cyclic RGD Peptides
entry
protected
polymera [M]0/[C]0
Mn GPC
(kDa)
Mn theo
(kDa) PDI
1 10% lin-RGD 99 52 42 1.05
2 10% lin-RDG 99 49 42 1.06
3 1% cyc-RGD 99 45 37 1.05
4 0.1% cyc-RGD 99 47 36 1.07
5 2.5% cyc-RDG 99 48 38 1.04
6 no peptide 99 45 36 1.04
7 1% cyc-RGD 199 74 74 1.11
8 1% cyc-RGD 49 25 18 1.05
9 1% cyc-RGD 24 15 8.9 1.10
aDetermined by GPC with 0.2 M LiBr/DMF solution. GPC data
collected postpolymerization with side chains protected. GPC traces
and data for all other polymers can be found in the Supporting
Information.
Biomacromolecules Article
dx.doi.org/10.1021/bm300795y | Biomacromolecules 2012, 13, 2546−25532549
by 1H NMR to ensure complete deprotection of the polymer
side chains.
In order to determine whether the copolymers described
here were true random copolymers or contained gradients in
composition, we examined the relative rates of incorporation
for norbornene monomers 1−4 in homopolymerization
reactions. Previously reported polymerizations with other
peptide-conjugated norbornenes have demonstrated kinetic
evidence for random copolymer formation.37 Kinetic studies
were conducted by observing the disappearance of monomer
and appearance of polymer by 1H NMR at monomer-to-
catalyst ratios of 100:1. First-order kinetics was observed for all
monomers examined with similar rates of incorporation for
homopolymer formation (Figure 2). Monomer Nor-cycRGD
(4) reacts at a slightly lower rate than monomers 1−3, possibly
due to its larger size and increased steric hindrance closer to the
reactive norbornene moiety. Nevertheless, all homopolymeriza-
tion reactions reached full conversion within 12 min, indicating
that RGD content in the final polymers can be controlled by
the initial monomer feed ratios.
Following synthesis and characterization of RGD function-
alized polymers and controls, samples for cell adhesion were
prepared. A 2.5 wt % aqueous solution of polymer in the
presence of BS3 was spin-coated on amine functionalized
coverslips. The coverslips were allowed to dry overnight prior
to biological evaluation. Representative thin films were
examined by AFM and ranged in thickness from 54 to 65
nm as dry films; upon absorption of water, the films swelled to
79−87 nm. The films were homogeneous and smooth.
Cell Adhesion and Viability. Cell adhesion was initially
evaluated qualitatively via phase contrast microscopy 24 h post
seeding of HUVECs on cross-linked polynorbornene thin films.
A range of 1−10% linear RGD containing polymers (Table 2,
11−14) were examined and compared to controls that
contained either no peptide (9) or the scrambled polymer
with 10% lin-RDG (10). Polymers containing linear RGD
required peptide concentrations above 1% in order to promote
cell attachment after 24 h. As expected, control polymers 9 and
10 did not promote cell adhesion. Polymer 14, carrying 10%
lin-RGD, was used as a comparison with cyclic RGD polymers
since thin films of 14 demonstrated good cell attachment.
Polymers incorporating cyclic RGD at concentrations
between 0.01 and 2.5% (Table 3, 16−22) were subsequently
examined for their ability to support cell adhesion and survival
24 h post seeding. Consistent with enhanced binding, these
cyclic RGD containing thin films supported cell adhesion at
concentrations as low as 0.05% (17), a 50-fold lower
concentration than the minimum RGD concentration for
linear RGD films. Positive cell adhesion of these synthetic
polynorbornene thin films corresponds to integrin recognition
of RGD concentrations in the low nanomolar range. Cell
adhesion with 2.5% cyc-RGD (22) was observed to be
comparable to that observed on thin films bearing 1% cyc-
RGD (21). From the results of these cell adhesion assays, thin
films containing 1% cyc-RGD (21) and 0.1% cyc-RGD (18)
were examined quantitatively in cell viability and spreading
assays.
Cell viability was assessed using a Live/Dead Viability assay
(fluorescent dyes calcein-AM and ethidium homodimer-1), 24
h after seeding on polymer thin-film samples carrying either
linear or cyclic RGD. Fluorescence images were acquired, and
the number of live cells (green) versus dead cells (red) was
quantified for thin films containing 10% lin-RGD (14), 1% cyc-
RGD (21), and 0.1% cyc-RGD (18) (Figure 3). Negative
control samples included scrambled sequences 10% lin-RDG
(10), 2.5% cyc-RDG (15), and a polymer film with no peptide
(9). Under serum-supplemented conditions (Figure 3, A), 87%
of cells were alive in samples with 10% lin-RGD, while both cyc-
RGD samples provided 95% cell viability. Examination of the
fluorescence images illustrates that the negative controls have
no attached cells (Figure 3, C−E). While cells exhibit similar
characteristics on films with 10% lin-RGD (Figure 3, F) and
0.1% cyc-RGD (Figure 3, H), samples with 1% cyc-RGD
(Figure 3, G) show an enhanced ability to support cell
attachment. Under more stringent serum-free conditions
(Figure 3, B), a significant decrease in cell viability was
Figure 2. Log plot of the homopolymerization of monomers 1−4 with
[M]0:[C]0 = 100:1 in 4:1 CD2Cl2/CD3OD. Linear least-squares fitting
provided the following slopes [kobs (sec
−1)]: monomer 1: 0.0052,
monomer 2: 0.0049, monomer 3: 0.0054, monomer 4: 0.0045.
Table 2. Cell Adhesion on Polymer Thin Films Containing
Linear RGD Peptides
polymer % linear RGD % linear RDG (control) cell adhesion (±)
9 0 0 −
10 0 10 −
11 1 0 −
12 2.5 0 +
13 5 0 +
14 10 0 +
Table 3. Cell Adhesion on Polymer Thin Films Containing
Cyclic RGD Peptides
polymer % cyclic RGD % cyclic RDG (control) cell adhesion (±)
9 0 0 −
15 0 2.5 −
16 0.01 0 −
17 0.05 0 +
18 0.1 0 +
19 0.25 0 +
20 0.5 0 +
21 1 0 +
22 2.5 0 +
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observed for 10% lin-RGD (59%), and modest decreases were
found for samples with 0.1% cyc-RGD (81%) and 1% cyc-RGD
(89%). As shown in Figure 3 (B, L, and N), both 10% lin-RGD
(Figure 3, L) and 0.1% cyc-RGD (Figure 3, N), which differ
100-fold in peptide concentration, demonstrate similar levels of
cell survival. Impressively, samples with 1% cyc-RGD (Figure 3,
M) show similar adhesion and spreading in serum-free and
serum-supplemented conditions. The superior cell viability of
thin-film samples containing cyclic RGD peptides is consistent
with the enhanced binding affinity of cyclic peptides for
integrins, leading to increased cell adhesion and survival on cyc-
RGD polynorbornene thin films. Specifically, the binding of
cyclic RGD peptides to the αvβ3 integrins, which are
overexpressed in HUVECs, has been reported to be
subnanomolar in affinity.22,23
Cell Spreading. The time frame for cell attachment and
spreading of HUVECs on cross-linked polynorbornene thin
films was also investigated. HUVECs plated on thin films were
examined at intervals of 15, 30, 45, 60, 90, 120, 180, 240, and
300 min using phase contrast microscopy. The more stringent,
serum-free conditions were utilized for the comparison of cell
spreading on 1% cyc-RGD versus 10% lin-RGD thin films
alongside negative controls (no peptide and scrambled
sequences; Figure 4). HUVECs on polymers containing both
1% cyc-RGD and 10% lin-RGD showed excellent adhesion and
spreading within 300 min. With 1% cyc-RGD, half of the cells
Figure 3. Quantitative and qualitative assessment of HUVEC cell viability on cross-linked polynorbornenes using a fluorescent Live/Dead Viability
assay. Green fluorescence (calcein-AM) indicates live cells, and red fluorescence (ethidium homodimer-1) indicates dead cells. Cell viability in
serum-supplemented media (A) and serum-free media (B) 24 h post seeding. Fluorescence images of HUVEC adhesion after 24 h in serum media
(C−H) of polynorbornene thin films incorporating no peptide (C), 10% lin-RDG peptide (D), 2.5% cyc-RDG (E), 10% lin-RGD (F), 1% cyc-RGD
(G), and 0.1% cyc-RGD (H). Fluorescence images of similar samples in serum-free media are shown in I−N. Scale bars =100 μm.
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were spread as early as 15 min (Figure 4, E), while 10% lin-
RGD provided similar results at 90 min (Figure 4, C). This
significantly faster rate of adhesion is consistent with the
increased affinity of cyclic RGD peptides for cell surface
integrins.23 As illustrated in Figure 4 (A), cell spreading and
overall adhesion are significantly enhanced for the 1% cyc-RGD
polymer compared to 10% lin-RGD. Additionally, cells cultured
on the polymer thin films exhibit morphology and spreading
similar to positive control samples of HUVECs seeded directly
in wells of tissue culture treated plates.
■ CONCLUSIONS
The results reported here provide an efficient method for the
preparation of linear and cyclic RGD-conjugated norbornene
monomers 3 and 4. Monomers containing the RGD cell
recognition motifs were copolymerized with Nor-PEG (1) and
Nor-Amine (2) to provide excellent yields of polynorbornenes
with varying concentrations of linear or cyclic RGD peptide
side chains. Cross-linked thin films of polymers carrying cyclic
RGD were active at a 100-fold lower peptide concentration
than linear RGD-containing polymers for cell viability of
HUVECs. Polymer samples with 1% cyc-RGD were observed to
be superior for cell attachment, viability, and spreading under
stringent, serum-free conditions. The disclosed copolymer
formation with RGD based monomers provides evidence for
the broad utility of ROMP as a controlled method for
incorporating a range of peptides into polymers. These results
have important implications for the synthesis of biomaterials
that support cell adhesion, and studies investigating the impact
of incorporating multiple cell-recognition motifs and increasing
the linker length between the polymer backbone and the RGD
moiety are currently ongoing. The evaluation of these materials
for supporting stem cell attachment and growth for biomedical
applications is also underway.
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